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ABSTRACT
Equine herpesvirus 1 (EHV1), a member of the alphaherpesvirinae, is a significant viral 
pathogen of horses causing a variety of clinical problems including respiratory disease, 
abortion and neurological disorders. The complete DNA sequence of EHV1 strain Ab4, a 
pathogenic UK isolate has been determined. There are 81 open reading frames (ORF) 
predicted from the DNA sequence. Most of these predicted gene products have not been 
identified and their functions in the virus life cycle are not known. Among these putative 
genes, five 1, 2, 67, 71 and 75 had no detectable homologues in HSV1 and VZV,
and appeared to be unique to EHV1 (Telford et a i,  1992). This feature suggested that these 
genes may have specific roles in the virus life cycle in the horse. The research presented in 
this thesis has concentrated on investigating the role of the five genes in the virus life cycle. 
The project included three parts: (1) Construction and characterisation of deletion mutants in 
the target genes. For construction of deletion mutants the majority of the encoding sequence 
of each target gene was removed and replaced by the E. coli lacZ gene as a marker gene. 
The isolation of viable mutants in the five target genes demonstrated that none of these genes 
were essential in the virus life cycle in vitro. Their growth characteristics, host range and 
temperature sensitivity in tissue culture were indistinguishable from those of wild type virus 
with the exception of the gene 71 deletion mutant (ED71). ED71 grows less well than wild- 
type virus and its revertant, produces smaller plaques and has an obviously higher 
particle/pfu ratio of progeny virus than the wild-type virus and revertant in vitro. (2) 
Identification and characterisation of the target gene products. To raise specific antisera the 
genes were separately expressed as B-galactosidase fusion proteins in E.coli. These 
consisted of amino acids 4-202 of the putative gene 1 protein, amino acid sequence 2-205 of 
the putative gene 2 protein, amino acids 12-260 of the putative gene 67 protein, amino acids 
434-797 of the putative gene 71 protein and amino acids 14-130 of the putative gene 75 
protein. Two antisera, anti-67 and anti-71, have been raised against the gene 67 and gene 71 
fusion proteins in rabbits. Use of the deletion mutants in conjunction with the antisera,
allowed the unambiguous identification of the protein products of genes 67 and 71. Anti-67 
serum specifically recognised a 36KD Mr polypeptide in infected cell extracts which was 
absent from mock and mutant ED67 infected cell extracts and was not recognised by the pre- 
immune serum. In the lytic replication cycle, the protein is regulated as an early polypeptide 
and modified as a phosphoprotein. With immunofluorescence and cellular fractionation 
experiments, the protein has been shown to be associated with intracellular membranes and 
distributes as novel ribbon or filament like structures, concentrated in a perinuclear location 
within the cytoplasm of infected cells. The protein does not co-localise with either tubulin, 
actin or Golgi bodies. However, the precise localisation of the gene 67 protein within cells is 
unclear. The gene 67 protein is also a component of virions and is located in the 
nucleocapsid/tegument. Anti-71 serum, specifically recognises a 192KD Mr infected-cell 
polypeptide. This protein is absent from mock and mutant ED71 infected cell extracts and is 
not recognised by pre-immune serum. This result confirmed that the 192KD polypeptide 
was encoded by EHV 1 gene 71. Gene 71 is regulated as a leaky late gene during EHV 1 lytic 
infection. The 192 KD gene 71 protein is associated with cellular membranes and is also a 
component of the virion envelope with a Mr > 200KD. Post-translational modification 
experiments showed that the gene 71 protein was sensitive to tunicamycin and monensin; the 
M r of the protein was greatly reduced by deglycosylation with exoglycanases, which 
demonstrated that the gene 71 protein was post-translationally modified as a glycoprotein 
with limited N and heavy O-linked glycosylation. These features of the gene 71 protein 
indicate that the protein is a class I membrane glycoprotein which is consistent with the 
features of the gene 71 protein predicted from sequence analysis (Telford et al., 1992a).
During the course of this study, it became clear that the gene 71 protein had very similar 
properties to that of gp300, a EHV 1 glycoprotein, which had been characterised as being
heavily O-linked with a Mr over 400 KD in SDS-PAGE linked by DATD. gp300 had been
o-
previously found to be encoded by EHV1 gene 28 (Whittaker et al., 1990; 1992^. To 
determine the relationship between the gene 71 protein and gp300, a comparative experiment 
was carried out with anti-71 and a monoclonal antibody, P I9, which specifically recognised
gp300 (Whittaker, et al., 1992a).The comparative data shows that gp300 and the gene 71 
protein have the same molecular weights under the same gel conditions and are both absent 
from ED71 infected cell extracts, but restored in ED71 revertant infected cell extracts. This 
data clearly confirmed that gp300 was encoded by EHV 1 gene 71. Its previous designation 
as the product of gene 28 was incorrect. ED 71 has been found to be impaired in growth in 
vitro and produces smaller plaques as well as having a high particle/pfu ratio. Since the 
revertant of ED71 grows identically to wild-type virus, the deletion of gene 71 is responsible 
for the phenotype of ED71. As the gene 71 protein has been characterised as a class I 
membrane glycoprotein, the results suggested that the gene 71 protein may play a role in 
virus entry into cells, egress from cells or transmission from cell to cell. (3) To functionally 
analyse the role of the gene 71 protein, ED 71 was characterised in terms of efficiency of 
entry into cells in vitro, egress from cells and transmission from cell to cell, compared with 
wild-type and revertant virus. The results showed that the deletion of gene 71 affected viral 
nucleocapsid envelopment and resulted in greatly decreased egress of infectious virus 
progeny from cells. ED71 also displays a defect in entry into cells. These defects have a 
consequential effect on efficiency of the virus transmission via release and readsorption to 
uninfected cells.
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CHAPTER 1. INTRODUCTION
1.1 GENERAL DESCRIPTION OF HERPESVIRUSES
To date eight different herpesviruses whose natural host is man have been identified: herpes 
simplex virus type 1(HSV1), herpes simplex virus type 2 (HSV2), varicella zoster virus 
(VZV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV) and human 
herpesviruses (HHV) types 6-8. They appear to be ubiquitous, and serological studies show 
that a large proportion of people throughout the world have been exposed to and may be 
latently infected with one or more herpesvirus. Clinical manifestations of herpesvirus 
infections range from inapparent infection to localised disease and fatal systemic illness. 
HSV1, HSV2 and VZV, alphaherpesviruses, are neurotropic viruses which typically cause 
mild primary infection of epithelial cells of the skin giving rise to vesicular lesions. HSV1 
is typically associated with lesions of the mucocutaneous epithelial lining of the oral cavity 
(herpes labialis) and eyes (herpeskeratitis), while HSV2 is predominately associated with 
lesions of the genital tract (herpes genitalis) (Whitley, 1985). VZV results in the childhood 
disease known as chicken pox (varicella). HCMV, a beta-herpesvirus, tends to be species - 
specific in vitro. HCMV infection in normal adults is wide spread, but results in a benign 
and asymptomatic disease. However, the disease can be disseminated and severe in 
children or immunosuppressed patients. EBV, a gammaherpesvirus, is associated with 
Burkitts lymphoma (a B-cell malignancy) and in South East Asia, with nasopharyngeal 
carcinoma (an epithelial cell malignancy). HHV6, (Ablashi et al., 1987) was found to be 
wide spread in adults and segregated into two groups (HHV6A and HHV6B) based on 
biological, immunological and molecular analyses. The only disease in which HHV6B has 
been implicated is exanthum subitum, a transient childhood illness (Yamanishi et al., 
1988). HHV7 was isolated from peripheral blood lymphocytes (PBLs) of a healthy 
individual in 1989 (Frenkel et a l., 1990). Since then HHV7 has been isolated from saliva of 
as many as 75% of healthy adults (Levy et al., 1990) and analysis of the viral DNA 
indicates it differs from the other known herpesviruses- no disease has been associated with 
this virus. Very recently herpesvirus-like DNA sequences have been found associated with
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various forms of Kaposi's sarcoma, but not normal tissue (Chang et al., 1994). The DNA 
sequences of Kaposi's sarcoma herpesvirus (KSHV) or HHV8 are highly homologous to 
genes of HSV and EBV. A high prevalence of KSHV in endemic as well as AIDS- 
associated Kaposi's sarcoma was found suggesting that KSHV might be associated with 
immunodeficiency in general, and indeed KSHV has been associated with lesions other 
than Kaposi's sarcoma in non-AIDS immunocompromised patients (Rady et al., 1995).
Herpesviruses also cause several diseases in animals. Equine herpesvirus 1 (EHV1) is the 
major cause of abortion and respiratory disease in horses. Pseudorabies virus (PRV) causes 
Aujewsky’S'disease in swine. Bovine herpesvirus 1 (BHV1) is the etiologic agent of 
infectious bovine rhinotracheitis. Lucke virus causes renal adenocarcinomas in the frog 
(Gravell, 1971). Marek’s disease virus (MDV) induces transformation of lymphoblastoid 
cells in chickens (Churchill and Biggs, 1968).
In general, following primary infection, alphaherpesviruses can persist in neuronal cells in a 
latent form and may give rise to periodic recurrence of the disease during the life time of 
the host. EBV is also capable of establishing latency in lymphocytes. It efficiently 
immortalizes B-lymphocytes in vitro (Dambaugh et al., 1986). The sites and essential 
features of betaherpesvirus latency are unknown.
1.2. CLASSIFICATION OF HERPESVIRUSES
Members of the herpesviridae have been classified on the basis of morphology and
cytopathology (Matthews, 1979, 1982). All members possess a large double-stranded DNA 
genome present within an enveloped particle (150-200 nm in diameter). The virion is 
composed of four distinct elements; the core, capsid, tegument and envelope. The core 
contains the genomic DNA (Booy et. al., 1991). It is surrounded by an icosahedral shaped 
capsid assembled from 162 capsomers of which 150 are hexomeric and 12 pentameric 
prisms (Wildy et al. , 1960, Schrag et al., 1989). The amorphous material arranged around 
the nucleocapsid is known as the tegument. The envelope is the outermost structure of
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virus and comprises a lipid bilayer derived from host cell nuclear and plasma membranes 
from which protrude numerous viral-encoded glycoprotein spikes of approximately 8 nm in 
length ( Heine etal 1972 ). Herpesviruses differ widely in their pathogenic
potential but share important biological properties. Most notable is the ability, after primary 
infection, to establish latent infections throughout the lifetime of the host. Other biological 
features in common to all herpesviruses include : (1) Viral DNA is synthesised and capsid 
assembly takes place in the nucleus and (2) They encode a variety of virus-specified 
enzymes, particularly those involved in nucleic acid metabolism and DNA replication.
1.2.1. Subclassification on the basis of biological properties
On the basis of host range, reproductive cycle, cytopathology and characteristics of latent 
infection herpesviruses have been classified into three sub-families, referred to as alpha, 
beta and gammaherpesvirinae (Barahona et al., 1974; Honess and Watson, 1977; Honess, 
1984; Roizman etal., 1981; Roizman, 1982).
Alphaherpesvirinae
Many members of this subfamily are neurotropic and exhibit a wide host range in vitro. 
Their productive cycle is short and they spread rapidly in tissue culture with mass 
destruction of infected cells. Latent infections are frequently established in the sensory 
ganglia (Wildy et al., 1982). Members of this group include HSV1, HSV2, VZV, PRV, 
EHV1, equine herpesvirus type 3 (EHV3), equine herpesvirus type 4 (EHV4) and bovine 
herpesvirus type 2 (BHV2).
Betaherpesvirinae
This group exhibits a restricted host range and a long reproductive cycle. Infected cells 
often became enlarged (cytomegalia) and persistently infected cell cultures are readily 
established. The establishment of latency may occur in a variety of tissues including 
secretary glands, kidneys and lymphoreticular cells. HCMV is a member of this subfamily.
3
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nammaherpesvirinae
This sub-family also has a narrow host range which is specific either for B lymphocytes, the 
gamma 1 subgroup, e.g. EBV, or T lymphocytes, the gamma 2 subgroup, e.g. herpesvirus 
saimiri (HVS). The length of the reproductive cycle and cytopathology are variable and 
latent infections are frequently established in lymphoid tissue. This group includes EBV, 
HVS, equine herpesvirus type 2 (EHV2), equine herpesvirus type 5 (EHV5) and bovine 
herpesvirus type 4 (BHV4)
1.2.2. Subclassification on the basis of genome structure
Comparisons of the predicted amino acid sequences have shown that genetic relationships 
of individual viruses agree in general with the biological classification. However some 
exceptions do exist, e.g. bovine herpesvirus type4 (BHV4) has a long replicative cycle and 
is enveloped primarily by budding on smooth cytoplasmic membranes of Golgi body 
elements to give rise to the formation of cytoplamic inclusions. On this basis it was 
classified as a cytomegalovirus (Storz et. al., 1984). However, the BHV4 genome is 144 
kbp in size and has polyrepeated DNA segments at both termini. This bears closer 
resem blance to the genome of the lymphotropic virus HVS, a member of the 
gammaherpesvirinae, than to the cytomegalovirus (Ehlers et al., 1985). Furthermore, the 
recently identified HHV6, was originally assigned to the gammaherpesvirinae on the basis 
of its tropism for lymphocytes. However, on the basis of its sequence homology and gene 
organisation, HHV6 is more related to HCMV and more properly belongs to the 
betaherpesvirinae than gammaherpesvirinae. EHV2 and EHV5 were previously classified 
as betaherpesviruses. However, sequence analysis has revealed that EHV2 and EHV5 
share greater amino acid sequence similarity with EBV and HVS than other herpesviruses. 
On the basis of genome similarity and biological properties, they were reclassified as 
gammaherpesviruses.
4
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1.3. THE PATHOGENESIS OF EQUINE HERPESVIRUSES
1.3.1. Introduction
Equidae are susceptible to infection by at least five viruses of the herpesviridae, EHV1 2, 
3, 4 and 5.
EHV1, an alphaherpesvirus, is responsible for respiratory, sporadic and epizootic 
abortigenic and neurologic diseases. Epizootic abortion caused by EHV 1 infection can 
cause economically devastating losses (Plummer and Watersori963).
EHV2 and EHV5 are gammaherpesviruses. EHV2 originally comprised an antigenically 
and genomically heterogeneous group of viruses (Browning and Studdert, 1987). 
Considerable antigenic and biological diversity among EHV2 isolates has been reported. It 
was found that the numbers of hours prior to the commencement of viral replication and the 
time required for completing virus induced cytopathology varied across different isolates 
of EHV2. A large degree of genetic heterogeneity between EHV2 isolates was also 
identified by restriction endonuclease analysis (Browning and Studdert, 1987). Based on 
these findings, the existence of a new type of equine herpesvirus was proposed, and EHV2 
was subdivided into EHV2 and a new type, provisionally designated EHV5 which has 
growth characteristics similar to EHV2.
EHV2 and EHV5 were previously classified as betaherpesviruses based on their 
resemblance in many of their biological properties to CMV of man and other animals 
(Hsiung et al., 1969; Plummer et a l, 1969). However, EHV2 and EHV5 share certain 
biological properties with viruses classified in the gammaherpesvirinae. They are not 
restricted to primary cell culture from natural host species. They grow not only in equine 
cells, but also in rabbit and feline kidney cells (Plummer et al. , 1969, 1973) . Contrary to 
the provisional classification of EHV2 and EHV5 as betaherpesviruses, it has been shown 
(Telford et al., 1993) that EHV2 and EHV5 share greater amino acid sequence similarity 
with EBV and HVS than with other herpesviruses. In 1994, Agius and Studdert reclassified
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EHV2 and EHV5 as gammaherpesviruses based on their genomic relationship and 
biological features.
The natural route of infection of EHV2 appears to be the upper respiratory tract, as 
suggested by the epidemiological similarities between EHV2 and EHV5 and EHV1 and 
EHV4 (Bagust et a l ,  1972; Sherman et al., 1977). In contrast to knowledge of the disease 
produced by EHV1 and EHV4, the consequences of infection of horses by EHV2 and 
EHV5 are largely unknown (Plummer et al., 1963; Erasmus , 1970). Although the 
incidence of infection of horses by EHV2 and EHV5 has been shown virologically to be 
very high, little evidence has been forthcoming which identified the virus unequivocally as 
the particular or initiating cause of any disease. The viruses can be isolated from normal 
tissues, such as the respiratory tract, leukocytes and conjunctivas in both naturaltyPlummer, 
et a l, 1963) and experimentally infected horse (Gleeson, and Studdert, 1977; Bryans and 
Prickett, 1969).
EHV3, a second equine alphaherpesvirus, is the cause of a benign progenital exanthematous 
disease (Ludwig, et a l, 1971; Bryans and Allen, 1973). EHV3 infection causes small 
seldom noticed vesicles in the skin of the vulva or the penis. These lesions may enlarge 
peripherally for a few days and may coalesce to form larger erosions. Secondary bacterial 
infections localised to the viral lesion may produce severe necrotising; balanitis which is 
medically the most serious consequence of the infection. Progenital disease occurs in 
maiden colts and fillies. Infection by the virus can be acquired by the respiratory route and 
infection appears not to constitute a threat of abortigenic disease (Bryans and Allen, 1973).
EHV4, an alphaherpesvirus, is responsible for respiratory disease of young animals as well 
as for sporadic and epizootic abortigenic disease. For a long time, EHV1 and EHV4 were 
believed to be the same virus, named as rhinopneumonitis virus (ERV) (Doll and Bryans, 
1957; Doll et a l ,  1956). In 1959, Shimizu et a l  found EHV1 could be divided into two 
subtypes on the basis of cross-neutralization tests. This was subsequently confirmed by
6
introduction
other workers (Matumoto et al., 1965, Mayr et al., 1965; Borgen and Ludwig, 1974). The 
epidemiological data have shown that although respiratory disease is common in all horse 
populations, EHV1 induced abortion has a far higher incidence in the U. S. A. and parts of 
Europe than it does in Australia, South Africa, Japan and Great Britain (Platt, 1973; 
Burrows and Goodridge, 1979; Coggins, 1979; Mumford and Rossdale, 1980). The relative 
rarity of EHV 1 abortion in Ireland, where rhinopneumonitis occurs annually in young 
stock, led Farrelly to suggest, as early as 1966, that there are two strains of EHV1: an 
abortigenic strain and a non-abortigenic strain. Using endonuclease analysis of virus DNA, 
Sabine et al. (1981) first demonstrated that there are two subtypes of EHV1. Virus isolates 
within each subtype have similar restriction endonuclease profiles which are entirely 
d ifferent from the other subtype. Using restriction endonuclease analysis in 
epizootiological studies of EHV1 and EHV4, Allen et al., (1983) and Studdert, (1983) 
found that EHV4, like EHV 1, causes epizootics of respiratory disease in young horses, but 
is rarely the cause of abortion storms or the neurological syndrome. Kinetic analysis of 
DNA and DNA reassociation suggests that the EHV1 and EHV4 share only 17% of their 
genome nucleotide sequence (Allen and Turtinen, 1982). Based on these studies, Studdert 
et al., (1981) suggested that viruses with a respiratory subtype or subtype 2 restriction 
enzyme pattern be renamed EHV4. Both subtypes are respiratory pathogens but only 
viruses which have a subtype 1 (EHV1) restriction enzyme pattern are commonly 
associated with abortion.
1.3.2. Abortion caused by EHV1
Though abortigenic disease in an individual mare can conceivably arise as a result of 
recrudescence of a latent infection, most such disease results from a progression of 
pathological events originating from reinfection of the respiratory tract in an 
immunologically experienced mare during the terminal four months of pregnancy (Bryans 
and Prickett, 1969). Because abortigenic disease is a disease of immunologically 
experienced individuals, infection of such individuals usually does not result in appearance 
of clinically detectable respiratory disease. The incubation period, from infection of the
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respiratory tract until abortion varies from 9 days to, in rare cases, several months (Doll 
and Bryans, 1962). If foetuses are inoculated directly with the virus, abortion always 
ensues within 3 to 9 days, which is the incubation period from infection of the susceptible 
foetus to abortion.
As opposed to most foetuses aborted as a result of microbial placentitis or infection of 
mares by equine arthritis virus, those infected by EHV 1 show no postmortem autolytic 
changes. Demonstrable lesions are confined to the foetus, no gross or microscopic lesions 
of the viral infection have been described on the placental tissues, and the majority of 
foetuses are viable until immediately before they are aborted. Histologically, the lung 
presents lesions of bronchopneumonia with necrosis of bronchial epithelium and 
pathognomonic intranuclear herpetic inclusion bodies which are most prominent in 
epithelial cells of the small bronchi. The liver is hyperemic and may contain miliary 
petechial hemorrhages and areas of focal necrosis.
Although the lesions demonstrable in aborted foetuses are qualitatively the same, they vary 
quantitatively to a great degree. It appears however th a t, no matter how severe the lesions, 
the disease of the foetus is not incompatible with its life in utero during the period from 
infection to abortion. It has been suggested that lesions histologically demonstrable in the 
uteri of mares after their foetuses were infected by transplacental inoculation are 
interpretable as evidence that abortion is an immunologically mediated phenomenon 
(Bryans and Prickett, 1969).
1.3.3. Respiratory disease
Respiratory disease caused by EHV1 and EHV4 is a disease of young, immunologically 
inexperienced horses. The primary infection is usually contracted during their first year of 
life, frequently about the time of weaning. After an incubation period of about forty hours, 
disease presents as febrile respiratory illness. The relative severity of physical symptoms 
of disease appears, from observation of both naturally acquired and experimentally induced
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infections of young horses, to be related to the infecting virus subtype, i.e. disease caused 
by EHV1 virus is generally more severe than disease caused by EHV4. The viral infection 
in experimentally infected foals produces an acute brochopneumonia with necrosis of the 
bronchial epithelium. The virus infects the upper respiratory mucosa causing vesiculation 
of the epithelium in which the temperature may reach 41.5 °C. Infected foals and yearlings 
display a serious trickling nasal efflux early in the course of disease. The lesions produced 
by virus in the upper respiratory tract are routinely superinfected by bacteria (Streptococcus 
Zooepidem icus). The secondary infection may produce pyrogenic tonsillitis and 
inflammatory hypertrophy or abscessation of the retropharyngeal and intermandibular 
lymph nodes and commonly cause bronchopneumonia especially in foals (Prickett, 1970). 
The morbidity rate within herds of immunologically naive weanlings approaches 100%.
1.3.4. Neurological disease associated with infection of EHY1
Neurological disease associated with infection of EHV1 was identified by Saxegaard 
(1966) who first isolated EHV1 from two adult horses which showed serious neurological 
symptoms. These symptoms caused by EHV1 can affect animals of any age, including 
suckling foals (Jackson and Kendrick, 1971). It may be preceded either by the occurrence 
of respiratory disease in young animals or abortions, or as the only clinical manifestation of 
infection by the virus. Infection is acquired via the respiratory tract and young horses may 
therefore show signs of respiratory disease. The earliest sign of neurological disease is a 
proprioceptive defect of the hind limbs, evident by a reluctance to move or ataxia with 
dragging of the feet. These signs are the result of lesions in the spinal cord resulting from 
vasculitis. In contrast to herpesviral encephalomyelitis in other species, neurological 
disease associated with infection of horses by EHV 1 apparently does not occur as a result 
of a productive viral infection of the central nervous system (CNS). There is no evidence 
of infection of neurones or other cells of the CNS and virological evidence for such 
infection (Little and Thorsen, 1976; Charlton et a l ,  1976) is rendered equivocal by the fact 
that EHV1 viraemia is demonstrable in many cases of the disease. Jackson et al. (1977) 
suggested that EHV 1 produces a neurologic syndrome which results from a pathogenic
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mechanism apparently unique among herpesviruses. Vasculitis in affected horses is not 
confined to the CNS. Similar lesions have also been demonstrated in the endometrium, 
uvea, nasal mucosa, lungs and at other anatomical sites (Little and Thorsen ,1976; Charlton 
et al. , 1976; Jackson et al., 1977) in affected animals. Although the virus is not routinely 
isolatable from the CNS, it is commonly present in peripheral blood leukocytes during the 
course of CNS disease. Histological evidence (inclusion bodies) of viral infection of 
endothelial cells in the equine foetus as well as evidence for the presence of viral antigen in 
endothelial cells of vessels of the CNS of horses with EH V 1 neurological disease has been 
presented (Patel et al., 1982).
Evidence for the presence of immune complexes, presumed to be EHV1 viral antigen- 
antibodies, in the serum of horses inoculated with a "paretic" EHV1 isolate and for 
thrombocytopenia indicative of the early formation of thrombi in the same experimental 
subjects has been presented (Jackson et al., 1977). These workers demonstrated that the 
initiation of the inflammatory alterations of vessels in the CNS is proliferation and necrosis 
of endothelium. The presence of viral antigen in the endothelium and the pattern of 
progressive histological alterations of vessels which leads to functional damage to the CNS, 
suggests that EHV1 encephalomyelitis of the horse is the result of a generalised Arthus 
(type III) immunological reaction analogous to that which is responsible for equine purpura 
haemorrhagica.
1.3.5. EHV 1 latency
An ability to establish latent infections is crucial to the survival of herpesviruses in the 
im m une environm ent which results from  the host's reaction to infection. 
A lphaherpesviruses use neurological tissue as their site of latency. It has been 
demonstrated that after infection with HSV at a peripheral site and the invasion of the 
sensory nerve endings, the virus ascends by retrograde axonal transport (Oches, 1974; 
Kristensson, 1988) in nerve axons to the nuclei of associated sensory ganglia. At this stage,
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either viral replication resulting in neuronal destruction occurs or a latent infection is 
established.
Periodically the latent viral genome may be reactivated spontaneously. It passes down the 
axon to epithelial cells at or near the primary site of infection where a productive infection 
occurs. Using a combination of in vitro tissue culture and animal models, latency may be 
functionally dissected into at least four sequential stages: (i) viral replication in the 
peripheral tissue in the absence of viral replication in the ganglia; (ii) establishment of a 
latent state in sensory nerves; (iii) subsequent maintenance; and (iv) reactivation of the 
latent virus leading to a productive infection at or near the primary site of inoculation.
It has been demonstrated that, depending on the site of primary infection, latency can be 
established in any peripheral nervous tissue, including the autonomic ganglia (Price et. al, 
1975; Martin et al., 1977; Warren et al., 7978). In situ hybridisation (Cook et al., 1974) 
and immunofluorescence analysis (McLennan and Darby, 1980) have confirmed that latent 
virus reactivates from the neurones of ganglia. Following corneal inoculation of HSV, 
examination of DNA isolated from latently infected murine ganglia and central nerve 
system (CNS) revealed that the latent DNA was in a different physical form compared to 
that observed both during acute infection and in virions. Rock and Fraser (1983) 
demonstrated a lack of terminal fragments of HSV DNA in latently infected tissue. 
Efstathiou et al., (1986) confirmed that latent HSV DNA in murine and human trigeminal 
ganglia is in the endless configuration.
Given that virtually any HSV 1 deletion mutant can establish latency in mice (Weber et al., 
1987; Sears et al., 1985; Leib et al., 1989; Katz et al., 1990) and that viral DNA replication 
(Steiner et al., 1990; Harris and Preston, 1992) and gene expression (Sederati et al., 1989) 
are not prerequisites for latency, it is possible that cellular factors play an important role in 
the repression of viral gene expression. The maintenance of the latent state of HSV is 
dependent upon the presence of nerve growth factor (NGF). Deprivation of NGF leads to
11
introduction
the destabilisation of latency in primary sympathetic and sensory neurones in culture 
(Wilcox and Johnson, 1988; Wilcox et al., 1990). In addition in vivo, the severing of 
sensory neurones prevents the transport of NGF to the neural cell body and results in 
reactivation (Carton and Kilbourne, 1952).
Transcription of the HSV genome during the latent phase is restricted to the latency 
associated transcripts (LATs), which were identified in murine, rabbit and human latently 
infected sensory ganglia by in situ hybridization (Stevens et a l., 1987; Rock et al., 1988; 
Croen et al., 1988; Stevens et al., 1988). LATs are located in the long repeat region of the 
HSV1 genome and are therefore present in two copies per genome. LATs initiate 3' to the 
IE1 gene and are antisense to the IE1 transcripts. The primary LAT transcript is 8.3 kb 
which gives rise to a family of LAT RNAs, including very stable ones of 2 and 1.5 kb 
(Croen et al., 1987; Gordon et al., 1988; Rock et al., 1987; Spivack and Fraser, 1987). 
Sequence analysis of the LATs revealed that the predominant LAT species contains two 
putative ORFs, ORF1 and ORF2 (Wechsler et al., 1989). Despite the presence of these 
ORFs, no protein products from the predicted LAT ORFs have been detected (Spivack and 
Fraser, 1987; Wagner et al., 1988).
As LAT deficient viruses are capable of establishing, maintaining and reactivating from 
latency, it appears that LATs are not essential at any stage of the lytic cycle (Steiner et al., 
1989; Javier et al., 1988; Sederati et al., 1989). However LAT is important for efficient 
reactivation from sensory neurons, since LAT transcription-negative mutants have been 
shown to reactivate poorly by transplant or induced reactivation in the mouse (Block et a l, 
1990; Hill et a l ,  1990; Ho, and Mocarski, 1989; Javier et a l, 1988). The role of LAT in 
latent infection is still unclear.
A large number of induction procedures have been developed which reactivate latent HSV 
in vivo. Trauma to the ganglia or neurectomy prevents, or substantially reduces, the 
transport of NGF to the neural cell body, and leads to the reactivation of latent virus (Walz
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et al., 1974; Berger et al., 1990; Price and Schmitz, 1978). Reactivation can also be 
induced by physical or chemical traumas. In addition, manipulation of the host immune 
system by the administration of immunosupressive drugs (Openshaw et al., 1979; Hurd and 
Robinson, 1977), superinfection by bacteria (Stevens et al., 1975) and anaphylactic shock 
(Good and Campbell, 1948), all induce the reactivation of latent HSV.
Although comparatively little effort has been applied to investigation of latency for equine 
herpesviruses, compared to that for HSV, convincing evidence has accumulated which 
supports the concept that equine viruses survive as a result of sharing with other 
herpesviruses the ability to establish themselves latently in their natural host species. 
Epizootiological observations of diseases caused by EHV1 provides circumstantial 
evidence that stresses resulting from such influences as transport, other infections or 
vaccinations, mixing of horses from different herds together at sales or race meetings 
increase the likelihood of the occurrence of herpesviral disease (Bryans and Allen, 1989). 
Edington et al. (1985) and Browning (1988) presented the first experimental evidence that 
EHV1 could exist in a latent form and be reactivated following immunosuppression with 
dexamethazone and prednisolone. They found that after three months of initial infection, 
EHV 1 was recovered from six ponies in a group of eight within two weeks of corticosteroid 
treatment. No clinical signs of respiratory disease were detected after virus reactivation. 
The two animals from which virus failed to be recovered, showed a significant increase in 
complement fixing antibody suggesting that reactivation has gone undiagnosed at both the 
clinical and laboratory level (Mumford, 1985). Welch et al. (1992) found that ten weeks 
following an experimental infection of five ponies with EHV1 and EHV4, latent virus DNA 
could be detected by PCR using primers from the gB gene. Additionally virus was 
predominantly recovered from the lymphoid tissues of the respiratory tract by co­
cultivation. In addition, latent EHV 1 and EHV4 persisted at significant levels in PBL.
Slater et al. (1994) demonstrated that the trigeminal ganglion is a location for EHV 1 
latency and subsequent reactivation in experimentally infected horses. Four specific
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pathogen-free (SPF) ponies were infected intranasally with EHV 1. No virus was detected 
in clinical specimens by 10 days post-infection. Two months later a reactivating stimulus 
was administered to all ponies and virus was shed into the nasal mucus (for 10 days) which 
proved the presence of a latent infection. After a further 6 weeks, co-cultivation of 
explanted trigeminal ganglia from two out of the four ponies yielded cultures positive for 
infectious virus. Apart from the nasal epithelium, no infectious virus was recovered from 
any other tissue. PCR also confirmed the presence of virus DNA in the ganglia from six 
ponies. These data shows that EHV1 in common with other members of the 
alphaherpesvirus subfamily establishes latency in sensory ganglia from which virus can be 
reactivated. These observations suggested that a site of latency from which virus can 
reactivate is the trigeminal ganglion, which is epidemiologically important for reactivation 
because reactivated virus from it may be directly transferred to peripheral respiratory 
tissues from which transmission to susceptible hosts can occur.
Baxi et al. (1995) have investigated LATs of EHV1 in neural tissues obtained from SPF 
ponies that had been experimentally infected with EHV1. They labelled the EHV1 
genomic fragments and carried out in situ hybridization to RNA from latently infected 
trigeminal ganglia. Six positive neurones were observed among approximately 3000 
neurones examined (0.02%). Only one fragment , the BamHI E fragment (n.p. 108710- 
118620) yielded positive results in sections obtained from 2 out of 4 ponies. The BamHI E 
fragment contains EHV1 genes 64 (HSV1 homologue IE 175), 63 (HSV1 homologue 
IE110) and the 5' end of gene 62 (HSV1 homologue UL1). The use of subcloned probes 
from this fragment showed that the region around the 3' end of gene 63 is transcribed 
during latency. Nothern blots with riboprobes revealed that the LATs are transcribed from 
the strand opposite to gene 63 and localised to the neuronal nuclei. These findings 
demonstrated that (i) equine neurones are a cellular site of EHV1 latency; (ii) a very small 
proportion of neurones contained transcriptionally active EHV1 during latency; and (iii) at 
least one region of the EHV1 genome is transcriptionally active during latency (Baxi et a l,  
1995). These findings are consistent with those obtained for HSV1, PRV1 BHV1 and
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feline herpesvirus type 1 (FHV1), where latency transcripts mapping antisense to 
immediate early genes have been demonstrated in sensory ganglia.
Sequence analysis of the EHV 1 BamHI E fragment has showed that the region located 
approximately 700 bp from the 3' end of gene 63 has a RNA polymerase II transcription 
site and is similar to HSV1 LAT, including a TATA box, CAAT box, SP1 -binding site and 
LPBF region. The putative EHV1 LPBF (CCAGCTGG) differed from the HSV1 LPBF 
only in the interchange of two central bases in the palindromic sequences, where GC is in 
the EHV 1 promoter region, instead of CG (Zwaagstra et a l, 1991; Baxi at al, 1995). Since 
deletion of the HSV LPBF causes a decrease in promoter activity in the transcription of 
HSV1 LATs (Zwaagstra et al, 1991), it is speculated that the change observed in the EHV1 
genome may decrease the promoter activity for EHV1 LATs; it may also explain why a 
very low number of LAT-positive neurones were observed. At the moment the role of the 
EHV1 LATs in virus latency is unknown.
1.4. IMMUNE RESPONSE TO EHV1 INFECTION IN THE 
HORSE
Infection of horses by EHV 1 results in an immune response demonstrable by development 
of antibodies, a T cell response to viral antigens and development of resistance to 
reinfection (Bryans, 1969; Pachciarz and Bryans, 1976). The primary virus neutralizing 
antibody (SN) response to infection acquired by intranasal administration of virus is 
detectable eight to nine days later. Complement fixation antibody titres reach their highest 
level about three weeks after primary infection but are no longer detectable after 60 days. 
The SN antibody responses are more persistent and last for more than a year (Burrows and 
Goodridge, 1973). In addition to the development of specifically reactive immunoglobulins 
which are detectable in both serum and nasal secretions (Thompson, 1978), the occurrence 
of T cell responses to EHV1 infection can be demonstrated by viral antigen induced 
transformation of PBL (Pachciarz and Bryans, 1976) and development of delayed type 
hypersensitivity and immune lymphocyte cytotoxicity for virus infected cells (Bryans, 1969)
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in naturally or experimentally infected horses. Resistance to reinfection of the respiratory 
tract is of short duration and immunologically experienced horses may be reinfected 
repeatedly. Such reinfection may be accompanied by cell-associated viraemia and may result 
in abortion or neurological disease (Bryans, 1969). The virological and immunological 
(antibody response) measurements illustrate that immunity to reinfection of horses by the 
same virus which produced a previous infection lasts for as short a period of time as 3 
months.
1.5. STRUCTURE OF THE EHV1 VIRION
The EHV1 virion is morphologically indistinguishable from other members of the 
herpesvirinae. The virion is approximately 150-170 nm in size and is composed of four 
major subvirion components: the envelope, tegument, capsid and core (Plummer and 
Waterson, 1963; Abodeely et al., 1970; Darlingon and Moss, 1968; O'Callaghan and 
Randall, 1976).
Abodeely et a l  (1970) found, using comparative electron microscopy, that EHV1 capsids 
are approximately 100 nm in diameter and contain a linear double stranded DNA molecule. 
The morphologically distinctive herpesvirus capsid contains 162 capsomers. 12 capsomers 
are ‘pentons’ and 150 capsomers are ‘hexons’ which show 5:3:1 axial symmetry (Wildy et 
a l, 1960; McCombs et a l ,  1971). Depending on their positions on the surface lattice the 
hexons are classified into three P, E and C (Stevens et a l, 1986). Perdue et a l  (1975) 
found that three distinct species of EHV1 nucleocapsids were isolated from infected mouse 
fibroblast (L-M) cell nuclei which were classified on the basis of their densities in 
Renografin gradients as Light (L), Intermediate (I) and Heavy (H). These capsids 
comprised six major proteins (I, II, III, IVa and V) and several minor proteins, each 
comprising less than 1% of the total nucleocapsid protein. Analysis of the DNA content of 
the three nucleocapsid species indicated that preparations of H nucleocapsids contain more 
DNA than do those of the I and L nucleocapsids species. L and I nucleocapsids lack a 
dense inner core structure characteristic of the H species ( Perdue et a l ,  1975). Using
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biochem ical assays, Newcomb et a l,  (1989) demonstrated that neither L nor I 
nucleocapsids contained any significant amounts of DNA.
The capsid is surrounded by an amorphous asymmetrical material designated the tegument 
(Roizman & Furlong, 1974). Several EHV1 proteins have been tentatively assigned to this 
structure (O'Callaghan et a l, 1983; Turtinen, 1983; Allen and Bryans, 1986). The final 
outermost component is the viral membrane or envelope, which is probably derived from 
the host cell nuclear membranes (O’Callaghan and Randall, 1976; Darlington and Moss, 
1968). In herpesviruses, this triple layered structure includes viral glycoprotein spikes 
projecting from the surface (Manservigief a l, 1977; Sarmiento et a l, 1979; Noble et a l,  
1983; Buckm aster et a l ,  1984; Spear, 1993a; 1993b). Six major and six minor 
glycoproteins have been identified in the envelope of EHV1 (Turtinen and Allen, 1982; 
Turtinen, 1983; Allen and Bryans, 1986). The six major glycoproteins are between 240,000 
and 40,000 in molecular weight, and are designated gp2, 10, 13, 14, 17/18 and 22a based on 
the original nomenclature of O'Callaghan and Randall, (1976). Furthermore, gpl3, gpl4, 
and gp 17/18 mapped to positions collinear with HSV glycoproteins B, C, and D (Allen and 
Yeargan, 1987; Allen and Coogle, 1988; Whittaker et a l, 1992b). gp2 (gp300 or gene 71 
protein) has been characterised as an O-linked class I membrane glycoprotein (Whittaker et 
a l, 1990, 1992a) encoded by EHV1 gene 71 (Sun et a l, 1994) which is non-essential for 
virus growth in vitro. (Sun and Brown, 1994). Sequence analysis has predicted that EHV1 
encodes at least 12 membrane-associated glycoproteins which are counterparts of HSV1 
glycoproteins gB, gC, gD, gE, gG, gH, gl, gK, gL, gM, gN and UL20 protein (Telford et 
a l,  1992). Alphaherpesvirus membrane proteins play an important role in virus entry into 
cells, egress from cells and transmission from cell to cell (Manservigi et a l,  1977; 
Sarmiento et al., 1979; Noble eta l., 1983; Buckmaster, 1984; Spear 1993a, b). They also 
play important roles in interaction with the host immune system and in determination of 
viral pathogenicity (Powell ., 1979; Bishop e ta l., 1983; 1984).
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1.6. THE EHV1 GENOME
The EHV1 genome is a large, linear double-stranded DNA molecule. It contains 150,223 
bp and the G+C content is 56.7% (Telford et al., 1992). Analysis of the complete DNA 
sequence, electron microscopy and restriction endonuclease mapping have demonstrated 
that EHV1 consists of two covalently linked components, referred to as the long (L) and 
short (S) segments (Whalley et al., 1981; Henry et a l,  1981; Ruyechan et al., 1982; Telford 
et al., 1992). The S component comprises an unique sequence (U s) flanked by a large 
inverted repeat (IRS/TRS). The L component consists of an unique sequence (U l)  flanked 
by a small inverted repeat ( IR l/T R l). The sizes of these components are: Us , 11,861 bp; 
TRs/IRs, 12,714 bp; U l ,  112,870 bp; IR l/T R l,32 bp. The S region inverts leading to the 
presence of two equal molecular isomers in EHV1 virion DNA which differ in the 
orientations of Us as indicated by the existence in certain restriction endonuclease 
digestions of three terminal fragments (2 0.5M and 1 1M) and two 0.5 M joint fragments 
(Henry et al., 1981; W haPeyet al., 1981). Based on the arrangement of reiterated sequences 
of genomes, herpesviridiae fall into 5 classes (A to E). The viral DNA of group D is 
characterized by having two unique regions ( U l  and Us) with Us being flanked by inverted 
repeats (IRS and TRs) which allow inversion of Us, giving rise to 2 isomeric forms. EHV1 
belongs to this group (Figure 1) (Chowdhury et al., 1990; Yalamanchili and O'Callaghan,
1990).
DNA sequence analysis identified a high percentage of the genome as having protein 
coding potential which is tightly packed and is present almost equally on both DNA 
strands. A total of 83 open reading frames (ORFs) with the potential to encode 76 distinct 
polypeptides were initially identified within the genome ( Figure 2). Sixty three genes, 1 - 
63 are located within the Up region and nine genes (68-76) within Us- Genes 64-67 are in 
the IRS/TRS repeat sequences and therefore are represented twice (Telford et al., 1992). A 
feature of the EHV 1 genome is that several transcription units overlap and share a common 
polyadenylation site with transcribed mRNAs of different lengths. A similar feature is also 
found in the HSV1 genome (McGeoch e ta l., 1985). ORFs 44 and 47 are homologous to
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Figure 1. EHVI genome arrangement and isomers.
The horizontal lines represent EHV1 unique sequences (U l and Us) and filled rectangles 
represent EHV1 repeat sequences larger than lKbp in length (IRs and TRs). The arrows 
indicated the relative orientation of L and S segments in the isomers, (a) indicates repeat 
sequence with (a') its complement.
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Figure 2. Predicted EHV1 gene ORFs and gene arrangement.
The genome is shaded, the thinner and thicker portions denoting the unique regions (Ul  and 
Us) and inverted repeats (TRl , IRl , TRs , IRs ), respectively. The scale is in kbp. Protein- 
coding regions are shown as open arrows with gene nomenclature below. ORF 35.5 is shown 
by a thinner arrow to reveal the region of overlap with ORF 35. ORFs 44 and 47, represented 
as filled arrows, are probably expressed as a spliced mRNA. Vertical arrows indicate 
candidate polyadenylation sites in the appropriate strand. The locations of reiterations (■) and 
candidate origins of DNA replication (□) are indicated above the genome.
It is published by Telford et al., 1992.
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the two exons of the HSV1 gene UL15, which is expressed as a spliced mRNA (Costa et 
al., 1985; Dolan et al., 1991), and are probably also expressed as a spliced mRNA to 
produce a single protein. A second ORF, gene 35.5 has been mapped within the gene 35 
ORF.
DNA hybridisation studies and DNA sequence analysis indicated that the EHV1 genes are 
closely colinear with their counterparts in HSV1 and VZV. The gene layout of EHV1 is 
very similar to that of HSV1 and VZV although UL is in the inverted orientation compared 
to HSV1 (Telford et al. 1992; Davison and Wilkie, 1983a). Only three EHV1 genes (genes 
1, 67 and 75) have no position and sequence counterparts in VZV and HSV1, while another 
five EHV1 genes (genes 2, 15, 59, 70, 71) lack significant sequence homology in VZV and 
HSV1 (Telford etal., 1992).
Most of the predicted EHV 1 gene products remain unidentified and their functions are not 
known. However, based on the complete DNA sequence data and present knowledge of 
HSV1, the properties or functions of EHV 1 proteins are predicted in table 1 (Telford et al., 
1992; Whalley etal., 1989; Allen and Coogle, 1988; Guo etal., 1989; Flowers et al., 1991; 
Whalley et al., 1991; Audonnet et al., 1990; Elton et al., 1991; Tutinen and Allen, 1982; 
Whittaker, et al., 1992a,b; McGowan et al., 1994; Jons et al., 1996). Among the known or 
putative EHV1 proteins, eight class I membrane proteins are encoded by EHV1 genes 33, 
16, 72, 74, 39, 73, 6 and 10, which have high homology with their counterparts (gB, gC, 
gD, gE, gG, gH, gl, gK and gN) in HSV1. These glycoproteins share three features in 
common. First, they are all predicted to have cleavable N-terminal signal sequences which 
include a particularly hydrophobic amino acid region of around 10 residues and one or 
more residues with charged side chains between the N-terminus and the hydrophobic 
region. Second, these proteins all have hydrophobic regions near their C-terminus which 
are predicted to serve as membrane spanning domains. Third, these proteins are all 
glycoproteins and have potential sites for the addition of N-linked oligosaccharides (Spear, 
1984). One additional EHV1 gene 71 was also predicted to encode a class I membrane
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C h a r a c t e r i s t i c s  o f  EHV- i P r o t e i n s
!e n e Starr* S tO P J C o d o n s M r VZV counterpart* HSV-1 counterparr' P r o o e m e s  or functions  of HSV - 1 proteins'*
1 1 .298 1 .906 2 0 2 2 1 .6 7 1 _ _
2 2 . 5 6 2 1 .945 2 0 5 2 3 . 3 9 8 1(261 —
3 2 .341 3 . 6 1 4 2 5 7 2 8 .0 2 1 2(163) —
4 4 , 2 4 9 3 . 6 4 7 2 0 0 2 2 . 3 7 9 3(263) U L 5 5 0 8 1 )
5 5 . 8 7 4 4 . 4 6 2 4 7 0 5 1 . 3 1 8 4 (436 ) U L 54 (6 7 7 ) Transcriptional activator
5 7 .0 4 2 6 .0 1 1 3 4 3 3 8 . 0 4 2 5(665) U 1 5 3 ( 5 4 4 ) M e m o r a n e  g lycoprote in
7 10.301 7 , 0 5 5 1081 1 1 8 . 9 5 6 6 (1 9 2 1 ) U L 5 2 0 9 1 2 ) DNA h e i i c a s e / p n m a s e  c o m p le x
8 1 0 .2 0 0 1 1 . 0 3 7 2 4 5 2 6 . 3 6 4 7(453) UL5 1(369)
9 12 .115 1 1 . 1 3 5 3 2 6 3 5 . 2 0 7 8(292) U L 50(299) O e o x y u n d m e  m p n o s p n a t a s e
I!3 1 2 .0 8 4 1 2 .3 8 6 100 10 .301 9A( 113) U L 4 9 A (3 8 | P oss iO le  tr a n s m e m o r a n e  protein
11 1 2 .549 1 3 . 4 6 3 3 0 4 3 3 . 2 3 9 9 (257) U L 49(281) T e g u m e n t  protein
1'I 13 .505 1 4 . 9 4 4 4 7 9 5 3 . 6 4 4 10(838) U I 4 8 ( 5 3 1 ) T e g u m e n t  protein
i:3 1 5 .3 1 7 1 7 . 9 3 2 87 1 9 6 . 9 6 5 11(397) U L 47(230) T e g u m e n t  protein
i *■i 18 .083 2 0 . 3 2 6 7 4 7 3 2 . 3 0 5 12(987) U L 46 (5 0 2 )
if 2 1 . K 6 2 0 . 4 8 7 2 1 9 2 3 . 7 9 8 — U L 4 5 (4 6 | Vm on protem
it 22 .351 2 1 . 4 4 5 4 6 8 5 0 . 8 8 7 14(3651 U L 44(108) M e m o r a n e  g r ycooro tem  (gC)
t? 2 4 . 2 3 4 2 3 . 0 2 9 401 4 3 . 2 0 3 15(153) U L 4 3 (4 5 i Multioty n y c r o o n o o ic  protein
!E1 2 5 .5 9 6 2 4 . 4 7 9 4 0 5 4 5 . 0 8 4 16(185) U L 42(101) CNA p o ly m e r a s e  p ro cess iv i ty  factor
19l 2 5 .2 5 2 2 7 . 7 5 5 4 9 7 5 6 . 5 4 0 17(876) U L 4 K 7 0 6 ) H o s t  snutorf vm on protem
20( 2 9 .3 5 9 2 7 . 8 9 4 321 3 6 . 0 1 5 1 8 (1053) U L 40(899) R ib o n u c le o t id e  r e c u c t a s e  (RR2)
21 3 1 .2 7 6 2 8 . 9 0 4 7 9 0 8 8 . 3 9 4 19(1992) UL39( 1600) R ib o n u c leo t id e  r e o u c t a s e  (RRi)
22 3 2 .9 1 6 3 1 . 5 1 9 4 6 5 5 1 . 3 0 4 2 0 (8 0 9 ) U L 33(762) C a o s i d  protem
23 3 3 .2 9 2 3 6 . 3 5 4 10 2 0 1 1 1 .5 0 5 2 1 (1 3 1 4 ) UL37(I  7 33 )
2J 2 6 . 5 3 8 4 6 . 8 5 3 3 4 2 1 3 6 7 . 0 6 1 2 2 ( 2 2 4 3 ) U L 3 6 (2 3 2 5 ) T e g u m e n t  protem
25 47 .311 4 6 . 9 5 2 1 19 1 3 .5 9 6 23(1 14) U L 3 5 {7 2 | C a o s i d  protem
25 4 8 . 2 2 0 4 7 . 4 0 3 2 7 5 3 0 . 6 7 9 2 4 (6 2 0 ) U L 34(555) P o s s i o i e  v m c n  protem
17 4 8 . 8 5 7 4 8 . 2 6 9 162 1 7 .9 9 3 2 5 (2 3 1 ) U L 3 3 (2 5 4 )
23 4 8 . 7 6 3 5 0 . 6 2 5 6 2 0 6 7 . 2 9 7 2 6 (1 4 9 9 ) UL32(  1 393) P r o c a o le  ' /m en protem
;9 5 0 ,5 1 8 5 1 . 5 9 8 3 2 6 3 6 . 5 2 4 2 7 (1 9 8 ) UL3 K 852)
:o 5 5 . 1 8 4 5 1 . 5 2 2 12 2 0 1 3 5 . 9 4 9 2 8 (3 1 3 0 ) U L 3 0 (3 4 3 2 ! DN A  p o ly m e r a s e
!l 5 5 . 4 5 3 5 9 . 0 8 2 1 2 0 9 1 2 9 . 9 7 6 2 9 ( 3 2 3 3 ) U L 2 9 (2 3 5 2 ) s s O N A  O m cm g protem
■p 5 9 .2 4 3 5 1 . 5 7 0 7 7 5 3 5 . 3 0 8 3 0 (1 9 2 7 ) UL28( 18 0 4 ) P r c o a o ie  v m o n  protem
:3 5 1 . 4 3 2 5 4 , 3 7 4 9 8 0 1 0 9 . 3 0 0 3 1 (1 9 8 0 ) U L 2 7 (2 0 2 0 ) M e m o r a n e  grycooro tem  (gB)
4 5 4 . 5 7 8 6 5 . 0 6 0 160 1 7 .3 0 5 3 2 (1 5 8 ) —
5 5 7 . 0 9 3 6 5 . 153 6 4 6 6 3 . 5 7 5 3 3 (7 8 5 ) U L 26(790) P r o t e a s e
S. . 5 6 . 142 6 5 . 1 5 3 3 2 9 3 4 . 6 7 9 3 3 .5 (861 U L 2 5 . 5 ( 2 15) C a o s i d  a s s e m o f y  protem
5 5 3 .9 7 5 6 7 . 2 1 2 5 8 7 6 3 . 6 8 9 34(1 138) U L 2 5 0  2 5 5 ) Vmon protem
7 6 9 . 8 9 7 6 9 . 0 7 9 2 7 2 2 9 . 1 8 6 3 5 (4 3 8 ) U L 24(380)
a 6 9 . 9 1 0 7 0 . 9 6 8 3 5 2 3 8 . 7 4 8 3 6 (6 0 4 ) U L 23(590) T hym id ine  k m a s e
3 7 1 .1 9 2 7 3 . 7 3 8 8 4 8 9 2 . 3 3 7 ' 3 7 (8 8 9 ) U L 22 (4 5 4 ) M e m o r a n e  g fy co p ro te m  (gH)
3 7 5 .2 2 4 7 4 . 6 3 2 5 3 0 5 7 . 9 1 2 3 8 (7 7 7 ) U L 2M 482)
76 .7 9 3 7 7 , 5 1 2 2 3 9 2 5 . 5 3 4 3 9 (3 3 4 ) U I 2 9 ( 1 2 3 ) Muitioiy n y d ro p n o c ic  protem
7
7 7 .7 0 3 8 1 . 3 3 3 13 7 6 1 5 2 . 1 7 5 4 0 ( 3 9 3 5 ) UL 1 9 (4074) Maior c a o s i d  protem",
3 2 .0 8 3 8 3 . 0 2 7 3 1 4 3 3 . 3 4 0 4 1 (9 5 5 ) UL 18 (7 2 4 ) C a o s i d  protem
IJ 8 4 , 3 1 9 8 3 . 1 4 8 7 3 4 3 1 . 0 7 4 4 5 / 4 2 ( 2 2 2 2 ) UL 1 5 (2 0 1 6 ) P o s s ib l e  0 N A  p a c x a g m g  protem* 1
/ 8 8 . 9 1 7 8 7 . 8 8 5
i 3 4 .4 8 0 8 6 . 5 0 0 7 0 6 7 6 . 3 1 6 4 3 ( 1 0 3 0 ) UL! 7 ( 1 0 0 5 )
i 3 6 .5 2 0 8 7 . 7 2 2 3 7 0 4 0 . 8 0 0 4 4 (7 3 9 ) UL 1 6 ( 4 9 1)
3 8 .9 4 7 8 9 . 9 0 0 3 1 7 3 5 . 3 1 4 4 6 (3 1 0 ) UL 14(21 1)
8 9 .2 6 9 9 1 . 1 5 3 5 9 4 6 5 . 2 4 4 4 7 (7 8 7 ) UL 13(638) Virion protem x m a s e
9 1 .3 0 5 9 2 .3 3 1 5 0 8 5 5 . 0 6 4 4 8 (7 3 5 ) UL 12(793) D e o x y r ib o n u c le a s e
9 2 .7 8 3 9 3 . 0 0 7 7 4 3 . 4 0 8 4 9 (4 7 ) U L 1 1 (4 3 | M yn sty ia te d  vmon protem
94.471 9 3 . 1 1 9 4 5 0 4 9 2 1 8 5 0 (6 0 7 ) UL 1 0 (4 9 3 ) . Multiply h y d ro o n o o ic  protem
9 4 .3 8 9 9 7 . 0 5 2 8 8 7 9 7 . 2 7 0 5 1 (1 9 3 3 ) U L 9 0  5 3 7 ) C n -o m d in g  protem
9 7 .1 7 3 9 9 . 3 2 3 7 1 6 7 7 . 7 6 9 5 2 (8 9 8 ) U L3(532) D NA h e i i c a s e / p n m a s e  c o m p le x
100.331 9 9 . 4 2 0 3 0 3 3 3 . 3 5 2 5 3 (5 3 6 ) UL 7(376)
TABLE 1 —Continued
Gene Start* Stop® C o d o n s Mr VZV counterpart* HSV-1 counterpart* Propertie s  or f u n c t io n s  of HSV-1 proteins®
56 1 0 2 . 3 9 0 1 0 0 . 1 2 9 7 5 3 8 3 . 9 8 8 5 4 (1 6 6 5 ) U L 6 0 0 6 5 ) P o s s ib le  virion protein
57 1 0 2 . 3 7 4 1 0 5 . 0 1 9 881 9 9 . 4 4 8 55 (2 8 7 7 ) U L 5(2321) D NA h e l ic a s e /p r im a s e  c o m p le x
58 1 0 5 . 0 6 9 1 0 5 . 7 4 6 2 2 5 2 4 . 2 8 6 56(586) UL4(376)
59 1 0 6 . 4 1 5 1 0 5 . 8 7 6 17 9 1 9 .4 5 1 57(24) —
60 1 0 7 , 1 1 5 1 0 6 . 4 7 7 2 1 2 2 3 .6 8 1 58(532) UL3(432)
61 1 0 8 . 1 4 3 1 0 7 , 2 0 5 3 1 2 3 4 . 7 7 6 59(755) UL2(757) Uracil -DNA g ly c o s y l a s e
62 1 0 8 . 8 0 2 1 0 8 . 1 4 6 2 1 8 2 4 . 4 2 4 60(151) U L1(109) M em b r a n e  g lycoprote in  (gL)
63 1 1 1 . 9 8 4 1 1 0 . 3 8 6 5 3 2 5 8 , 6 2 7 61(259) IE 1 1 0 (1 4 0 ) Transcriptional act ivator
64 1 1 8 , 5 9 0 1 1 4 , 1 2 7 1 4 8 7 1 5 4 . 8 5 9 6 2 (1 6 8 7 ) IE17 5 ( 1 4 8 6 ) Transcriptional activator
65 1 2 1 . 3 6 7 1 2 2 , 2 4 8 2 9 3 3 2 , 1 1 5 6 3(323) US 1 (103) In vitro h o s t - r a n g e  factor
66 1 2 2 .8 6 1 1 2 3 ,5 7 1 2 3 6 2 5 , 0 3 2 6 4(146) US 1 0 (129) Virion protein
67 1 2 5 . 1 9 3 1 2 4 , 3 7 5 2 7 2 3 0 ,1 0 1 — —
68 1 2 6 . 2 7 4 1 2 5 . 0 1 8 4 1 8 4 6 . 7 8 6 — U S 2 (3 0 1 )
69 1 2 6 . 4 1 0 1 2 7 . 5 5 8 3 8 2 4 2 .5 4 1 66(522 ) U S 3 ( 4 18) Protem k in ase
70 1 2 7 . 6 8 0 1 2 8 . 9 1 5 411 4 5 . 2 6 7 — U S 4(25] M em b r a n e  g lycoprote in  (gG)
71 1 2 9 . 0 9 6 1 3 1 , 4 8 9 7 9 7 8 0 . 3 3 8 — U S 5[24] M em o r a n e  g lycoprote in
72 1 3 1 . 4 3 2 1 3 2 . 7 9 0 4 5 2 5 1 . 0 9 7 — U S 6 [ 6 1) M em b r a n e  g lycoprote in  (gD)
73 1 3 2 . 8 9 8 1 3 4 . 1 7 2 4 2 4 4 6 . 3 9 0 6 7(228) US7(  177) M em b r a n e  g ly coprote in  (gl)
74 1 3 4 . 4 0 5 1 3 6 . 0 5 7 5 5 0 6 1 , 1 8 0 68(220 ) U S 8 0  96) M em b r a n e  g lycoprote in  (gE)
75 1 3 6 . 0 5 4 1 3 6 . 4 4 6 1 3 0 1 4 . 8 5 4 — —
76 1 3 6 . 7 8 2 1 3 7 .4 4 1 2 1 9 2 2 . 4 1 7 6 5 (74 ) U S 9 ( 1 10) T e g u m e n t  protem
* Location of first b a s e  or its c o m p l e m e n t  in first ATG. e x c e p t  for ORF 4 4 ,  w n e r e  first b a s e  in e x o n  is given.
6 Location of third b a s e  or its c o m p l e m e n t  in s to p  c o d o n ,  e x c e p t  for ORF 4 7 .  w n e r e  last b a s e  in e x o n  is g iven.
c Positional c o u n t e r p a n s  are  lis ted r e g a r d le s s  of th e  d e g r e e  ol am ino  a c id  s e a u e n c e  c o n s er v a t io n .  G e n e s  lacking posit ional c o u n t e r p a n s  are 
indicated by h y p n e n s .  F as tA  s c o r e s  g r ea ter  th an  100 are  s h o w n  m p a r e n t h e s e s  and t h o s e  l e s s  th an  10 0  are s h o w n  in s a u a r e  brackets .
a G e n e  fu n ct ion s  are der ived  from M c G e o c h  (1 9 8 9 )  a n d  D av ison  ( 1 9 9 1b). with addit ional data  for th e  following H SV-i  g e n e s :  UL53.  D e b r o y e :  
al. (1985),  R a m a s w a m y  a n d  Holland (1992) ;  UL49.  Elliott and Meredith (1992) .  UL47.  M c L e a n  et al. (1990);  UL45.  H. M a rs d en  (persona!  
communication); UL42.  Gott lieb et al. (1990) ;  UL35.  M. D av ison .  A. D av ison ,  and F. Rixon. u n p u b l i s h ed  data.  UL26.  Liu and R oizm an (1 991b).  
Preston et al. (1992):  U L 2 6 .5 .  Rixon et al. (1988) .  Liu a n d  Roizman (1 9 9 1  a): UL15.  D a v is o n  (1992) :  UL13.  C u n n in g h a m  et al. (1992);  UL1. 
Hutchinson et al. (1992) .
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protein. Gene 71 is related to HSV1 US5 in location (McGeoch et al., 1985b), but there is 
no amino acid similarity between their protein products. This gene is predicted to encode a 
polypeptide which possesses a single asparagine-linked glycosylation site and hydrophobic 
amino-and carboxy-terminal domains. It also contains an extensive region encoding a high 
proportion of serine and threonine residues. The region between residues 22 and 465 is 
composed of 87% serine and threonine residues and likely to be heavily O-glycosylated 
(Telford et a l, 1992). EHV1 genes 17, 41 and 52 are predicted to encode respectively, 
three multiple hydrophobic membrane glycoproteins, counterparts of HSV1 genes UL43, 
the UL20 and UL10 (Telford et al., 1992). gM encoded by EHV1 gene 52 has been 
identified as a 58 KD protein, present both in infected cells and virions (Pilling et al, 
1994). EHV1 gene 62 is also predicted to encode a glycoprotein (Telford et al., 1992), the 
counterpart of HSV 1 gL (Hutchinson et a l., 1992a).
A number of EHV1 glycoproteins which include the counterparts of HSV1 gB, gH, gL, gl 
and gE may form functionally multimeric assemblies. It has been found that the HSV 1 gB 
counterpart forms homodimers or possibly homotrimers on virion and cell membranes 
(Claesson-Welsh and Spear, 1986). EHV1 gB has also been demonstrated to form a dimer 
in infected cells (Sullivan et al., 1989); HSV1 gH and gL form a functional 
heteromultimeric unit (Hutchinson et al., 1992a; Roop et al., 1993) and coexpression of gL 
is essential for appearance of the processed form of gH on the cytoplasmic membrane 
(Hutchinson et al., 1992a). A similar interaction has also been found for EHV 1 gL and gH 
(Stokes et al., 1996; Sun et a l ,unpublished data) as well as for HCMV, HHV6, EBV and 
PRV (Kaye e ta l ,  1992; Liu e ta l., 1993; Yaswen et al., 1993; Klupp etal., 1994). HSV1 
gC, gl and gE are believed to modulate the immune response to infection; gC acts as a C3b 
receptor (Eisenberg et al., 1987; Friedman et al., 1984; McNearney et al., 1987); gE and gl 
form a complex to function together as a Fc receptor, gE binds to the Fc region of IgG and 
this Fc-binding activity can be modulated by the presence of gl (Baucke and Spear, 1979; 
Frank and Friedman, 1989; Johnson et al., 1988b). EHV1 genes 16, 73 and 74 also encode
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gC, gl and gE homologues of HSV1, respectively, but whether EHV1 gC, gl and gE have
the same functions as their HSV 1 counterparts is not known.
EHV 1 gC was also reported as a complement receptor (Huemer et al 1995).
1.7. THE EHV1 LYTIC CYCLE
The replication cycle of EHV 1 has been studied in L-M cells.
In the hamster model EHV 1 causes a consistently reproducible lethal
hepatitis and virus is released into the blood in large amounts. All animals die
withlO^Pfu/animal
approximately 72 hours post inoculatiorj, and more than 95% of the hepatic parenchyma 
cells show typical intranuclear inclusions (Bracken and Randell, 1957; Gentry et al., 1960; 
O'Callaghan et al., 1972). In the mouse model, by 2 days after intranasal inoculation, the 
mice begin to show abnormal signs and by day 3 all mice are hunched with ruffled fur and 
a conspicuous weight reduction. Some mice showed signs suggesting a mild neurological 
involvement. The mice die from the fourth to the seventh day after inoculation. 
Approximately 50% of animals recover from the infection and become clinically normal by 
day 10. Virus is consistently isolated from the nasal tissues, trachea and lungs from all 
mice tested during the first week after inoculation and occasionally isolated from the CNS, 
eye and liver. Virus titres reach a peak at 3 to 5 days after inoculation, coincident with the 
time of maximum clinical signs. The virus in lungs and turbinate bones is cleared by day 
12 after inoculation (Awan et al. 1990). The maximum virus titre was obtained from EHV1 
infected monolayers of L-M cells at 18-24 hours post infection and 95% of the infectious 
virus is released from infected L-M cells (O'Callaghan et al. , 1978, 1983).
1.7.1. Initial steps in EHV1 infection
Virus infections are initiated through specific interactions between viral attachment proteins 
and their receptors on the surfaces of permissive cells. Entry of herpesviruses into cells 
appears to be a complex process involving numerous viral components, principally 
envelope g lycoproteins, and more than a single cell surface receptor. For 
alphaherpesviruses the initial interaction between viral attachment proteins and cellular 
receptors is followed by virus penetration through the host membrane, involving membrane
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fusion which causes the viral nucleocapsid and tegument proteins to be delivered into the 
cytoplasm. These two steps constitute the virus entry process.
It is now known that for most cell types, initial attachment of alphaherpesviruses to 
permissive cells is mediated by an interaction of a member of the gC family with cellular 
glycosaminoglycans, predominately heparin sulphate (HS) proteoglycans (Spear et a l, 
1992; WuDunn and Spear, 1989). WuDunn and Spear (1989) demonstrated that the initial 
interaction between HSV and the cell membrane is binding to the cell surface receptors (HS 
moieties). Agents which block this interaction or enzymatic digestion of HS effectively 
prevent viral adsorption and subsequent penetration. Virions devoid of gC are impaired in 
the ability to bind to cells, but nevertheless infect cells, albeit inefficiently (Cai 1988; 
Herold et al., 1991). It seems likely, therefore, that there is another heparin binding 
glycoprotein to mediate the binding of the mutant to cells. Early studies using antibodies 
(Dubuisson et a l, 1992; Fuller and Spear, 1985; Johnson et al., 1990), cell membrane 
fractionation (Kuhn, et al., 1990), and virosomes (Johnson et al., 1984) suggested that gB 
and gD m olecules are also involved in the virus attachment process. The HSV1 
glycoprotein gB has been found to bind to HS under physiological conditions (Herold et al.,
1991). gB of pseudorabies virus (PrV) can also bind heparin coated beads; however, it does 
so only in conjunction with gC (Mettenleiter et al., 1990; Sawitzky et al., 1991). HSV1 
gD has been shown to bind to a limited number of specific cellular receptors (Johnson et 
al., 1990; Johnson and Ligas, 1988a). Brunetti et al., (1994) have shown that HSV gD 
binds to mannose-6-phosphate receptors, although the relevance of the gD-mannose-6- 
phosphate receptor interaction in virus infection has yet to be established. That gD acts as a 
receptor-binding protein is further supported by observations that cells expressing gD are 
resistant to infection with HSV (Campadelli-Fiume et al., 1988; Johnson, and Spear, 1989). 
Liang, et al. (1991) showed that affinity-purified bovine herpesvirus 1 (BHV-1) gB, gC and 
gD could inhibit virus attachment at 4°C and that gC inhibited not only wild-type (wt) 
BHV-1 but also a gC-negative mutant to a lower degree. Glycoproteins gB and gD 
inhibited wt and gC negative viruses to the same extent, which suggested that BHV-1
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attachment is a complex event in that the wt virus uses gC to carry out the initial interaction 
with cellular receptors, which is followed by interactions of gB and/or gD with their 
receptors. Karger and Mettenleiter (1993) showed that the attachment of PRV and BHV-1 
to permissive cells can be divided into two stages, an initial heparin inhibition-sensitive 
stage and a subsequent heparin-resistant stage. By using isogenic viruses with individual 
viral proteins deleted, they found that although the wt virus and the gD-negative mutant 
have similar initial binding, the gD-negative mutant was considerably impaired in the 
heparin-resistant binding, suggesting that the initial attachment of PRV and BHV-1 to cells 
is via a gC-HS interaction, followed by a gD-mediated HS-independent attachment. A 
similar attachment mechanism has also been revealed for HSV (Fuller and Lee, 1992; 
McClain and Fuller, 1994). Overall the available data collectively suggest that attachment 
of alphaherpesviruses to most permissive cells is a complex event, involving at least gC and 
gB binding to cellular HS and gD binding to other, undefined cellular receptors.
After the adsorption of virus onto cells, the following step is virus penetration into cells. 
Herpesviruses penetration can be mediated by both the fusion of the viral envelope with the 
cell membrane (Morgan et al., 1968) and by phagocytosis whereby virions are engulfed at 
the surface and transported to the interior of the cells within a phagocytic vacuole 
(Hummeler et al., 1969; Dales and Silverberg, 1969). However, the predominant pathway 
for productive entry of HSV1 is by fusion at the cell membrane (Rosenthal et al., 1989). 
An electron microscopy study revealed that EHV 1 particles can enter cells by a viropexis 
mechanism in which particles are engaged by pseudopodia, forming fusion vacuoles 
containing from one to numerous viral particles (Abodeely et al., 1970). It has been found 
that the penetration of HSV KOS is 100 fold less likely to occur at a mildly acidic condition 
(pH 6.3) than at a physiological pH (pH 7.4) (Rosenthal et al, 1989). The relevant 
observations from electron microscopy studies have demonstrated that fusion predominates 
at pH 7.4 and endocytosis at pH 6.3.
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It is proposed that multiple interactions involving virion glycoproteins and cell surface 
components are required to trigger fusion of the virion envelope with the cell plasma 
membrane, following the initial binding of HSV1 to the cell surface (Spear, 1993 a). A 
receptor-antireceptor interaction may be required. At least three HSV1 envelope 
glycoproteins (gB, gD and gH) have been found to play essential roles in viral penetration 
(Cai et al., 1988; Desai et al., 1988; Ligas et al., 1988; Little et al., 1981). It has been 
demonstrated that neutralising monoclonal antibodies against gB, gD and gH individually 
block viral penetration, but have a negligible effect on viral adsorption (Fuller and Spear, 
1987; Highlander et al., 1987, 1988). The most compelling evidence for this conclusion 
comes from the characterisation of viral mutants with deletions of the relevant genes. For 
HSV1 and PRV, it is clear that gB (gll), gD (gp50) and gH are each required for viral 
penetration, but not for the initial binding of virus to the cell surface (Cai, et al., 1988; 
Ligas and Johnson, 1988; Forrester et al. 1992; Rauh and Mettenleiter, 1991a; Rauh et al. 
1991a,b; Peeters, 1992a,b). The evidence is that mutant virions devoid of each of the 
glycoproteins mentioned above are able to bind to cells at normal efficiency, but fail to 
penetrate. Polyethylene glycol, a membrane fusogen, can partially overcome the block to 
initiate infection.
Most members of the gB, gD and gH families encoded by herpesviruses are required for 
virus-induced cell fusion as well as for virion penetration (virion-cell fusion) (Cai et al. 
1988; Ligas and Johnson, 1988; Rauh and Mettenleiter, 1991b; Peeters, 1992a, b; Wilson et 
al., 1994; Roop et al., 1993). In addition, monoclonal antibodies specific for gB, gD and 
gH can inhibit HSV-induced cell fusion (Navarro e ta l., 1992; Noble et al., 1983; Minson et 
al., 1986). However, there is at least one exception, in that PRV gp50 (gD) is not required 
for cell fusion (Rauh and Mettenleiter, 1991b; Peeters et al., 1992b). This finding and 
others summarized by Spear (1993a) indicated that, although cell fusion and viral 
penetration both require virus-induced membrane fusion, these two processes are mediated 
and regulated somewhat differently.
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It is likely that members of other viral glycoprotein families are also required for HSV1 
penetration. Two of the principal HSV 1 candidates are gK and gL. gK is a membrane 
glycoprotein with potential membrane-spanning domains (Debroy et al., 1985; Pogue-Geile 
and Spear, 1987; Ramaswamy and Holland, 1992). It plays a role in controlling virus- 
induced cell fusion (Debroy et al., 1985; Pogue-Geile and Spear, 1987) and is an essential 
gene. gL was found to be essential for HSV replication in vitro (Hutchinson et al., 1992a, 
1992b) due to its requirement for appropriate processing and transport of gH. EHV1 gL 
also forms a complex with gH (Stokes et al., 1996; Sun et al., unpublished data). However, 
whether EHV1 gL and gH also play the same role as their counterparts in HSV1 is 
unknown. Osterrieder et al. (1996b) have found that a EHV 1 gene 52, gM, deletion mutant 
exhibits slower penetration kinetics compared with those of the parental EHV1 indicating 
that EHV 1 gM is involved in virus penetration.
It is possible that some tegument proteins may also participate in the molecular interactions 
required for viral penetration. A temperature-sensitive mutant of HSV1 maping to UL25 
which encodes a tegument protein (Addison et a l., 1984; Preston, 1990) was found to be 
impaired in penetration at the non-permissive temperature.
The precise roles of gB, gD and gH in viral penetration are not known. It is proposed that 
interactions of these proteins with other virion proteins and with cell surface components 
leads to fusion between the virion envelope and the cell plasma membrane. Members of the 
gB and gH families have been detected in all herpesviruses analyzed to date, with the 
conservation of amino acid sequence being considerably greater for gB than for gH. It 
has been shown that expression of BHV 1 gl (gB) can complement the defect of a gll (gB-) 
PRV mutant, but not the other way round (Rauh et al., 1991b) and coexpression of BHV1 
gB allows infectivity of a recombinant HSV that has been exposed to neutralizing anti-gB 
antibody (Misra and Blewett, 1991). This apparent conservation of the structure and 
function of members of the gB family is consistent with required interactions with 
conserved domains of other virion proteins or highly conserved cell surface receptors.
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It has been found that cells transformed to express a member of the gD family are resistant 
to infection by the homologous virus and, in most instances can be infected by a 
heterologous herpesvirus. Interference with viral infection is a property of all members of 
the gD family encoded by HSV 1, HSV2, PRV and BHV1 (Campadelli-Fiume et a l, 1988; 
Petrovskis et al., 1988; Johnson and Spear, 1989; Chase, et a l, 1990; Tikoo et al, 1990). 
For HSV, it has been established that resistance to infection is due to inability of virus to 
penetrate into the gD-expressing cells, not to failure of virus to bind to the cells 
(Campadelli-Fiume et a l ,  1988; Johnson and Spear, 1989). An understanding of the 
mechanism of interference could shed some light on the role of the members of gD family 
in penetration. There are some models to explain the mechanism. One is competition 
between the cell-associated glycoprotein and the virion-associated glycoprotein for a cell 
receptor needed for viral penetration (Campadelli-Fiume et a l, 1988; Johnson and Spear,
1989). Other models for gD-mediated interference suggest that cell-associated gD itself or 
some unidentified virion component inhibit penetration. With attention focused on the 
genetic determinants of viral sensitivity to interference, it has been shown that the structure 
of gD present in the virion is probably the principal determinant. Amino acid substitutions 
at position (25 or 27) of the mature form of gD can render the virus resistant to gD- 
mediated interference (Campadelli-Fiume e ta l ,  1990; Dean et al., 1994). In addition a 
mutant form of gD with a substitution at position 25 has been shown to lack interference 
activity (Campadelli-Fiume et al., 1990). Mutant virions carrying gD with substitution at 
position 27 have been shown to exhibit altered specific infectivity in comparison with wt 
virus, even on cells that do not express gD (Dean et a l, 1994), suggesting cell factors also 
play a role in governing interference. HSV 1 mutants that are totally resistant to 
interference on Hep-2 cells expressing HSV 1 gD are only partially resistant to 
interference on L cells expressing HSV 1 gD (Dean et al., 1994). Thus, it appears that 
determinants of interference include cell-associated and virion-associated gD (gp50, gIV), 
other virion proteins and cell components.
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1.7.2. Alteration of host macromolecular synthesis
The sequential expression of herpesvirus genes during lytic infection usually occurs against 
a declining background of host macromolecule metabolism (Roizman and Roane, 1964; 
Rakusanova et al., 1971). This inhibition of cellular DNA, RNA and protein synthesis, or 
"host shut-off" is a complex multistage process. The mechanisms involved are poorly 
understood. Most information about the process are from studies on HSV1. Host shut-off 
induced by HSV 1 can be divided into two phases: early and late host shut-off. The early 
host shut-off is seen in the presence of actinomycin (Fenwich and Walker, 1978) and can be 
induced by UV-irradiated HSV1 (Nishioka and Silverstein, 1977) indicating that a virion 
component is responsible for the phenomenon. This is known as virion host shut-off (vhs) 
and has been mapped to UL41 (Kwong et a l ., 1988, 1989). EHV1 also contains a 
counterpart gene of HSV1 UL41 (gene 19). However, whether it also functions as a vhs 
gene is unknown. During the early host shut-off cellular polyribosomes are disaggregated 
(Sydiskis and Roizman, 1967) and host mRNAs subsequently degraded (Schek and 
Bachenheimer, 1985). The early host shut-off is followed by late shut-off which is 
conditional upon the synthesis of viral RNA and proteins. This shut-off is responsible for 
the enhanced reduction of host protein synthesis and for a decrease in cellular DNA 
synthesis (Fenwick, 1984). However, the mechanism of this effect is still unclear.
Available information has shown that EHV 1 infection also causes inhibition of host DNA 
synthesis at an early stage of infection and eventually can shut off 95% of host DNA 
synthesis ( Randall and Walker, 1963; O'Callaghan et a l ,  1968a). At early times, EHV1 
inhibits dram atically cellular RNA synthesis in L-M and human carcinoma cells 
(O'Callaghan, et a l ,  1968b; Lawrence, 1971). It has been demonstrated that host cell 
replication is shut off a few hours after infection, but total protein synthesis initially 
continues at a linear rate which suggests a smooth transition from the synthesis of host 
protein to viral protein during the early stage of infection. However, the rate of total protein
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synthesis began to decrease between 5 and 6 hours after infection and progressively 
decreases during the course of infection (Caughman etal., 1985; Lawrence, et al., 1971).
1.7.3. Replication of viral DNA
EHVl DNA replication in EHV1 infected L-M cell is first detected 4-6 hours post-infection 
and is complete by 16-18 hours post-infection (O'Callaghan et al., 1968a, b). EHVl DNA 
replication has also been studied in Syrian hamsters where it begins at 3-4 hours post 
infection and increases until the animal dies at 12-14 hours post-inoculation (O'Callaghan et 
al., 1972). The mechanism of herpesvirus DNA replication is not fully understood. In 
HSV, electron microscopic analysis shows that DNA molecules circularise after infection 
(Friedman et al., 1977; Hirsch et al., 1977). This has been found to result in the direct 
ligation of the terminal 'a' sequence (Jacob and Roizman, 1977; Davison and Wilkie, 
1983b). At late times after the infection, large head to tail concatamers lacking termini 
appear which are hypothesised to be generated by a rolling circle mechanism (Jean and 
Ben-Porat, 1976; Jacob et al., 1979). The initial sites of viral DNA replication have been 
demonstrated to be virus specific structures located within the infected nucleus and which 
are induced by infection (Quinlan et al., 1984). These structures grow and coalesce as 
infection proceeds (Rixon eta l., 1983).
I.7.3.I. Origin of DNA replication
DNA sequence analysis of EHV 1 has shown that the genome contains three candidates for 
origins of DNA replication (oriL and 2 oriS; Telford et al., 1992). The first EHV 1 origin of 
replication (oriS) had been previously identified by analysis of EHVl defective interfering 
(DI) particles (Baumann et al., 1989). Since DI DNA must contain cis-acting DNA 
sequences, such as DNA replication origins, the conserved regions in the DI DNA were 
examined by plasmid based transfections. A 200 bp fragment within 0.83-0.85 map units 
was shown to contain an origin of replication activity. Sequence analysis indicated that this 
region has significant homology to HSV1 and VZV origins of DNA replication. It 
contains, adjacent to $n A+T rich palindrome, a 9-bp (CGTTCGCAC) sequence which is
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identical to that recognised by the origin-binding protein encoded by the HSV1 gene UL9 
(Elias and Lehman, 1988; Stow, 1992; Stow and Davison, 1986). As oriS is located in the 
short repeat region (IRs/TRs), the EHV1 genome contains two copies of oriS. A third 
EHV1 origin of replication (oriL) is located between genes 39 and 40, homologues of UL22 
and UL21 in HSV1. Sequence analysis showed that it also contained the 9-bp sequence 
(CGTTCGCAC), adjacent to an A+T rich palindrome, which is conserved in all human 
herpesvirus origins of replication (Telford et al., 1992; Robertson et al., 1991). It has not 
yet been demonstrated to function as an EHV1 DNA replication origin.
I.7.3.2. Gene products required for replication
During the course of HSV 1 infection, several virus specific gene products are involved in 
viral DNA replication. Some of them are associated with the virus particle and others have 
been identified in virus infected cells. A set of seven genes (UL5, UL8, UL9, UL29, UL30, 
UL42 and UL52) products were found to be both necessary and sufficient for origin 
dependent DNA replication (McGeoch et al., 1988a; Wu et al., 1988; Stow, 1992). The 
counterparts of these genes are also present in EHV1 genome, genes 57, 54, 53, 31, 30, 18 
and 7 (Telford et a l., 1992).
These gene products are the follows:
(1) A HSV1 encoded polymerase (Pol) has been demonstrated which is distinguishable 
from the host cell polymerase (Knopt, 1979; Haffey et al., 1990). This enzyme is encoded 
by UL30 (Quinn and McGeoch, 1985). A polypeptide encoded by UL 42 has been found to 
act as an accessory subunit of DNA polymerase (Gottlieb et a l., 1990). UL42 can increase 
the ability of Pol to synthesize longer DNA products (Gottlieb et al., 1990). The DNA 
polymerase has an intrinsic 3'-5' exonulease/RNase activity similar to E.coli Poll (Crute 
and Lehman, 1989a). Both UL30 and UL42 are essential for virus growth (Aron et al., 
1975; Marcy et al., 1990; Johnson et al., 1991).
E H V 1 genes 30 and 18 are homologues of UL30 and UL42. Allen et al, (1977) 
demonstrated that EHV 1 also induced a viral specific DNA polymerase which has different
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immunological specificity from the host enzyme and a high salt requirement for maximal 
activity. It is far more sensitive to phosphonoacetic acid (PAA) than the enzyme encoded 
by HSV1 (Honess and Watson, 1977; Allen et al., 1977).
(2) A HSV1 induced DNA-dependent ATPase has been identified( Crute et a l, 1988). 
Three products with Mr s of 130, 97 and 70 KD encoded by genes UL52, UL5 and UL8 
respectively have been identified in the purified complex which contains the activity (Crute 
et al., 1989b; McGeoch et al., 1988b). The UL52 and UL5 genes have been found to 
enable close co-ordination of the priming of the lagging strand DNA with unwinding of the 
replication fork. The UL8 protein is important for efficient nuclear uptake of the helicase- 
primase complex (Calder et al., 1992). However, the precise role which each subunit plays 
in these activities is unclear. The EHV 1 homologues are genes 7, 57 and 54, resepectively.
(3) The major HSV 1 DNA binding protein (mDBP) has been demonstrated to preferentially 
bind to single stranded DNA (Bayliss et al., 1975). This protein is encoded by HSV gene 
UL29. It has characteristics of a helix destablizing protein. It binds to ssDNA and 
enhances the denaturation of a polydeoxyadenylic acid-polydeoxythymidylic acid duplex 
(Ruyechan, 1983; Ruyechan and Weir, 1984). It is also likely that this protein specifically 
interacts with other replication proteins and plays a role in organising DNA replication 
proteins (de Bruyn Kops and Knipe, 1988; Bush et al., 1991). The EHV1 homologue is 
gene 31.
(4) A HSV 1 origin binding protein is encoded by gene UL9 which has been found to 
specifically bind to an origin of replication (Olivo et al., 1988). It has been demonstrated 
that UL9 also contains a helicase activity which is required for UL9 function (Stow, 1992). 
UL9 plays an essential role in DNA replication (Elias and Lehman, 1988; Weir and Stow,
1990). The EHV1 homologue is gene 53
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1.7.4. Transcriptional features of viral genes
Most of the knowledge concerning regulation of herpesvirus gene transcription and
expression has been obtained from studies of herpes simplex virus (HSV). It has been
found that HSV1 gene expression is a co-ordinately regulated and sequentially ordered
process in which at least three classes of viral gene products, termed alpha- ,beta- and
gamma- (Honess and Roizman, 1974, 1975) or immediate-early(IE), early (E) and late (L)
proteins (Clements et al., 1977) were defined on the basis of their temporal appearance
during the course of infection and the metabolic requirements for either de novo protein or
DNA synthesis. Transcription of the immediate early (IE) gene occurs without de novo
protein synthesis and is mediated by host RNA polymerase II (Mackem and Roizman,
1980, 1981; Costanzo et a l ,  1977). Initiation of early (E) genes expression requires one or
more functional IE polypeptides and occurs prior to and is independent from viral DNA
synthesis. Late (L) gene expression is dependent on or is dramatically enhanced by the
onset of viral DNA replication. Thus late proteins can be differentiated from IE and early
proteins on the basis of their reduced production in the absence of viral DNA replication
during infection. This "cascade" expression pattern of HSV1 genes is, however, more
complex than a simple 3-fold one (Wagner, 1985). The late genes can be subclassified into 
.either leaky-late, which requires 3 to 5 hours of protein synthesis before expression, or true- 
late which are also dependent on viral DNA replication (Weinheimer and McKnight, 1987; 
Jones and Roizman, 1979; Harris-Hamilton and Bacheheimer, 1985). In general, the IE 
genes code for transcriptional regulatory proteins, E genes are involved in DNA replication 
and L genes are structural and assembly proteins.
( Similar, although apparently not identical, patterns of temporal regulation have been 
demonstrated for several other herpesviruses such as HCMV (Blanton and Tevethia, 1981; 
Wathen and Stinski, 1982) and PRV (Ihara et a l, 1983). EHV1 gene expression has been 
found to be temporally regulated in a manner (IE, E and L) similar to that demonstrated for 
HSV (Caughman et a l, 1985; Cohen et al, 1975b; Gray eta l., 1987a, 1987b).
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I.7.4.I. Transactivation of Immediate Early Gene Expression by the EHY1 Gene 12 
product, homologue of HSV 1 Vmw65
Several experiments have shown that a virion component located outside the nucleocapsid 
is responsible for the regulation of HSV1 immediate early gene expression. Using a series 
of co-transfection experiments, Campbell et al., (1984) identified that this transactivating 
virion component was the major tegument protein, Vmw65 (also know as VP 16), which is 
essential for the assembly of progeny virions (Ace etal., 1988).
A consensus AT-rich cis-acting sequence, TAATGARATTC (R=purine) was shown to be 
responsible for mediating the responsiveness to transactivation by Vmw65 (Mackem & 
Roizman, 1982a,b,c; Cordingley et al., 1983). This consensus sequence was found to be 
present in the far upstream regions of all the HSV1 IE genes (Murchie & McGeoch 1982; 
Mackem & Roizaman, 1982a,b; Whitton & Clements, 1984). Vmw65 itself does not 
possess any intrinsic DNA binding activity, neither specifically for the TAATGARAT 
element nor non-specifically for double stranded DNA (Marsden et al., 1987, Preston et al., 
1988). However, studies of the interaction between Vmw65 and cellular proteins revealed 
that Vmw65 formed a specific complex, called an immediate early complex (IEC), with the 
TAATGARAT motif, only in the presence of cellular proteins under conditions that support 
the binding of these cellular factors to DNA (McKnight et al., 1987; O'Hare & Goding, 
1988; Preston et al., 1988). The protein Oct-l(NFIII,OTF-I), present in a wide range of cell 
types, has been demonstrated to be one of the cellular component of the complex (Ephrussi 
etal., 1985; Gerster and Roeder, 1988). It has been found that Vmw 65 is composed of two 
distinct and functionally separable domains. The C-terminal 78 amino acids enriched for 
negatively charged amino acid residues specify the transactivation activity, whereas the N- 
terminal region is essential for the IEC formation.
EHV1 gene 12 has been shown to encode a functional homologue of HSV1 Vmw65, 
despite its predicted lack of a carboxy terminal acidic domain (Lewis et al., 1993; Purewal 
etal., 1994). Elliott and O'Hare (1995) found that EHV1 gene 12 could activate the EHV1
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IE promoter and the HSV 1 IE110 promoter efficiently. Closer examination of the sequence 
between -360 and the RNA start site (+1) of the EHV1 IE promoter (Harty et a l, 1989) 
revealed the presence of four potential octamer binding motifs, E l, E2, E3 and E4 (Elliott 
and O'Hare 1995). El and E2 diverge by only one residue from the canonical octamer 
consensus site (ATGCAAAT). E3 containing a POU-specific site diverges by a single 
base in the 5' region (Sturm and Herr, 1988; Verrijzer et a l, 1990). The in vitro complex 
formation assay has shown that the four octamer binding motifs could form a strong binary 
complex with Oct-1 and the gene 12 product (Elliott and O'Hare, 1995). Like Vmw65, the 
EHV 1 gene 12 transactivator utilises octamer DNA binding sites El and E4 to interact with 
the EHV1 IE gene promoter and stimulate expression of the EHV1 IE gene (Elliott and 
O'Hare, 1995).
I.7.4.2. Immediate Early Gene Expression
Gray et al., (1987 a) demonstrated that during EHV1 productive infection sequences within 
the short component of the viral genome are the first to become transcriptionally active. A 
6.0 kb IE transcript which mapped to the inverted repeat sequences (m.u. 0.78-0.83 and 
0.95-1.0) was identified in the absence of protein synthesis. DNA sequence analysis of the 
regions identified an ORF (gene 64) consisting of 1487 codons (4461bp) with high 
homology to HSV 1 Vmw 175 (Grundy et a l , 1989; Telford, et a l ,  1992). This predicted IE 
ORF contains a high G+C content (74.3%) in its codon usage. A similar high G+C content 
(81.5%) has also been found in the HSV1 IE gene, Vm wl75 (McGeoch et a l,  1986 b). 
Sequence analysis has mapped two sequences resembling signals for transcription initiation 
(TATA boxes; McKnight and Kingsbury, 1982) upstream of the initial ATG of the EHV IE 
gene, at -654 and -319. Transcription originating from this region would result in a leader 
sequence of approximately 600 bases for the IE gene. SI nuclease and primer extension 
analysis demonstrated that a 372-nucleotide sequence is removed by splicing, to produce a 
220 bp leader sequence upstream of the gene 64 start codon (Harty et a l,  1989). The HSV- 
1 ICP4 transcript also has a 250 base leader (McGeoch et al., 1986 b; Rixon et a l, 1982). 
These sequence features of the putative EHV 1 IE gene demonstrated high amino acid
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homology and comparable location of the gene to the two previously characterised IE 
proteins, HSV1 ICP4 and the VZV gene 62 protein (McGeoch et al., 1986b; Paterson and 
Everett, 1988; Davison and Scott, 1985).
Four abundant IE polypeptides, designated IE 1, IE2, IE3 and IE4, have been detected in 
infected cells released from a protein synthesis block (Caughman et al., 1988), but they 
have never been detected in infected cells under normal conditions. The same situation has 
also been observed for expression of PRV 180 KD IE protein (Ihara et al., 1983), which 
was not detected in extracts from unblocked wild-type PRV infections. The presence of a 
single 6 kb IE mRNA and the finding of four IE polypeptides raised the question whether 
the four IE proteins were related proteins from the same gene. Characterisation of the four 
IE proteins revealed that the EHV1 IE proteins (IE 1-4) are related structurally and 
antigenically and appear to be either produced simultaneously or processed to yield the 
individual forms immediately (Caughman et al., 1988). In vitro translation experiments 
have demonstrated that a family of IE proteins is generated in vitro from the 6.0 kb mRNA 
size class and that these translated IE proteins correspond in overall size and antigenicity to 
those synthesised in infected cells (Caughman et a l., 1985). These findings demonstrated 
that a family of EHV IE proteins including IE 1-4 are translated from the 6.0 kb IE mRNA 
size class (Caughman et al., 1985). However, the mechanism involved in their generation 
is not clear.
Using an EHV1 IE gene expression vector and recombinant target promoter-CAT reporter 
constructs, Smith et al. (1992) demonstrated that the EHV1 IE gene was capable of both 
transactivation and trans-repression. The EHV1 IE gene , expressed from the predicted IE 
ORF, was found to be able to independently activate the EHV 1 TK promoter by as much as 
60-fold and could activate the HSV-tk promoter by approximately 17-fold. It was also able 
to transactivate two EHV 1 beta- and gamma-promoters; however, in this case there is a 
requirement for additional gene products from the EHV1 Xbal G (map unit 0.01-0.06) 
restriction fragment which contains EHV 1 gene 5, the homologue of UL54 (ICP27) of
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HSV1. In addition, it has been demonstrated that the EHV1 IE protein can repress 
expression from its own promoter (Smith et al., 1992). Two cis-acting autoregulatory 
elements have been mapped to a region within -288 to +73 of the IE transcription initiation 
site with a Vmwl 75-like binding site 5'-ATCGTC(N4)CGCGG-3' sequence spanning the 
transcriptional start of the EHV 1 IE gene (Smith et al., 1992). Recently, Kim et al., (1995) 
demonstrated that the IE protein could bind to sequences from -11 to -14 of the EHV1 IE 
transcription initiation site. They also found that the IE protein binds to a degenerate 
version of the consensus sequence 5'-ATCGT-3' in EHV1 early and late promoters in which 
only C or G residues are essential for the binding (Kim et al., 1995). These findings 
suggest that formation of a specific complex between the EHV 1 IE protein and EHV 1 gene 
promoters including its own promoter could activate early and late gene transcription and 
autoregulate its own expression .
I.7.4.3. Early and late gene expression
Caughman et al. (1985) have characterised the EHV1 infected cell polypeptides (ICPs) 
during the course of infection in the presence or absence of an inhibitor of virus DNA 
synthesis. At least 34 EHV 1 ICPs ranging in apparent molecular weights from 16.5 KD to 
213 KD were detected. Twelve were classified as late proteins since inhibition of viral 
DNA replication resulted in significantly reduced synthesis and/or accumulation of these 
polypeptides; 17 were classified as early proteins since their synthesis is not reduced by the 
inhibition of viral DNA replication and at least three polypeptides (137KD, 74KD and 
31.5KD) accumulate in large amounts in phosphonoacetic acid (PAA) treated cultures 
compared to cultures in which the infection process was unimpaired.
EHV1 genes (63, 5 and 65) that are homologous to three HSV1 IE genes (ICPO, ICP27 and 
ICP22) are transcribed as early genes (Holden et al., 1992; Telford, 1992; Smith et al, 
1993). Sequence analysis reveals that EHV1 gene 63 possesses a low level of homology to 
HSV ICPO, but it retains the zinc finger motif (Zhao et al., 1992). EHV1 gene 5 is the 
homologue of ICP27 of HSV 1 and its product has been found to function synergistically
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with the IE gene product to transactivate late promoters (Smith et a l ,  1992, 1993; Zhao et 
al., 1995). It can upregulate the expression of the EHV 1 IE promoter by itself although the 
gene 5 product by itself does not efficiently transactivate early or late promoters (Zhao et 
al., 1995). EHV1 gene 65, homologous to the HSV1 US1 gene (ICP22) has been found to 
be transcribed as a major early transcript of 1.4 kb and a minor late transcript of 1.7 kb 
(Holden et al., 1992). Gene 65 encodes a series of proteins with a Mr of 42 to 47 KD 
which are localised to the nucleus and present in the EHV1 virion (Holden et a l, 1994). 
Using a gene 65 expression vector cotransfected with a EHV 1 chimerical promoter-CAT 
reporter construct and EHV 1 effector plasmids, Holden et al., (1994) demonstrated that the 
gene 65 protein also minimally trans-activates EHV1 promoters, but acts synergistically 
with the gene 5 product to transactivate EHV 1 promoters; it also enhances transactivation 
of early promoters by the IE protein and enhances the transactivation of both early and late 
promoters by the IE and gene 5 proteins.
1.7.5. Assembly and egress of virions
It has been shown that pharmacological agents that impinge on the secretary organelles, 
such as monensin (Johnson and Spear, 1982) and tunicamycin (Pizer et al., 1980) interfere 
with formation and release of HSV from infected cells. Furthermore, the mutant cell line 
gro29, which is defective in protein secretion, is unable to release virions when infected 
with HSV 1, despite normal viral gene expression. These studies suggest that the secretory 
pathway is critical to HSV release. Other cell lines defective in a variety of enzymes 
required for processing of N-linked oligosaccharides have been shown to produce less 
infectious virus than normal cells when infected with HSV1, suggesting specific 
oligosaccharide chains contribute to efficient viral maturation and egress (Campadelli- 
Fiume e ta l., 1982; Serafini-Cessi e ta l., 1983). The cellular localization of assembly, 
maturation and release of herpes viruses has not been mapped in detail. Nevertheless, 
evidence has been obtained in several systems that the nucleocapsid is first assembled as a 
ONA-free precursor capsid, into which viral DNA is subsequently packaged (Roizman and 
Sears, 1990; Roizman and Furlong, 1974; Schwartz and Roizman, 1969). In general,
36
introduction
herpes viruses are unique among enveloped viruses in that the primary site of envelopment 
appears to be at the nuclear membrane especially the inner lamella, though the process may 
occur at nuclear matrix, cytoplasmic, or plasma membrane sites (Ben-Porat and Kaplan, 
1972; Dargen, 1986; Darlington and Moss III, 1968; Johnson and Spear, 1982; McCracken 
and Clarke, 1971; Morgan e ta l ,  1954; O'Callaghan and Randall 1976; Poliquin et al., 
1985; Spear, 1984; Stackpole, 1969). Johnson and Spear (1982) suggested a model for 
HSV1 envelopment and viral egress by which HSV1 virions were first enveloped at the 
inner nuclear membrane, where they acquired viral glycoproteins lacking Golgi 
modification. Subsequently, these immature virions were transported to the Golgi 
apparatus, where precursor glycoproteins were modified as the enveloped particles moved 
through the Golgi stacks.
Darlington and Moss (1968) demonstrated that the envelopment processe for EHV1 strain 
Ky D are the same as that of HSV 1 (strain H4) and PRV. Envelopment of virus at the inner 
nuclear membrane could be seen in sections coincident with or shortly before the increase 
in release (5 to 8 hours after infection). When viral capsids, with or without DNA, came 
into contact with the inner membrane, this membrane became noticeably thicker at the point 
of contact. The particles became completely enclosed in this thickened membrane and 
appeared to pinch off leaving the nuclear membrane intact in a manner analogous to the 
formation of pinocytic vesicles at the plasma membrane. After release from the nucleus, 
the enveloped particles were found in the cytoplasm in vacuoles, sometimes enclosed in an 
additional membrane containing several particles which was apparently derived from 
cytoplasmic elements (Darlington and Moss 1968).
Whealy et al., (1991) have investigated PRV viral glycoprotein processing and virus egress 
using brefeldin A (BFA), which had little effect on initial synthesis and cotranslational 
modification of viral glycoproteins in the endoplasmic reticulum (ER), but disrupted 
subsequent glycoprotein maturation and export into post-Golgi cellular compartments 
(Dorns et a l ,  1989; Lippincot-Schwartz et al., 1989; Misumi e ta l., 1986). Their results
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showed that envelopment of PRV involved initial acquisition of a membrane by budding of 
capsids through the inner leaf of the nuclear envelope followed by deenvelopement and 
release of these capsids from the ER into the cytoplasm in proximity to the trans-Golgi. 
The released capsids then acquire a bilaminar double envelope containing mature viral 
glycoproteins at the trans-Golgi. The resulting double-membrane virus is transported to the 
plasma membrane, where membrane fusion releases a mature, enveloped virus particle 
from the cells.
A view of VZV maturation has recently been produced by Harson and Grose (1995) who 
investigated the entire route of VZV egress from the nucleus to the outer cell membrane. 
Based on observations from transmission electron microscopy(TME) at intervals post 
infection, they provided a hypothesis of VZV egress. The nucleocapsid passed through the 
inner nuclear membrane and acquired its initial envelope. The enveloped particle then 
travels through the perinuclear space where it is engulfed within a vacuole formed in a 
similar manner to the premelanosome. A vacuole containing one or more viral particles is 
pinched off and resides within the cytoplasm. After the viral glycoproteins are processed 
during transit in the Golgi, they collect within transport vehicles, in a manner similar to 
tyrosinase, and travel to fuse with a smooth endoplasmic reticulum (SER)-derived vacuole 
containing nascent virions. Once viral glycoproteins, including VZV gH-gL complex, have 
entered the vacuole, the vacuole can fuse with one or more neighbouring vacuoles to form a 
larger vacuole. In turn, the vacuole exhibits the exocytic properties of a melanosome, 
whereby it can travel through the cytoplasm and fuse with the outer-cell membrane (Harson 
and Grose, 1995).
Mutants in a number of HSV1 genes have been shown to affect the egress of virus from 
infected cells (Baines et al., 1991; Campadelli-Fiume et a l, 1990; Desai et al., 1988; 
Baines & Roizman, 1992). These genes encode gD, gH, gL and the U L 11 and UL20 
proteins. Desai etal. (1988) found that a temperature-sensitive mutant which contains an 
amino acid substitution in gH entered cells efficiently at the non-permissive temperature
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and replicated to give nearly normal yields of intracellular infectivity. The intracellular 
virions contain, predominantly, an immature form of gH, while excreted virions were 
devoid of gH and were not infectious. Additionally, no gH was found on the surface of 
infected cells. On the other hand, virions excreted at the permissive temperature contain 
mature gH and were infectious. No loss of gH results from incubation of these virions at 
the non-permissive temperature. This data indicats that gH is an essential component of 
infectious virions.
MacLean et al. (1989) identified that the U L 11 gene of HSV1 encodes a myristylated 
protein. They also found that a U L11 deletion mutant in which 40% codons of coding 
sequence(109bp of the 288bp coding sequence) was disrupted by a lacZ insertion grows 
about 20-fold less well than wild-type and its revertant, and produces smaller plaques. 
Baines and Roizman, (1992) demonstrated that a deletion mutant lacking 61% of the 
codons (176bp of the 288bp coding domain) of HSV1 U L11 gene reached titres 30-250 
fold lower than those obtained from cells infected with wild-type virus. Electron 
microscopic analysis indicated that both full and empty capsids accumulated in the nuclei, 
juxtaposed with the inner lamellae of the nuclear membranes. There was a > 1,00-fold 
decrease in the amount of infectious extracellular virus released from Vero cells infected 
with the deletion mutant compared with that from cells infected with wild-type virus. 
Furthermore, the onset of release of infectious virus from cells infected with the UL11- 
virus was significantly delayed. These data indicated that the absence of the UL11 gene 
causes a reduced capacity to envelope and transport virions into the extracellular space.
Baines et a l  (1991) have isolated a HSV1 deletion mutant in which 53% of the UL20 gene 
ORF had been deleted. It was found that the yields of UL20“ virus were approximately 10- 
to 100-fold lower than those of wild-type virus in 143 tk" cell cultures. No infectious virus 
was produced in Vero cells by this mutant. Electron microscopic examination of Vero cells 
infected with the U L20- mutant revealed that enveloped and unenveloped capsids 
accumulated in the cytoplasm, possibly in the space between the inner and outer lamellae of
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the nuclear membrane, and that virtually no virus was present in the extracellular space. 
This data indicates that UL20 encodes a protein with a hitherto unrecognised function 
which enables the transit of virions to the extracellular space. Avitabile et al. (1994) found 
that in Vero cells infected with UL20" virus, immature viral glycoproteins associated with 
virions sequestered in the space between the inner and outer nuclear membranes and only a 
limited amount of viral glycoproteins containing complex-type oligosaccharides with sialic 
acid are transported to the plasma membranes. In contrast to the observation in Vero cells, 
in infected 143TK- cells UL20" virions are exported to the extracellular space, although the 
yields of infectious progeny are lower than that of wild-type virus, and the amount of viral 
glycoproteins exported to the plasma membranes of cells infected with the wild-type parent 
or with UL20" virus are similar. These observation suggest that in Vero cells UL20 is 
required for the packaging of virions by the outer nuclear membranes into transport vesicles 
which carry the virions through the Golgi apparatus, where the glycoproteins are fully 
processed, to the extracellular space and for the transport of membrane-associated viral 
glycoproteins from the trans-Golgi compartment to the plasma membrane. This 
requirement is obviously cell-type-dependent.
Arsenakis et al. (1988) have found that a baby hamster kidney (BHK) cell line expressing 
gD ( e.g. the BJ-1 clonal cell line) of HSV-1 strain F allows the wild-type virus to attach, 
but virus was internalized by endocytosis and degraded. Using this cell line a mutant 
(HSV-1(F) U-10) which was capable of infecting the BJ-1 clonal cell line was selected. 
Marker rescue and sequencing studies mapped the mutation to a fragment which encoded a 
small numbers of genes including the gD gene and demonstrated that in the mutant virus 
amino acid Leu-25 of gD was replaced by proline since exposure of the BJ-1 cells to the 
nonneutralizing monoclonal antibody AP7 which recognised an epitope of gD including 
Leu-25 rendered the cells infectible with wild-type virus (Minson et al., 1986). 
Campadelli-Fiume et al. (1991) found that at late time point infection although the amount 
of virus recovered from HSV-1 (F)-10 -infected cells was 5- to 10- fold lower than those 
recovered from HSV1 (F)-infected cells, the amount of virus recovered from the
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extracellular fluid was approximately 50-fold less than that recovered from extracellular 
medium of cultures infected with the wild-type parent. In addition, a large number of 
unenveloped capsids accumulated in the cytoplasm juxtaposed to the cytoplasmic 
membranes, suggesting that the process of envelopment of HSV-1(F)-U-10, is very slow 
and that virus egress from cells is impaired. These data indicate that several HSV1 gene 
products are involved in the different stages of virion formation and release from infected 
cells.
1.8. ANIMAL MODELS FOR THE STUDY OF EHV1 INFECTION
EHV1 infection is an infection of major importance, especially in the thoroughbred 
industry, and there is much interest in the development of effective vaccines or 
chemotherapeutic agents to prevent infection or disease, or to reduce virus shedding in 
infected animals. It therefore became essential to develop suitable animal models for 
studying the immune response to EHV1 infection, its pathogenicity and to evaluate the 
efficiency and safety of vaccines. For this reason, three laboratory animal models have 
been established.
1.8.1. A hamster model
The Syrian hamster has been used for studying EHV 1 infection and aspects of immunity to 
EHV1 infection for a long time (Anderson and Goodpasture, 1942; Wilks and Coggins, 
1977). Intraperitoneal (i.p.) challenge with a virulent isolate of EHV1 (strain Ky B) at a 
dose of 5x l0 6 pfu/hamster resulted in 100% mortality of infected hamsters by day 3 with 
peak levels of virus in the liver at between 48 and 60 h p.i. and in the lungs at 3 days p.i., 
indicating that the acute disease produced by EHV 1 infection with hamsters dying in 3 to 5 
days is most unlike the equine disease and the serious limitation of this model is that it does 
not permit full assessments of immune effector mechanisms. However, using this model 
Wilks and Coggins. (1977) demonstrated that passive transfer of immune splenocytes, 
peritoneal exudate cells or antiserum can protect the animal from EHV 1 challenge.
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Stokes et al. (1989) developed a subacute hamster model using EHV1 strain Ky D and 
DSN inbred hamsters. Animals infected by i.p. or intra-nasal (i.n.) administration of low 
titre (5x 105 pfu/animal) EHV 1 (Ky D) developed a self-limiting infection in which virus 
clearance was complete by day 6. I.p. inoculation of virus resulted in a systemic infection, 
virus being isolated from the major organs by day 4. while i.n. inoculation is more similar 
to the natural route of infection and has been used to administer other respiratory pathogens 
(King etal., 1987). Following infection of DSN inbred hamsters either i.p. or i.n. with 
EHV 1 strain KyD, virus was isolated from the livers of all animals in both groups by day 2 
and consistently isolated from the liver, lung, heart, kidney and spleen of i.p. infected 
hamsters by day 4. The majority of virus was consistently isolated from the liver during 
infection. Infection resulted in the occasional death but usually animals were clinically 
affected for 4 days and then recovered. Virus clearance was apparent by day 6 p.i.
1.8.2. A murine model.
The pathogenesis of infection in hamsters differs quite strikingly from that in the natural 
host, eg the liver is a primary site of virus replication in the hamster and the histopathology 
does not resemble that observed in the natural respiratory disease. To avoid these 
disadvantages of the hamster model, a murine model was developed for studying the 
immunogenesis and pathogenesis of EHV1 (Awan et al., 1990). New-born mice had 
previously been shown to be susceptible to EHV1 following intracerebral inoculation (i.e.) 
(Patel and Edington, 1983). Awan et al. (1990) demonstrated that female BALB/c mice (3- 
4 week old) are generally considered refractory to EHV1 infection and can provide a 
relevant model system for several features of the infection which are apparent in the horse. 
Mice are not only very convenient for study, but a wealth of information exists already on 
their responses to herpesvirus infections^
Two days following i.n. inoculation of EHV1 at a dose of 5 x l0 6pfu/mouse, mice began to 
show abnormal signs and by day 3 all mice were hunched with ruffled fur and a
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conspicuous weight reduction. Some mice showed signs suggesting a mild neurological 
involvement. Death occured from the fourth to the seventh day after inoculation, with 
approximately 50% of animals recovering from the infection and becoming clinically 
normal by day 10. Virus was consistently isolated from the nasal tissues, trachea and lungs 
from all mice tested during the first week after inoculation and occasionally from the CNS, 
eyes and liver. Virus titres reached a peak at 3 to 5 days after inoculation, coincident with 
the time of maximum clinical signs. Virus was cleared from the lungs and turbinate bones 
by day 12 after inoculation. Histological evidence of virus replication was observed in the 
lung after 24 h inoculation. Electron microscopy showed that alveolar and bronchiolar 
tissues cells contained signs of herpesvirus infection including disrupted chromatin; altered 
nuclear membrane; the presence of dense cored virions in the nucleus; and both 
cytoplasmic and extracellular enveloped particles. An important feature of EHV 1 infection 
in its natural host is the viraemic spread of virus during the acute disease. A vireamia was 
also observed in EHV1 infected mice during the acute phase of the infection. 
Approximately 1 in 5x10^ blood cells were demonstrated to be infected.
Immune responses against EHV 1 infection were also analysed for the presence of 
antibodies specific to EHV 1 by means of an ELISA and virus neutralisation test. Following 
the i.n. inoculation of mice with EHV1 an active humoral and T cell immune response was 
detected. Using an ELISA antibody first appeared on the 12th day after inoculation with 
EHV1, peaked at day 25 and showed a marked fall by day 30. In contrast to HSV1, the 
antibody levels of EHV 1 infected mice waned markedly on the last occasion tested (day 30) 
(Nash etal, 1985; Awan e ta l, 1990). No neutralizing activity from mouse serum could be 
detected at any time after i.n. or i.p. inoculation with either live or inactivated virus, in 
contrast to the hyperimmune sera previously raised in mice by repeated subcutaneous (s.c.) 
injection of virus antigen together with adjuvant. A powerful skin reaction of the classical 
delayed type hypersensitivity (DTH) to injection of heat-inactivated antigen into the 
primary infected mouse skin suggested that cell-mediated responses are activated during the 
primary infection. These data indicated that the antibody response to EHV1 in the murine
43
introduction
model following i.n. inoculation was relatively poor with no neutralizing antibody against 
EHV1 present in serum, implying that local responses or cellular immunity are likely to be 
more important factors in protection from EHV1 infection. Azmi and Field (1993) have 
examined the cell-mediated response to EHV1 infection in the murine model by means of 
adoptive transfer of immune cells. They found that adoptive transfer of immune cells from 
mice primed by live or heat-inactivated EHV 1 conferred an enhanced DTH response in 
recipients. Only the immune cells from mice previously primed with live EHV1 gave 
protection against infection, indicating an important role for specific cell-mediated 
responses in protective immunity to EHV1 infection.
1.8.3. Specific pathogen-free (EHV-free) foals
Colostrum-deprived specific pathogen-free (EHV-free) (SPF) foals are taken from their 
dams at birth and reared by hand using bovine colostrum (Chong et al., 1991). They are 
free from EHV infection and also from maternal antibodies. They have proved to be 
invaluable in the study of EHV infection. Tewari et al. (1993) have examined the response 
of SPF foals to EHV1 infection. Following primary and secondary i.n. inoculations with 
EHV1 at a dose of 107pfu/foal, five SPF foals showed clinical signs of primary infection 
including nasal excretion of virus, which continued for 11 days, and viraemia. On 
secondary infection, clinical signs were minimal and virus was recovered on only day 1 p.i., 
and vireamia was not detected (Tewari et al., 1993). The serological response of SPF foals 
to EHV1 was observed (Tewarmf al., 1993). Both complement fixing and virus 
neutralizing antibodies against EHV1 were detected by day 15 p.i. and reached peak titres 
between 40-60 days p.i. The titre of complement fixing antibodies declined prior to 
secondary EHV1 infection, 12 weeks later. In contrast, virus neutralizing antibodies were 
sustained and remained at maximum levels until re-infection, 12 weeks later (Tewari et al., 
1993). Immune blotting using EHV1 antigens showed that following primary infection 
with EHV 1, no specific antibodies against viral proteins were detected in primary infected 
SPF sera up to day 15, but by day 60-85 p.i. the sera could recognise four or five major 
EHV 1 proteins with molecular weights 110/115 k, 78k, 58k, and 48k (corresponding to
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gplO, gpl4, gplBa and/or gpl8b, and gp21/22a). On secondary infection with EHV1, 12 
weeks after the primary inoculation no increase in intensity of the bands was seen and no 
new bands were detected by the secondary infected SPF sera (Tewai et al., 1993). These 
observations showed that a primary i.n. inoculation with EHV1 resulted in a strong 
serological response recognising EHV1 specific antigens in SPF foals. W hilst 
reinoculation with the same virus produced a boost to EHV1 antibodies, no additional 
antigens were recognised.
1.9. VACCINES AND VACCINATION
Vaccination for the prevention of herpesviral diseases of the horse caused by EHV1 is 
based on the concept that naturally acquired immunity to respiratory diseases caused by 
EHV1 is a product of the immunogenic conditioning of repeated infections (Doll et al., 
1963); it seems clear that immunological responses critical to the development of protective 
immunity to infection or disease are induced specifically by the antigenicity of the envelope 
glycoproteins of the virus (Papp-Vid and Derbyshire, 1979); that immunity to reinfection is 
short lived (Bryans 1969; Von Steinhangen, 1988); and that immunity to reinfection against 
abortigenic infection is required from the onset of the sixth month of gestation until term 
(Doll et a l, 1963). Two vaccines have been in wide-spread use in the United States; one is 
a live virus product attenuated by multiple passages in swine cell cultures followed by 
passage in equine cells (Burki et a l, 1990). It was originally recommended as a preventive 
vaccine for abortigenic infection by EHV1. Now it is limited to use for respiratory disease 
(Burki et a l ., 1990). The second vaccine used in the U.S.A. is a formalin inactivated, 
adjuvanted formulation of an attenuated strain of EHV 1 (Bryans, 1978; Bryans, and Allen, 
1982; Burrows et a l ,  1984). Since the inactivated vaccine was made available to 
veterinarians, the mean incidence of EHV 1 abortigenic infection in central Kentucky during 
a six year period declined from 7.4/1000 pregnancies to 2.3/1000 (range 1.0- 3.1/1000) 
(Burki et a l,  1990; Burrows et a l , 1984). Although the overall incidence of the disease 
decreased, both single and multiple abortions continued to occur in herds vaccinated with 
either the inactivated or the modified live virus vaccines during this period indicating
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incomplete protection. The attenuated live vaccine can lead to the establishment of latent 
infection which can be reactivated by wild-type (WT) EHV1 infection. It can also cause 
recrudescence in wt EHV1 infected horses (Allen and Bryans, 1986; Onions, 1991).
Therefore, several attempts have been undertaken to improve the efficiency of vaccines. 
These attempts include developing more suitable animal models for studying the host 
immune responses to EHV 1 infection and pathogenesis and constructing more efficient 
and safe vaccines such as attenuated deletion mutants and subunit vaccines comprising 
expressed virus glycoproteins. Some have been tested for evidence of their suitability as 
potential vaccine candidates on the established animal models. A thymidine kinase- 
deficient (TK_) mutant of EHV1 was tested in the mouse model and SPF foals for 
infectivity, pathogenicity and induction of immunity to EHV1 infection (Slater et al., 
1993). Compared to wild-type virus, the T K ' mutant, PR1, produced markedly mild 
clinical disease following both i.n. and i. c. inoculation, and, in particular, no mortality 
occurred. PR1 did however establish productive infections following i.n. inoculation. High 
titres of virus were recovered from target organs although virus did not persist for as long 
as wt EHV1 and no viraemia was detected. In contrast to that with wt EHV1, the 
serological response was very weak in PR1 infected animals. However, primary i.n. 
infection with wt EHV1 protected against subsequent challenge with wt
EHV1 5 weeks later (Slater et al., 1993). PR1 could also not be reactivated by 
administration of dexamenthasone and could not be co-cultivated from any tissues of the 
ponies infected with PR1 (Slater et a l, 1994). A deletion mutant (ED71), which is a EHV1 
gene 71 negative mutant and is demonstrated to be defective in entry into cells, egress 
from cells and subsequent transmission from cell to cell (Sun and Brown, 1994; Sun et a l, 
1996), was also tested in the murine model for pathogenesis and immunogenesis (Tim 
Fitzmaurice, personal communication). The result showed that in the primary infection 
ED71 was attenuated and conferred good protective immunity to subsequent EHV1 
challenge, both in reduction of virus recovered from tissues and numbers of animals found 
positive for virus.
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Some EHV1 glycoproteins (subunit vaccines) have also been expressed and tested in 
animal models for stimulating the protective immunity against EHV1 infection. Tewari et 
a l (1994) tested host immune responses following immunization with extracts of insect 
cells infected by baculoviruses expressing EHV1 gD and gH. In contrast to the gH 
recombinant infected cells, the gD recombinant infected cells produced neutralizing 
antibodies to EHV1 and a protective immunity against subsequent EHV1 challenge, 
determined by accelerated clearance of virus from the target organs in the respiratory tract. 
In the mouse model both glycoproteins induced delayed-type hypersensitivity and 
lymphoproliferation to EHV1 antigen. Osterrieder et al. (1995) also tested various 
formulations of recombinant glycoprotein gpl4  (gB) in a murine model. They found that 
only V L P -gpl4 , a truncated g p l4  expressed as a fusion protein with human 
immunodeficiency virus type 1 gag to produce virus-like particles (VLP) in insect cells 
induced both a good humoral and a prominent delayed-type hypersensitivity (DTH) 
immune response to EHV 1.
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CHAPTER 2: MATERIALS AND METHODS
2.1. MATERIALS.
2.1.1. Cells
The following cell lines were used in this study.
Baby hamster kidney 21 clone 13 cells (BHK21/C13)
Equine dermal cells (NBL-6)
Rabbit kidney cells (RK13)
Human foetal lung fibroblasts (HFL)
African green monkey fibroblasts (CV-1)
Mouse embryo fibroblasts (3T6)
2.1.2. Viruses
Equine herpesvirus type 1 (EHVl)strain Ab4p (Telford et a l,  1992) was used as the wild-type 
virus. Virus stocks were prepared in NBL-6 cells and titrated on BHK21/C13 cells. Herpes 
simplex virus type 1 strain 17 + (HSV1 17+) (Brown et al., 1973) was used as a comparative 
virus in some experiments.
2.1.3. Cell culture media
BHK21/C13 cells and HFL cells were grown in Eagle's medium (Gibco) supplemented with 
10% new-born calf serum (Gibco), 10% (v/v) tryptose phosphate broth, 200mM L-glutamine 
(Gibco), 10,000 IU/ml penicillin and 10,000UG/ml streptomycin (Gibco). This is referred to 
subsequently as ETC 10.
Variations on the basic growth media were:
PIC Phosphate-free Eagle's medium containing 1 % newborn calf serum
EMC 10% Eagle's medium containing 1% carboxymethyl cellulose and 10%
newborn calf serum.
Emet/5C2 Eagle's medium containing one-fifth the normal concentration of methionine
and 2% calf serum.
Eglu/10C2 Eagle's medium containing one-tenth the normal concentration of
glucose and 2% calf-serum
Dulbecco’s Modified Eagle’s medium (Gibco) supplemented with 10% foetal calf serum 
(Gibco), 200mM glutamine (Gibco), 10,000 IU/ml penicillin and 10,000 UG/ml streptomycin 
(Gibco) was used for growth of 3T6, NBL-6, RK13 and CV1 cells.
2.1.4. Experimental animals
Ten female New Zealand white rabbits (w eight: 1000g-1500g; Bantin and Kingman or Harlan 
U.K. Ltd.) were used in this study.
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2.1.5. Bacterial strains
Escherichia coli strain NM522 [ re CAT, sup E,thi, (lac-proAB), hsd 5(r", m"), (F' pro AB, 
lac 192 M15)] (Gough and M urray,1983), JM109 [supE,thi, (lac-pnAB), (F'traD36, proAB, 
lac 192 M l5] (Yanisch-Perron et a l, 1985) and strain XL1-Bluer {[supE444hsdR17 recAl 
gyrA46 thi relAl ale] F ’proAB+ lacZAM15 Tn 10(tetr)} were used for transformation of 
recombinant plasmids and expression of fusion proteins.
2.1.6. Bacterial growth media
The media used for bacterial growth were:
L - b r o t h  10g/l NaCl, 10g/l b a c t o t r y p t o n e  (Difco), 5g/l y e a s t  e x t r a c t .
: L-broth agar L-broth containing 0.5% (w/v) bactoagar (Difco).
2xYT 85mM NaCl, 16g/l bactotryptone (Difco), 5g/l yeast extract.
2.1.7. Oligonucleotides
Synthetic oligonucleotides were synthesised in the Department of Virology by Dr J. 
McLauchlan, using a model 8600 Biosearch multiple column DNA synthesiser.
12.1.8. Plasmids
)UC19 (Yanisch-Perron et al., 1985) was used for cloning and subcloning fragments from the 
iHVl genome.
)UR278 (Riither & Miiller-Hill, 1983), a B-galactosidase gene fusion expression vector, was 
lsed for construction of EHV 1 fusion protein expression plasmids.
>CMV10 used for construction of the EHV1 gene 67 expression plasmid is a eukaryotic 
expression vector (Stow et. al., 1993).
-. 1.9. Antibodies
*19, a monoclonal antibody against EHV 1 glycoprotein gp300 ( Whittaker et al. , 1992). 
lonoclonal anti-a-tubulin. Sigma, 
lonoclonal anti-actin (amoeba), Sigma.
mti-rabbit IgG (whole molecule) Fluorescien Isothicanate (FITC) conjugated-antibody, 
>igma.
^nti-mouse IgG (whole molecule) tetramethylrhodamine (TRITC) conjugated-antibody, 
>igma.
lorse neutralizing antiserum against EHV 1, kindly supplied by Dr. Neil Edington.
1* 10. Enzymes
restriction enzymes, Vent polymerase, T4 DNA ligase, T4 polynucleotide kinase and calf
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I intestinal alkaline phosphatase (CIP) were obtained from either Bethesda Research 
Laboratories (BRL), New England Biolabs or Boehringer Mannheim Corporation. Lysozyme, 
Deoxynuclease I and Ribonuclease A were obtained from Sigma Chemical Co.
Glycosidases:
a. N-glycanase [peptide-N-4 (N-acetyl-B-glucosaminyl) asparagine amidase], Genzyme.
b. N e u r a m i n i d a s e  ( a c e t y l n e u r a m i n y l  h y d r o l a s e ) ,  S i g m a .
c. B-N-acetylhexosaminidase (2-acetamido-2-deoxy-B-D-glucoside- 
acetamidodeoxyglucohydrolase), Sigma.
d. L - f u c o s i d e  f u s o h y d r o l a s e ,  S i g m a .
e. B-galactosidase (B-D-galactoside galactohydrolase), Boehringer Mannheim.
2.1.11. metabolic Inhibitors 
Tunicamycin, Sigma 
Monensin, Sigma 
Brefeldin A , Sigma
Nocodazole (Methyl-(5[2-thienycarbonyl]-l H-benzimidazol-2yl)-Carbamate), Sigma
|2 .1.12. Radioisotopes
ill radioisotopes were supplied by Amersham International pic. They had the following 
Ispecific activities:
52P-Orthophosphate 
55S Methionine 
,4C glucosamine 
5H mannose 
)P-14 c  galactosidase 
S' [ 32P] dNTPs 
35S] dATP
specific activity 
3000Ci/mmol 
>1000 Ci/mmol 
50 mCi/mmol 
10 to 20 Ci/mmol 
270mCi/mmol 
3000Ci/mmol 
4000Ci/mmol
M.13. Chemicals
"he chemicals used were of analytical grade and most of these were supplied by either BDH 
chemicals, UK or Sigma Chemical Co. Exceptions were:
acetic acid glacial May and Baker Ltd., Dagenham, England,
unpicillin sodium B.P. (Penbritin) Beecham Research
d>S and TEMED Bio-Rad Laboratories,
loric acid and glycerol PROLAB.
aesium chloride and acrylamide Koch Light Ltd. (Suffolk, England)
-Deoxynucleotide-5'-triphosphate (dNTPs) Pharmacia 
[sopropylthio-b-D-thiogalactoside (IPTG) Bethesda Research Laboratories (BRL).
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Dimethylsulphate 
Dimethylsulphoxide (DMSO) 
Ficoll
G l u t a r a l d e h y d e  
P r o t e i n a s e  K
Materials and methods 
Flukw AG, Buchs SG, Switzerland 
Koch-Light Laboratories, England 
Pharmacia, Uppsalla, Sweden 
Agar Aids, Cambridge, England
Boehringer Mannheim GmbH.,
W. Germany
2.1.14. Commonly used buffers
A l k a l i n e  l y s i s  s o l u t i o n  I
A l k a l i n e  l y s i s  s o l u t i o n  II 
A l k a l i n e  l y s i s  s o l u t i o n  III 
C h l o r o f o r r m i s o a m y l a l c o h o l  
F o r m a m i d e  d y e  m i x
Gel soak I 
Gel soak II
Hybridization buffer 
Ligation buffer (1 Ox)
Phenol chloroform (1:1)
PBS -A
PBS complete
PBS /calf serum 
Random primer buffer (5x)
stop
and solutions.
lOmM EDTA, 50mM glucose, 25mM Tris-HCl pH 8.0 
and 5mg/ml lysozyme added prior to use.
200mM NaOH and l%(w/v) SDS.
5M potassium acetate, pH4.8.
This is a 24:1 mixture of chloroform and isoamylalcohol 
95% formamide, 20mM EDTA, 0.05% bromophenol 
blue, 0.05% xylene cyanol.
600mM NaCl, 1M NaOH.
600mM NaCl, 200mM Tris-HCl, adjusted to pH8.0 with 
HC1.
7% SDS, 0.5M NaP04 (NaH2P0 4 ; N a2HP0 4 ),pH7 .4 . 
200mM DTT, lOOmM MgCl2 , 0.5M Tris-HCl, pH 7.8.
This is a 1:1 mixture of phenol and chloroform.
170mM NaCl, 3.4mM KC1, lOmM Na2HP0 4 ,
1.8mM KH2PO4 , pH7.2.
PBS A plus 6 .8mM CaCl2 , 4.9mM MgCl2 - 
PBS complete containing 5% newborn calf serum.
Three solutions A, B, C at a ratio of 10:25:15 
respectively:
solution A: 18pi 2-mercaptoethanol, 5pl lOOmM 
dGTP, 5 pi lOOmM dATP, 5 pi lOOmM 
dTTP, 1ml (1.25M Tris-HCl, pH7.6, 0.125M MgCl2). 
solution B: 2M HEPES, pH6 .6 .
solution C: Hexadeoxyribonucleotides resuspended in TE 
at 90 OD units/ml.
lOOmM EDTA, 10% (w/v) Ficoll 400, 0.25% (w/v) 
bromophenol blue, 5x TBE.
aturated phenol Phenol saturated by mixing 1:1 with phenol saturation 
buffer, (lOmM Tris-HCl, pH7.5, lOmM EDTA, lOOmM 
NaCl).
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SSC (20x)
TBE(lx)
TE
T r i s - s a l i n e
T r y p s i n
T r y p s i n - V e r s e n e
V e r s e n e
X-gal
Materials and methods 
300mM trisodium citrate, 260mM NaCl.
2mM EDTA, 89mM boric acid, 89mM Tris-HCl pH 8.0. 
ImM EDTA, lOmM Tris-HCl pH8.0.
140mM NaCl, 30mM KC1, 280mM Na2HP04, lmg/ml 
glucose, 0.0015% (w/v) phenol red, 25mM Tris-HCl 
(pH7.4), 100 units/ml penicillin, 0.1 mg/ml streptomycin. 
0.25% (w/v) Difco trypsin dissolved in Tris-saline.
1 volume trypsin + 4 volumes versene.
0.6mM EDTA dissolved in PBS containing 0.002%
(w/v) phenol red.
25mg/ml or lOOmg/ml in dimethylformamide.
2.1.15. Miscellaneous.
Hybond™ N hybridization transfer membranes
Giemsa stain
Protein A-sepharose
Polaroid- 667 film
Repelcote
XS-1 film
e n 3-h a n c e
Amersham 
BDH 
SIGMA 
Polaroid (U.K.)
BDH Chemicals 
Kodak
Biotechnology Systems
52
Materials and methods
2.2. METHODS.
2.2.1. Growth of cells
BHK21/C13 and HFL cells were grown in 80oz roller bottles containing 100ml ETC10 
medium at 37 C for 3 days in an atmosphere of 95% air and 5% CO 2 . Confluent cells were 
harvested by washing the monolayers twice with 25ml of trypsin-versene, and resuspending 
the detached cells in 20ml of ETC 10.
The 3T6, NBL-6, RK13 and CV1 were grown in flasks and harvested under the same 
conditions using Dulbecco’s Modified Eagle’s medium. The yield of cells was determined as 
described by Freshney (1994) using an improved Neubauer counting chamber (Weber, 
England).
Cells were plated on 60mm or 33mm petri dishes or Linbro wells at a density of 4x10®, 2x10® 
5
and 5xlC cells per plate, respectively.
2.2.2. Preparation of virus stocks.
Virus stocks were prepared as described by Brown et al. (1973). Monolayers of NBL-6 cells in 
flasks were infected with 0.01 p.f.u./cell of EHV1, strain Ab4p in 20ml of Dulbecco’s 
Modified Eagle’s medium and incubated at 31 °C for 3-4 days, until c.p.e. was complete, when 
the cells were shaken into the medium. The cells were pelleted in 250ml plastic falcon tubes by 
spinning at 2K for 10 minutes at 4°C in a Fison's Coolspin. The supernatant and cell pellet 
were separated and two individual virus stocks prepared:
Supernatant stock: The supernatant was poured into 250ml centrifuge bottles and spun at 
12K for 2h (4°C) in a Sorvall GSA rotor. The supernatant was discarded, and the virus pellet 
resuspended in 1ml ETC 10 or PBS/calf serum per flask. The pellet was sonicated until 
homogeneous, before aliquoting into 2ml amounts and storing at -70°C.
Cell-associated stock: The cell pellet was resuspended in 0.2ml medium/ flask and thoroughly 
sonicated before spinning at 2K for 10 minutes at 4°C  in a Fison's Coolspin centrifuge. The 
supernatant was kept on ice while the process was repeated. The two supernatants were 
combined to give the cell-associated virus stock. This was aliquoted and stored as above.
In some cases the cell-associated and the supernatant stocks were mixed before aliquoting and 
storing at -70°C. •
2.2.3. Sterility checks on virus stocks
Brain heart infusion agar (BHI) plates and BHI plates containing 10% horse blood (BHI blood 
agar) were used for checks.
To check for fungal contamination of stocks, a small aliquot was streaked onto BHI plates in 
duplicate, which were sealed with parafilm and incubated at RT. Bacterial contamination was 
detected by plating onto BHI blood agar and incubating at 37°C. If no colonies were visible
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after 7 days incubation, the stocks were considered sterile.
2.2.4. Titration of virus stocks
Virus stocks were serially diluted 10-fold in PBS/calf serum. lOOpl aliquots added to 75% 
confluent monolayers of BHK21/C13 cells on 60mm petri dishes from which the medium had 
been removed. The plates were incubated at 37°C for lh, to allow adsorption of the virus to the 
cells. The plates were washed twice with PBS, before overlaying with 6ml EMC 10%, and 
incubated at 37°C for 3 days. Monolayers were fixed and stained with Giemsa at RT for 3h. 
A f t e r  washing, plaques were counted on a dissecting microscope and virus titres calculated as 
p.f.u./ml.
2.2.5. Preparation of EHV1 DNA
The DNA of EH V 1 stocks was prepared according to the method of Wilkie (1973) and Brown 
etal. (1984). To prepare a large scale EHV1 DNA stock, 10 flasks containing almost confluent 
monolayers of NBL-6 cells were infected with virus at a m.o.i. of 0.01 p.f.u./cell. The infection 
was continued at 31°C  until c.p.e. was extensive (3-4 days). The cells were shaken into the 
medium and spun at 2K for 10 minutes in a Fison's Coolspin. The supernatant was kept on ice 
while the nuclei were extracted from the cell pellet by treatment with 0.5% (w/v) NP40 in RSB 
(lOmM KC1, 1.5mM MgCl2, lOmM Tris-HCl, pH 7.5) followed by centrifugation (2K for 10 
minutes) to pellet the cell debris and nuclei. This was repeated before pooling the supernatants 
and spinning to pellet the virus at 12K for 2h in a Sorvall SS34 rotor.
The virus pellet, containing cell released and cytoplasmic virus was resuspended in NTE buffer 
(lOmM Tris-HCl, pH7.5, lOmM NaCl, ImM EDTA) before adding EDTA and SDS to a final 
concentration of lOmM and 2% (w/v) respectively to cause lysis of the virus. Viral DNA was 
extracted 3-4 times with saturated phenol and once with chloroform: isoamylalcohol, prior to 
precipitating with 2 volumes of ethanol at RT for 5 minutes. DNA was pelleted at 2K for 10 
minutes, washed with 70% ethanol, dried at 37°C and resuspended in a minimal volume of 
H2O containing RNase A (50 fig/ml).
2.2. 6. Transfection of DNA into cells using the calcium phosphate technique.
This method is a modification of that described by Stow and Wilkie (1976). Four hundred (il 
HEBS (130 mM NaCl, 4.9 mM KC1, 1.6 mM N a2H P 0 4, 5.5 mM D-glucose, 21 mM HEPES,
pH7.05) containing 10 fig/ml calf thymus DNA, 1-2 fig intact virus DNA, 1-10 |Xg plasmid 
DNA and 130 mM CaCl2, were added to confluent monolayers of BHK21/C13 cells on 60mm
petri dishes, from which the medium had been removed. Following incubation at 37°C for 40 
minutes, cells were overlaid with 6ml ETC 10.
Four to eight hour later the media was removed from the plates and they were washed twice 
with ETC 10. 1.5ml 25% (v/v) DMSO in HEBS was added and the plates incubated at RT for 4 
minutes. The DMSO was removed and the plates washed twice and overlaid with 6ml ETC 10.
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Incubation was continued at 37 °C until c.p.e. was complete.
2.2. 7. Isolation of single plaques from transfection experiments.
Once c.p.e. was complete, the cells were scraped into the growth media, transferred into a 
small glass vial and sonicated until homogeneous. Serial 10-fold dilutions of each transfection 
were made in PBS/calf serum and the 10-3 to 10"7 dilutions from each plated onto 70%
; confluent BHK21/C13 monolayers. After adsorption at 37°C for lh, the plates were overlaid 
with 4ml EMC 10% and incubated at 37°C for 30 h. 2 ml EMC 10 containing 0.6 mg/ml of X- 
9 gal was added to the plates and the plates were incubated for a further 12 h at 37°C. The plates 
1 were washed twice and single blue plaques were picked and seeded into linbro wells 
■ containing monolayers of BHK21/C13 cells. The cells were incubated for 2-3 days at 37°C. 
] When c.p.e. was complete, the linbro wells were stored at -70°C for temporary stock.
12 .2 .8. Marker rescue
I In vitro marker rescue methods were used to restore the deleted gene phenotype of the mutant 
■viruses. DNA (1 (Ltg) from a mutant virus was transfected onto BHK21/C13 cells with a 1-, 10- 
lan d  100- fold molar excess of a wild-type fragment containing the deleted gene ORF. The 
(following day, X-gal (0.6 mg/ml in EMC 10 ) was added into the medium. After two days, 
(white plaques were picked and their genomic structures were identified by restriction enzyme 
(digestions and Southern blotting. Before stock virus was prepared, the revertant was single 
fplaque purifed four times.
h .  2. 9. In  vivo  preparation of ^2p labelled viral DNA
This is a modification of the method described by Lonsdale (1979). Confluent monolayers of 
BHK21/C13 cells in Linbro wells were infected with either lOOpl of a plate stock or 2x10^ 
fc.f.u. of a virus stock. After adsorption for 45 minutes at 37°C, the virus was removed and the
-ells washed with and maintained in 450 pi PIC for 2h at 31 °C. One pCi of orthophosphate
;32P) 50 pi PIC was added per well and incubation continued at 31 °C for 2-3 days. At the 
ind of the incubation period, 0.5ml of 5% (w/v) SDS was added to each well. Trays were 
incubated at 37°C for 5-10 minutes before scraping the cells off the wells using a blue tip and 
idding them to 1ml of phenol. The samples were inverted and incubated at RT for 10 minutes, 
vith a further inversion after 5 minutes. They were centrifuged at 2K for 10 minutes at RT in a 
"ison's Coolspin before removing the top layer into 2 volumes of ethanol. After gently 
nverting the tubes, they were spun as before. The ethanol was poured off and the DNA dried 
or 10 minutes at 37°C with the test-tubes in an inverted position. Two hundred pi of RNAse A 
50 pg/ml) solution was added to each sample and left to dissolve for 2h at 37 C. The DNA 
vas then ready for digestion with the appropriate enzyme(s).
Materials and methods
2. 2. 10. Preparation of small amounts of virus infected cell DNA for Southern 
blotting
BHK21/C13 cell monolayers in 24 well linbro tray were infected at a m.o.i. of 5 pfu/cell at 
37°C. After 48 h the supernatant was removed and the cells lysed by incubating with 2ml of 
lysis buffer (0.6% (w/v) SDS, lOmM EDTA, lOmM Tris-HCl pH 74) containing 500pg/ml 
protease, for 4 h at 37 C. Infected cell DNA was extracted twice with an equal volume of 
phenol and once with chloroform; precipitated by the addition of 2 volumes of ethanol and 
dried in a vacuum desiccator. The DNA was dissolved in 200pl of water containing 50pg/ml 
RNase A. Restriction enzyme digests were usually carried out on 5% of the total sample 
(10pl).
2.2.11. Purification of EHV1 virions.
Virions were purified essentially by the method of Szilagyi & Cunningham (1991). 
Monolayers of BHK21 C l3 cells in roller bottles were infected with EHV1 strain Ab4 at a 
m.o.i. of 0.01 pfu/cell and incubated at 31°C for 3 days. Once c.p.e. was complete the 
supernatant was harvested and pelleted by low speed centrifugation (l,000g for 10 min at 4°C), 
and the virus particles in the clarified medium were pelleted by centrifugation at 12,000 r.p.m. 
for 2 h at 4°C. The pellet was then gently resuspended in 1 ml of modified medium (culture 
medium without phenol red or calf serum) and layered onto a 35-ml performed gradient of 5 to 
15% (w/v) Ficoll 400 (Sigma) suspended in this medium. After centrifugation in a swing-out 
rotor (12,000 r.p.m. for 2 h at 4°C in an AH629 cellulose nitrate tube), the higher L-particle 
band and lower virion band were withdrawn by side puncture. These virions were diluted in 
modified medium and pelleted by centrifugation (21,000 r.p.m. for 2 h at 4°C in an AH629 
tube). The virion pellet was gently resuspended in 200pl of modified medium and either used 
immediately or stored at -70°C.
2.2.12. Analysis of virus growth properties in  vitro .
Virus growth experiments in vitro were carried out essentially as described by Brown et al 
(1994). For multi-cycle growth experiments, confluent cell monolayers were infected at a 
multiplicity of 0.01 p.f.u./cell of stock viruses. Single-cycle growth experiments were carried 
out by infecting confluent monolayers at a multiplicity of 5 p.f.u./cell. After 1 h absorption, the 
monolayers were washed three times with PBS and overlaid with ETC 10. At specific times 
post-infection, cells were harvested, sonicated and stored at -70°C. Viruses were titrated on 
monolayers of BHK21/C13 cells at 37°C.
2.2.13. Temperature sensitivity
Confluent BHK21/C13 cells were infected in triplicate with stock viruses at a multiplicity of 5 
•f.u./cell. After 24h incubation at 31°C, 37°C, and 38.5°C, the monolayers were harvested, 
sonicated and the progeny virus titrated on BHK21/C13 cells at 37 C.
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2.2.14. Assay for rate of virus adsorption
ylonolayers of BHK21/C13 cells (4x106) in 50 mm petri dishes were precooled for 1 hr at 4°C 
and inoculated with virus at a multiplicity of infection (m.o.i.) of 300 pfu/plate and left at 4°C 
:or various lengths of time up to 4 hr. At various time points, the plates were washed three 
times with PBS and overlaid with medium containing 1% carboxyl methyl cellulose. The 
plates were incubated at 37°C for 2 days after which time they were fixed and stained. Plaques 
were counted, and the % of virus absorbed at each time-point determined, relative to the final 
time-point (4 hr) which represented 100% adsorption.
2 2.2.15. Assay for rate of virus penetration
Virus penetration was assessed by determining the rate at which adsorbed virus became 
resistant to inactivation by a low-pH citrate buffer. The method used was essentially as 
described by Huang and Wagner, (1964) and Highlander et al. , (1987). Confluent BHK21/C13 
cells (4x10^) in 50 mm petri dishes were separately infected with 400 pfu per plate of either 
purified wild-type virus, the mutant ED71 or Re71 and allowed to adsorb for 2h at 4°C. The 
unbound virus was removed by washing four times with PBS. The cells were then overlaid 
with Eagle’s medium and shifted to 37°C to allow viral penetration to proceed. At selected 
time points after the temperature shift, plates were either treated with 1 ml of citrate buffer (40 
mM citric acid, lOmM KC1, 135mM NaCl, pH 3.0) or with 1 ml of PBS for 5 min as a control. 
The monolayers then were washed three times with PBS and overlaid with Eagle's medium 
containing 1% carboxyl methylcellulose and incubated at 37°C for 2 days. The plaques were 
visualised with Giemsa stain and counted. Experiments were performed in triplicate. The 
amount of penetrated virions at each time point was determined as % of pfu from citrate buffer 
treated plate composed to PBS control.
2.2.16. Assay for virion release from infected cells.
BHK21 C l3 monolayers in 33 mm petri dishes were separately infected with ED71, wild-type 
virus or Re71 at a multiplicity of infection of 5 pfu/cell. After 1 h adsorption at 37°C, the 
unbound extracellular virus was removed by thoroughly washing the monolayers four times 
with PBS containing 1% calf serum. After each incubation period, the medium was removed, 
clarified at 1500 rpm for 5 min at 4°C and stored at -70°C. Cells were separately harvested in 
the same volume, sonicated and stored at -70°C until the titres were assayed.
2-2.17. Assay for virus spread from cell to cell.
Confluent monolayers (4x l06) of BHK21/C13 cells were infected with virus at a m.o.i. of 0.01 
pfu/cell. After adsorption at 37°C for 1.5 h, the plates were washed twice with PBS, overlaid 
with ETC 10 plus and minus, EHV1 neutralising horse serum (final concentration 1.25) and 
ncubation continued at 37°C. The infected cells were harvested at various time points after
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infection and virus titrated on BHK21/C13 cells.
2.2.18. Electron microscope analysis
BHK21/C13 monolayers (4 x 10^ cells) infected with virus at 3 pfu/cell, were scraped from 
petri dishes at 24 h post infection and pelleted in Been Capsules (Taab Laboratories). The 
pellet was fixed in 2.5% (v/v) glutaraldehyde in PBS, then post fixed in 1% (aqueous) OsC>4. 
The pellets were dehydrated through a series of increasing ethanol concentrations to 100%, 
then infiltrated with Epon 812 epoxy resin (Taab Laboratories). After polymerisation 80 nm 
sections were cut and stained with saturated uranyl acetate (in 50:50 ethanol/water) and 
subsequently stained with lead citrate. For counting, 50 complete cell profiles (non-serial and 
including nuclei) were examined.
■
2.2.19. Preparation of infected cell extracts
Infected cells were washed once with PBS and incubated with either extraction buffer [ 100 
mM Tris-HCl, pH 8.0, 10% (v/v) glycerol, 0.5% (v/v) NP40, 0.5% (w/v) Na deoxycholate, 
500uM PMSF (phenylmethylsulphony fluoride)] for immunoprecipitation. For Western 
blotting samples were harvested with sample buffer (50mM Tris pH 7.5, 2% (v/v) SDS, 7mM 
2-mercaptoethanol, 10% (v/v) glycerol) at 0°C for 30 min. The cells were scraped into buffer 
and then spun in a Beckman microfuge for 10 min and the supernatant stored at -70°C until use.
2. 2. 20. Radiolabelling of infected cell extracts
Monolayers of BHK21/C13 cells in 33 mm Petri dishes were infected with virus at a m.o.i. of 5 
pfu per cell. Virus was allowed to adsorb for 1 h at 37°C and the plates were washed twice 
: with PBS and further incubated in 2ml ETC 10 medium. If labelled extracts were required, 50 
| gCi/ml of [35S]-methionine in Emet/5C2 , 100 jnCi/ml of [32p]_phosphate in PIC or either 2.5 
|iCi/ml of [14c]-glucosamine or 3 pCi/ml of [^HJ-mannose in Eglu/10C2, were added to the 
cells and incubated usually from 5 h to 20 h post-infection (pi) (0 h pi being taken as the end of 
the 1 h absorption period). At 24 h p.i. the cells were washed once with PBS and scraped into 
either extract buffer (section 2.2.26.) for immunoprecipitation or sample buffer (section 2.2.27 
j ) for Western blotting.
2.2. 21. Surface labelling of virion glycoproteins
Exposed carbohydrate residues of viral glycoproteins on the virion envelope surface were 
labelled in vitro by the enzymatic labelling method of Wallenfels (1979). Briefly, the reaction 
' mixture containing (in a total volume of 460pd) 0.25 M Tris-HCl pH7.4, 400|ig purified 
virions, 2pCi U D P-[14C] galactose (270mCi/mmol), 0.28 units of galactosyl transferase and 
I 0.02 M MnCl2 was incubated with shaking for 1 h at 37°C, followed by 5 min at 0 C. The 
labelled virions were washed by centrifugation in lOmM-Tris pH 7.5 and ImM-EDTA to 
remove unincorporated U D P-[14C] galactose. The pellet was then resuspended in sample
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2.2 22. Preparation of virus-induced early polypeptides
To prepare extracts of proteins produced in the absence of viral DNA replication (loosely 
termed ‘early’ extracts) cell monolayers were pre-treated with phosphonoacetic acid (PAA) at 
300 pig/ml for lh, then infected and maintained in the continuous presence of PAA. Cells were 
harvested with sample buffer at various times p.i.
2.2.23. Preparation of virus-induced immediate early polypeptides
BHK21/C13 monolayers in 33-mm petri dishes were preincubated for 1.5 h before virus 
infection in ETC 10 containing 200 pg/ml of cycloheximide. Cells were infected at a 
multiplicity of infection of 10 pfu per cell; after 1 h adsorption, cells were washed and 
incubated for a further 5 h, all in the same medium. Actinomycin D was then added to a final 
concentration of 2.5 pg/ml. After 15 min, this cycloheximide-containing medium was 
removed, and plates were washed twice with medium containing 2% calf serum and 
actinomycin D (2.5 ftg/ml) and incubated for a further 2 h. Control cultures were treated in the 
same manner except that cycloheximide was omitted. The cells were washed once with PBS 
and lysed with sample buffer and analysed by Western blotting.
2.2.24. Subcellular fractionation
Subcellular fractionation was based on the method described by Bryant & Ratner (1990) and 
MacLean et. al. (1992) with some modification. Cell monolayers were rinsed twice with PBS 
and once with distilled water before being scraped into homogenization buffer (20 mMTris- 
HC1 pH8, 10 mM MgCl2, 0.5 mM EDTA, 7 mM 2-mercaptoethanol) and swollen on ice for 
20 min. The cells were then disrupted by Dounce homogenization (50 strokes) and centrifuged 
at 2000 r.p.m. for 3 min at 4 °C in a Fison's Coolspin to remove nuclei and any intact cells. The 
supernatant material was adjusted to 150 mM-NaCl and centrifuged in a Sorvall Ti50 rotor at 
45000 r.p.m. for 30 min at 4°C. The supernatant (cytosol) was removed and stored at -70°C, 
and the pellet (total membranes) was resuspended in homogenization buffer containing 
150mM-NaCl. A sample of the total membrane fraction was then adjusted to lM-NaCl and 
lOOmM-sodium carbonate buffer (pH 11.5) to bring the protein concentration to 1 mg/ml and 
incubated at 4°C for 30 min, and centrifuged as before. The supernatant contained those 
proteins which bound only at the low ionic strength, whereas the pelleted materials contained 
the proteins which bound to membranes at high ionic strength. The pellet containing high 
affinity membrane bound proteins was gently washed once with ice-cold distilled water and 
dissolved in 300pl of lx sample buffer (Section 2.2.21.), before storing at -70°C.
2.2. 25. SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Vertical slab gels were used for protein analysis. Fresh stocks of 30% (w/v) acrylamide were
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prepared in water at a ratio of acry-lamide:n,n’-methylene bisacrylamide (the cross-linking 
agent) 29.25:0.75. If the gels were cross-linked with N,N'-diallyltardiamide (DATD) the 
stocks of 30% (w/v) acrylamide were prepared in water at a ratio of aery 1 amide:DATD 
92.25:0.75. These were then filtered through Whatman N°1 filter paper before use. From 
these stocks, gel solutions containing the appropriate percentage of acrylamide were prepared 
in a buffer of final concentration 375mM Tris-HCl, pH8.9, 0.1% (w/v) Sodium dodecyl 
sulphate (SDS). To polymerise the gels, ammonium persulphate and TEMED were added at a 
final concentration of 3.65 mM and 2.75 mM, respectively. The gel solutions were poured 
between two well-washed glass plates separated by 1.5 mm spacers to within 3-4 cm of the top 
of the glass-plate sandwich. 400 |il of butan-2-ol was loaded on the top of the acrylamide 
solution, and following polymerisation a stacking gel, consisting of 5% (w/v) acrylamr e in 
122 mM Tris-HCl pH 6.7, 0.1% (w/v) SDS, was added, into which a twenty-one well-forming 
comb was placed.
2.2.26. Immunoprecipitation
100-200p,l of infected or mock infected cell extracts were incubated with rabbit antiserum (5- 
lOpl) for 16 h at 4°C. Following incubation, 60pl of protein A-sepharose (Sigma), diluted 1:1 
in the extraction buffer, was added and incubation continued at 4°C for a further 1-2 h. The 
protein A-sepharose pellet was then washed 4 times with the extraction buffer and the bound 
polypeptides on the protein A sepharose eluted by boiling the beads for 5 min in sample buffer 
and analysed by SDS-PAGE. The gels were fixed in 6.1% acetic acid and 46.7% methanol and 
soaked in EN^HANCE for lh  and washed in H 2 O for 20 min. The gels were dried and 
exposed to Kodak X-Omat films for fluorography.
2.2.27. Western blotting
Infected cells were harvested into sample buffer at a concentration of 10^ cells/ml. After 
boiling for 5 min, samples were loaded onto SDS-PAGE at approximately 10^ cells /well. 
Following electrophoresis, the gel was placed on a sheet of Whatman grade 182 filter paper 
presoaked in transfer buffer (25mM Tris-HCl pH 8.3, 192mM glycine, 20% (v/v) methanol) on 
top of a foam pad and a pre-soaked nitrocellulose membrane was placed face down on the gel, 
with care being taken to exclude air bubbles between the gel and the membrane. Finally a 
further sheet of pre-soaked filter paper and then another foam pad were placed over the gel and 
the sandwich (held tightly together in a plastic holder) was placed in an electrophoresis tank 
with the gel towards the cathode and the nitrocellulose towards the anode. Proteins were 
transferred to the nitrocellulose by electrophoresis in transfer buffer for at least 3 h at room 
temperature. The nitrocellulose sheet was blocked with 2% dried milk in PBS/0.05% (v/v) 
Tween 20 for 1 h at 37°C and incubated with 1:25 - 1:200 diluted antiserum in PBS/Tween 20 
0-05% (v/v) for 16 h at 4°C. The sheets were washed in PBS/Tween 20 0.05% (v/v) by gently 
shaking at 37°C, with 1 change of buffer over 15 min. The sheets were incubated with 1:1000
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diluted horseradish peroxidase(HRP)-labelled protein-A conjugate in PBS/Tween 20 
containing 1% (w/v) BSA. The sheets were then washed extensively in PBS/Tween20 with at 
least 3 changes over 1 h at 37°C. Finally bound antibodies on the sheets were detected with the 
ECL system (Amersham). The sheet was incubated with equal volumes of detection reagent 1 
and 2 for 1 min at room temperature. Following incubation, the detection reagents were 
drained off and the sheets were wrapped in Saran Wrap and exposed to Kodak film for 10 to 60 
seconds.
2.2.28. Immunofluorescence staining.
At 16 h p.i. or 30 h post transfection, cells on glass coverslips were washed once with PBS 
and fixed with 4% formaldehyde in PBS, pH7.4 for 10 min at room temperature; washed three 
times and permeabilised by 0.2% (v/v) Triton-X 100 in PBS for 30 min at room temperature. 
The cells were washed and incubated with a specific rabbit antiserum (dilution of 1:100) for lh 
at 37°C. The cells were washed three times with PBS and incubated with the second anti­
rabbit IgG (whole molecule) Fluorescien Isothiocyanate (FITC) conjugated-antibody ( 1:80 
dilution ) at 37°C for lh. If the first antibody was a monoclonal antibody, an anti-mouse IgG 
TRITC conjugated-antibody was used as the second antibody. The cells were then washed 
four times with PBS, before removing the coverslips, polishing the underside and mounting 
them on microscope slides using a small amount of fluorocolor. The coverslips were sealed 
with clear nail polish and immediately examined or stored in the dark at 4°C for up to a few 
weeks.
2.2. 29. NP40 treatment of purified virions.
The method used is described by Frame et al. (1987). Briefly, purified virions were incubated 
in the presence of 5% (v/v) NP40 and 600 mM-NaCl for 30 min at room temperature, and then 
diluted fivefold with 20 mM-tris HC1 pH 7.5, and centrifuged in a Sorvall SS34 rotor at 12000 
r.p.m. for 2 h at 4°C. One third volume of sample buffer was added to the supernatant. The 
non-soluble pellet was resuspended in lx  sample buffer in a equivalent volume to the 
supernatant fraction. The samples were used immediately or stored at -70°C.
2.2.30. Digestion of EHV1 virion glycoproteins with glycosidases
(1) Purified EHV1 virions ( 600pg) were incubated with 10 jLil of 1% (v/v) Triton X-100 in 
PBS at 0°C for 10 min and centrifuged at 10,000 g for 10 min. The supernatant was 
digested with 10 units/m l N-glycosidase [peptide-N-4(N-acetlyl-b-glucosam inyl) 
asparagine amidase, Genzyme] in 15pl of 0.2M-sodium phosphate buffer pH 8.6 and 3jll1 of 
100mM-l,10-phenanthroline at 37°C for 6 h.
(2) Following the treatment with N-glycosidase, one third of the above digestion half stored at 
-70°C. The remaining two thirds was adjusted to pH5.0 with 0. lM-citric acid and digested
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with 0.2 units of neuraminidase( acetylneuraminyl hydrolase, Sigma) at 37°C for 4 h.
(3). Finally, half of the above digestion was stored at -70°C and the remaining was digested 
again with 0.01 units of B-N-acetylhexosaminidase, 0.01 units of L-fucoside fusohydrolase, 
Sigma and 0.01 units of B-galactosidase(B-D-galactosidase galactohydrolase, Boehringer 
Mannheim) at 25°C for 4 h. The digested virions were boiled with lx  sample buffer ( 2.2.7 
section) for 5 min and subjected to Western blotting.
2 .2 .31.Treatment of infected cells with inhibitors.
Confluent BHK21/C13 cell monolayers were infected with virus at a multiplicity of 20 
pfu/cell or mock-infected. The cells were then incubated with medium in the presence of either 
2 Fg/ml tunicamycin (Sigma), 1 (iM-monensin (Sigma), 40 pM Nocodazole(Sigma) or 40 pM 
Demecolcine (Sigma) at 37°C from the end of the adsorption period (lh ) to 20 h p.i, 
respectively. The cells were then subjected to either Western blotting or immunofluorescence.
2.2. 32. Lipofection of BHK21/C13 cells with plasmid DNA
To transiently express the gene 67 protein product, BHK21/C13 cells were lipofected with 
pCMV67 DNA according to the method of Feigner et al., (1987). Briefly, 50% confluent 
monolayers of BHK21/C13 cells in 33 mm petri dishes were incubated with 2 pg of either 
pCMV67 DNA or pCMVIO DNA and 15p3 of liposomes in 1ml Opti-MEM 1 (GIBCO BRL) 
at 37°C for 4 h. The medium was then replaced by ETC5 and the incubation continued at 37°C 
for a further 26 h. The cells were then either fixed for immunofluorescence or lysed for 
Western blotting.
2.2. 33. Ligation.
Several strategies of ligation (Sambrook et al , 1989) were adopted to ligate fragments of 
EHV1 DNA to plasmid vectors. When both vector and DNA fragments cut with the 
appropriate restriction enzymes (RE) produced compatible or blundends of fragments, various 
quantities of fragment were ligated to lOOng of vector DNA in lx ligation buffer (see Section 
2.1.14) with 2 units of T4 DNA ligase at 16°C overnight. If the vector and fragment were cut 
with inappropriate REs, two types of fragment ends (5' overhangs and 3’overhangs) could be 
generated. A fragment with 5' overhangs had to be filled in to produce a blunt end fragment 
with 0.1 volume of 2.5mM dNTPs and 1 unit of DNA polymerase I, which carries the 5 '-> 3 ' 
DNA polymerase activity, was added to the digestion mixture; if the fragment had 3' 
overhangs, they had to be exonucleased into blunt ends with 1 unit of T4 DNA polymerase, 
which has a strong 3'—>5' exonuclease activity in lx T4 polymerase buffer before cloning into 
the vector cut with a blunt-cutting enzyme e.g. Sma I.
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2 .2. 34. Glycerol stocks of bacteria.
Glycerol stocks of bacteria were prepared by centrifugation of an overnight culture (10ml) at 
2000 rpm for 10 min and resuspending the pellet in 5ml L-broth, mixed with 5ml of 99.5% 
glycerol and storing at -20°C.
2.2. 35. Preparation of competent bacteria and transformation
Ten ml of 2xYT broth was inoculated with 15|il of a glycerol stock of bacteria and incubated 
with shaking at 37°C overnight to produce a saturated culture. One ml of this culture was used 
to inoculate 100ml of 2xYT broth which was shaken at 37°C for 2.5-3h to get the bacterial 
cells into mid-log phase. The bacterial cells were pelleted by spinning at 2K for 10 minutes in 
aFison's Coolspin and resuspended in 1/10th volume of transformation and storage buffer (10 
mMMgCl2, 10mM MgSOzj., 10%(w/v) PEG 3,500, 5% (v/v) dimethyl sulphoxide). After 15 
minutes on ice, the bacteria were considered competent for transformation. Typically, 5jil of a 
ligation mix or 1 jil plasmid preparation were incubated for 30 minutes on ice with 100 pi of 
competent E.coli. One ml of L-broth was added to the transformation mix and incubation was 
continued for a further hour at 37°C. For selection of transformations, lOOpl of the 
transformed bacteria were plated on to L-broth agar plates containing appropriate antibiotics, 
such as 100 pg/ml ampicillin and ±  25pg/ml X-gal. Plates were allowed to dry at room 
temperature, before incubating in an inverted position at 37°C overnight ( Chung and Miller, 
1988).
2.2.36. Small scale plasmid preparation.
Single, transformed, bacterial colonies were picked and resuspended in 5ml of L-broth 
containing lOOpg/ml ampicillin. Following growth at 37°C for 8-16h, 1.5ml aliquots of each 
culture were spun at low speed (6500g) in a microfuge, the supernatant discarded and the cells 
resuspended in lOOpl of alkaline lysis solution I (section 2.1.14). Following 5 minutes 
incubation at RT, 200pl of alkaline lysis solution II (section 2.1.14) was added, and the 
cultures mixed vigorously. After a further 5 minutes incubation at RT, 150pl of alkaline lysis 
solution III (section 2. 1.14) was added, mixed by vortexing and incubated at RT for 5 minutes. 
A white precipitate consisting of the cell debris was pelleted at high speed (13000g) in a 
microfuge. Plasmid DNA was extracted from the supernatant using an equal volume of 
phenolichloroform followed by 2 volumes ethanol precipitation at RT for 1 minute. The DNA 
was pelleted by spinning at 13,000g for 5 minutes in a microfuge, washed in 70% ethanol, 
dried in a Speedivac and resuspended in IOOjllI H 2O containing 50 pg/ml RNase A (Sambrook, 
at al. , 1989).
2* 2.37. Large scale plasmid preparation.
The method used was essentially as described by Maniatis et al ., (1982). A single transformed 
bacterial colony from a L-broth agar plate was inoculated into 5ml of L-broth containing the
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appropriate antibiotic and shaken at 37°C for 8-16h. The culture was transferred into 500ml L- 
broth containing the appropriate antibiotics in a 2 litre dimpled flask and shaken at 37°C 
overnight. The bacteria were pelleted by centrifugation at 8K for 10 minutes in a Sorvall GSA 
rotor, the pellet resuspended in 10ml alkaline lysis solution I (see section 2.1.14.) and 
incubated at RT for 10 minutes. Freshly made alkaline lysis solution II (20ml) was added and 
incubation continued for a further 10 minutes on ice. Ice-cold alkaline lysis solution III (15ml) 
was added, incubation continued on ice for 10 minutes and the bacterial debris pelleted by 
centrifugation at 12K for 10 minutes in a Sorvall SS34 rotor. DNA was extracted twice with an 
equal volume of phenol and once with an equal volume of chloroform. The DNA was 
precipitated by the addition of 2 volumes of ethanol, centrifuged at 2K for 30 minutes in a 
Sorvall SS34 rotor at RT, washed in 70% ethanol, pelleted as before, dried in the incubator and 
dissolved in water containing 50 (ig/ml RNase A.
In some instances, to remove residual host DNA and RNA, the DNA was further purified by 
isopycnic banding on ceasium chloride gradients. In this case, the DNA was only extracted 
once with phenol xhloroform . Ceasium chloride was added until the buoyant density was 
1.55g/ml and ethidium bromide was added to a final concentration of 0.5 mg/ml. The mixture 
was pipetted into Oakridge tubes, which were capped, sealed and centrifuged at 45,000 r.p.m. 
overnight in a Sorvall Ti50 rotor. The DNA was visualised on a long wave U.V. light box and 
the lower band which contained the supercoiled plasmid DNA was removed using a needle and 
syringe. After extracting the ethidium bromide at least 3 times with isoamyl alcohol, the DNA 
was ethanol precipitated as described above. The DNA concentration was quantitated by 
running a small quantity on an agarose gel alongside standards of known concentrations 
(Sambrook et al .,1989).
2.2. 38. Restriction enzyme digestion of DNA
The manufacturer's recommended buffers and conditions were generally used for each 
individual restriction enzyme. To achieve complete digestion, lpg  samples of EHV1 or 
plasmid DNA were digested with 2-5 units of restriction enzyme for 4h at the appropriate 
temperature. If the digested DNA was to be run on an agarose gel, 1/5- 1/6 volume of RE stop 
was added prior to loading, otherwise the digested DNA was recovered as described in Section
2.2.41.
2.2.39. Phenol-chloroform extraction of DNA from restriction enzyme digestion 
mixtures.
^  the digestion mixture was not at least 100pl, it was increased to this volume using dH20. An 
equal volume of phenol xhloroform was added, the mixture vortexed vigorously, and spun at 
13000g for 2 minutes in a microfuge. The top aqueous layer was removed into a separate 
ePpendorf tube and the bottom layer was back extracted with an equal volume of dF^O. An
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equal volume of chloroform was added to the aqueous layer and the mixture mixed and spun at 
I3000g for 2 minutes in a microfuge. The top layer was removed and the sample back 
extracted as before. To precipitate the DNA, 2 volumes of ethanol and 0.1 volumes of 3M 
sodium acetate were added. Following 15 minutes incubation on dry ice, the DNA was 
pelleted at 13000g for 5 minutes, washed with 70% ethanol and dried in a Speedivac, before 
resuspending in an appropriate volume of TE.
2.2.40. Agarose gel electrophoresis.
Restriction endonuclease analysis of viral or plasmid DNA used 0.4-2% (w/v) agarose gels 
boiled in lxTBE buffer. When cooled to about 45°C, the solutions were poured on to glass 
plates (16.5x26.5cm) whose edges had been sealed with gel tape and on to which 12-26 tooth 
combs had been placed. For non-radioactive samples, ethidium bromide was added to the 
agarose solution to a final concentration of 0.5mg/ml before pouring. The gels were allowed to 
set at RT for lh and then transferred to horizontal tanks containing lxTBE buffer. DNA 
samples were mixed with one-fifth volume of RE stop, loaded into the gel tracks and 
electrophoresed at 40-120V for 4-16 h (Sambrook etal., 1989).
For quantitation of fragment and vector DNA prior to transfection or ligation, gels containing 
ethidium bromide were poured in to a mini-gel Kit (Bio-Rad). Samples (generally 5-7pl) were 
run at 50 V for l-2h, visualized using a short wave (260) U.V. lamp and photographed on 
Polaroid film. A 1Kb DNA marker (BRL) of known concentration was run alongside the DNA 
samples to enable confirmation of the vector/fragment size and quantitation of each sample.
2.2.41. Recovery and purification of DNA from agarose gels .
Generally the DNA to be recovered had been digested with restriction enzymes before running 
on an agarose gel. In order to cause the minimum possible damage to the DNA, it was 
visualised using a long wave (300-360nm) U.V. lamp, a gel slice containing the desired DNA 
fragment cut out with a sharp scalpel and the DNA recovered and purified using Prep-A-Gene 
DNA Purification Kit (BIO-RAD) in accordance with the manufacturer’s instructions. For this 
purpose, the gel slice was cut into small pieces and dissolved at 55°C in the presence of Prep- 
A-gene binding buffer. The proper amount of Prep-A-gene matrix (20pgDNA/25pl) was 
added, the mixture vortexed briefly, incubated at RT for 10 min and spun at 2000rpm for 2 
min. The pellet containing the bound DNA was washed twice with the binding buffer and 
three times with the wash buffer. After the last wash, the bound DNA was eluted at 37°C using 
elution buffer. The yield was estimated as described in Section 2.2.40.
2.2.42. Southern blotting.
Southern blotting was carried out as described by Sambrook et al. (1989). Purified virus, 
infected cell DNA or plasmid DNA was digested with the appropriate restriction enzyme(s) 
before running on an agarose gel. The gel was visualised under short-wave U.V. light to
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confirm DNA digestion, then placed in 500ml Gel Soak I for lh, rinsed with deionised water 
and transferred to Gel Soak II for lh. After rinsing as before, it was transferred to 500ml 
20xSSC for a further lh. The gel was now ready for blotting onto either one sheet or two 
sheets simultaneously of Hybond N hybridization transfer membrane. For each transfer one 
sheet of membrane and five sheets of Whatmann 3MM chromatography paper, all cut to the 
exact size of the gel were required.
A bundle of 'Hi-Dry' towels was placed on the bench followed by three sheets of dry then two 
sheets of 20xSSC soaked 3MM paper. The membrane was placed on top of the filter papers 
followed by the gel, ensuring that there were no air bubbles between the gel and the membrane. 
A glass plate and heavy weight were placed on top and left for at least 4h during which time 
the DNA was drawn out of the gel and onto the adjacent side of the nitrocellulose. To transfer 
DNA to two membranes, this procedure was repeated on top of the gel.
The DNA was cross-linked to the membrane using a U.V. Stratalinker (Stratagene, USA) and 
hybridized to the random produced probe in a sealed bag containing 20ml hybridization buffer 
f  (see section 2.1.14). Hybridization was generally carried out overnight at 65°C. The membrane 
was washed for 3x30 min with 1 litre 2xSSC, 0.1%(w/v)SDS before drying and setting up for 
; autoradiography against Kodak XS-1 film.
2.2. 43. Purification of synthetic oligonucleotides
Eighty ml of 6 % (w/v) acrylamide, lxTBE, 9M Urea sequencing gel mix was polymerized 
with 160pl of 25% (w/v) APS and 60pl TEMED. This was then poured between two 20x22cm 
glass plates separated by 1.5mm spacers and a 10 tooth comb inserted at the top. The synthetic 
I oligonucleotides were eluted from the column with ammonium for 2 h and deprotected at 55°C 
for 5-6h, frozen on dry ice and dried in the Speedivac overnight. The oligonucleotide was 
resuspended in 100(Ltl H 2O. Glycerol (5pl) was added to 30|il of oligonucleotide solution and
loaded immediately onto the gel. Formamide dye mix (2|nl) was loaded in a separate well to act 
as a molecular weight marker and the gel was run at 10mA for 3-4h in lxTBE. The 
electrophoresis was stopped when the dye had migrated approximately two thirds of the length 
of the gel. The gel was removed, wrapped in cling-film and viewed against a white 
chromatographic plate using a hand-held long-wave U.V lamp (Sambrook et al., 1989). If the 
synthesis had been successful, then a predominant band with possibly a few lower molecular 
weight bands was observed. The top band was cut out with a scalpel, mashed with a glass rod, 
and incubated overnight at 42°C  in 1ml elution buffer (0.5M ammonium acetate, 0.25mM 
EDTA, 20% (w/v) SDS). This was filtered through a SPIN-X centrifuge unit (Costar) to 
I remove the acrylamide, phenol: chloroform extracted, ethanol precipitated, washed in 70% 
ethanol, dried and redissolved in dH2 0 . To quantitate the DNA, the OD26O was rea^ and the
conversion factor: 1 OD unit=20jig/ml was used.
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2.2.44. Sequence analysis of double strainedplasmid DNA.
Sequence analysis was carried out using the Sequenase Version 2.0 kit (Amersham) in 
accordance with the manufacturer’s instructions. Plasmid DNA (20jig) was denatured and
annealed to 30 ng of the 15-mer oligo primer which hybridizes upstream of the multicloning 
site of the pUR vector in a 5x annealing buffer (200mM Tris-H Cl, pH7.5, lOOmM MgCl2 and
250mM NaCl) in a total volume of 10|il. Annealing was carried out by first heating to 55°C 
for 5 minutes in a 1.5ml eppendorf tube, then allowing to cool to room temperature over a 
period of 30 minutes. The templates were briefly chilled on ice, before being labelled using a 
buffer which contained 1.5mM dCTP, 1.5mM dGTP, 1.5mM dTTP, 5|iiCi 35$ dATP, 6mM 
DTT and 3 units of Sequenase T7 DNA polymerase in a total volume of 16pl Labelling was 
carried out at RT for 5 minutes. Each template was extended and terminated by addition of 
3.5|xl of labelled template to 2.5pl of each of the 4 ddNTP termination mixes in microtitre 
wells, which had been pre-warmed to 37°C. Each ddNTP termination mix contained one 
ddNTP at a concentration of 8mM and dNTPs at a concentration of 80 mM. The plate contents 
were mixed by centrifugation in a Beckman centrifuge and the reactions carried out at 37°C 
for 10-30 minutes. Four fil formamide dye mix was added to each sample. The samples were 
boiled for 2 minutes before loading onto a gel for electrophoresis.
2.2.45. Electrophoresis and autoradiography of sequencing gels.
Electrophoresis was carried out at 70W through vertical gels 42x34x0.04 cm in size. Gels 
consisted of. 6% (w/v) acrylamide (cross-linked with 5%(w/v) N,N'-methylbisacrylamide) and 
9M urea in lxTBE. Polymerization was achieved by addition of 0.05%(w/v) APS and 
0.1%(v/v) TEMED. Spacers and gel combs were supplied by Gibco-BRL. Both plates were 
treated with repelcote enabling the gel to be transferred to Whatmann 3MM chromatography 
paper following electrophoresis and dried under vacuum. Dried gels were then exposed to XS- 
1 film (35x43 cm) and developed using a X-omat processor.
2.2. 46. Expression and purification of fusion proteins in E. c o l i .
A 5 ml overnight culture of E. coli transformed with the recombinant plasmid was added into 
100 ml L-broth containing 1 OOjug ampicillin. The culture was incubated with shaking at 37°C 
for 2 h, then IPTG (l|iM ) added and incubation continued for another 2 h at 37°C. Inclusion 
bodies were purified as described by Harlow and Lane, (1988). Cells from the 100 ml culture 
were pelleted by centrifugation at 7K for 10 minutes in a SS34 rotor and resuspended in 10 ml 
of lOOmM NaCl, ImM EDTA, 50mM Tris-HCl (pH 8.0) containing lysozyme (1 mg/ml) and 
incubated at room temperature for 20 minutes. The cells were pelleted at room temperature. 
The pellet was resuspended in ice-cold lOOmM NaCl, ImM EDTA, 0.1% (w/v) sodium 
deoxycholate, 50 mM Tris-HCl (pH 8.0) and incubated on ice with occasional mixing for 10 
minutes. MgCl2 and DNase I were added to a final concentration of 8 mM and 10 fig/ml, 
respectively. The suspension was incubated at 4°C with occasional mixing until the viscosity
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disappeared. The inclusion bodies were pelleted from the suspension by centrifugation at 6000 
r.p.m. for 10 minutes at 4°C. The pellet containing the inclusion bodies was washed once with 
2M urea in PBS, once with PBS, suspended in 4ml PBS and stored at -70°C.
2.2.47. Production of specific antisera against viral gene products.
To raise specific antisera, two New Zealand white rabbits were intramuscularly immunized 
with 0.9mg (total protein) of each purified bacterially expressed fusion protein in 0.25ml of 
PBS emulsified with an equal volume of Freund’s complete adjuvant. Each rabbit was boosted 
on days 14, 30, 60 and 90 with an emulsion of 0.5 ml (0.6 mg) of fusion protein in Freund’s 
incomplete adjuvant. Final antisera were collected on day 100. Antisera were checked by 
Western blotting and immunoprecipitation.
Results
CHAPTER 3: RESULTS
3.1. INTRODUCTION
The complete DNA sequence of equine herpesvirus 1 strain Ab4[ (EHV1, Ab4p), a 
pathogenic UK isolate, revealed that the EHV1 genome was 150,223 base pairs in size and 
contained 81 open reading frames predicted to encode 76 distinct polypeptides (Telford et al., 
1992). Among these putative genes, there are five, 1, 2, 67, 71 and 75 which either have no 
or poor homologues in HSV1 and VZV (Telford et a l, 1992). Genes 1 and 2 located in the 
left terminal region of U l, are encoded on opposing DNA strands and are predicted to encode 
membrane proteins of 203 and 206 amino acids respectively with very similar hydrophobicity 
profiles. Gene 67 in IRS/T R S is predicted to encode a protein of 272 amino acids. A 
comparable ORF, IR6, has also been identified in EHV1 Kentucky A strain (Breeden et a l,  
1992). Genes 71 and 75 are located in the short unique region of the EHV1 genome. Gene 
71 is predicted to encode a protein of Mr 80 KD. Two comparable US ORFs called EUS4 
and ORF1, have been identified in Kentucky A and D strains of EHVI respectively (Audonnet 
et al, 1990; Colie et a l,  1992). They are smaller than the gene 71 ORF in EHV1 strain Ab4. 
Gene 75 encodes a protein of 130 amino acids which was first identified in EHV1 strain Abl 
(Elton et a l, 1991). At the start of this project, the products of these putative genes had not 
been identified and their roles in the virus life-cycle were unknown. However, the fact that 
these genes were not conserved in other members of the herpesvirus family and were unique 
to EHV1 suggested that they may play specific roles in the natural host, possibly in the 
determination of pathogenesis.
The aim of this project was investigation of the role of the five unique EHV1 genes in the 
virus life cycle in vitro. This was subdivided into three parts: (i) Generation of deletion 
mutants in each of the five genes, (ii) Characterisation of the deletion mutants with respect to 
the role of the gene products in the virus life cycle, (iii) Expression of the gene products to 
raise monospecific antisera and identification and characterisation of the gene products.
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For the generation of deletion mutants in each target gene, appropriate restriction enzymes 
were used to remove the majority of the ORF without affecting the neighbouring genes. To 
aid selection of mutant virus the deleted sequence was substituted by the 4.1 kb E . coli lacZ 
gene cassette including a lacZ gene flanked by a SV40 early promotor and downstream SV40 
polyadenylation sequences as a marker gene (Rixon and McLauchlan, 1990). Functional 
analysis of the gene products was carried out by comparing the phenotype of the deletion 
mutants with wild-type and revertant viruses in vitro. For expression of the gene products, an 
E.coli B-galactosidase fusion protein expression system was used. The level of fusion protein 
expression from this system is generally high and purification of the protein relatively straight 
forward. Identification and characterisation of the gene products were achieved using specific 
antisera which were raised against the expressed fusion proteins and the relevant deletion 
mutant, compared to the wild-type and revertant virus.
3. 2. GENERATION OF DELETION MUTANTS IN EHV1 GENES 1, 2,
67, 71 AND 75
3. 2. 1. Cloning and subcloning of relevant EHV1 DNA fragments
To clone the genomic fragments containing each target gene, EHV1 strain Ab4 DNA was 
prepared from infected NBL-6 cells and digested with the appropriate restriction enzyme. The 
fragment predicted to contain each of the five genes was purified and separately cloned into 
the vector pUC19 to construct four recombinant plasmids which were designated p 1/2, p67, 
p71 and p75. To identify these recombinants, restriction enzyme digestion and Southern 
blotting were employed. At least three different restriction enzymes were used to identify each 
recombinant plasmid and digestion patterns were analysed by electrophoresis on agarose gels. 
The results indicated that each of the eight recombinant plasmids had the expected restriction 
enzyme digestion patterns (data not shown). For further identification, the four cloned 
fragments were labelled with 32p dCTP and hybridised to southern blotted EHVI DNA 
digested with restriction enzymes. The results represented in Fig. 3 show that radio-labelled 
p l/2  containing an EHVI 5.1 kb StuI fragment hybridised with the EHVI 5.1 kb StuI 
fragment which contains EHV1 genes 1 and 2 (Fig. 3, d lane 1 ); labelled p67 containing the
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gene 67 ORF in the 5.1 kb BamHI fragment hybridised to EHV1 4.7 kb and 5.1 kb BamHI 
fragments which contain the TRS and IRS copies of gene 67, respectively (Fig. 3, c lane 1). 
Labelled p71 containing the IRS copy of the gene 71 ORF in a 5.8 kb BamHI/EcoRI fragment 
of EHV1 DNA hybridised to a 10.5 kb BamHI fragment which includes the 5.8-kb 
BamHI/EcoRI fragment (Fig.3, b lane 1 ). Labelled p75, which contains the gene 75 ORF 
and a TRs copy of gene 67 in a EHV1 4.9 kb StuI fragment, hybridised with the 4.9 kb StuI 
fragment and the 10 kb StuI fragment containing the IRs copy of gene 67 (Fig. 3, a lane 1 ). 
To construct smaller plasmids (Spl, Sp67, Sp71 and Sp75) which contain the cloned genes 
and the unique restriction enzyme (RE) sites to carry out the deletion, approprate smaller 
restriction fragments were further subcloned into pUC19 and were identifed by restriction 
enzyme digestions. The results showed that the constructed recombinants had the expected 
RE patterns (data not shown). The nucleotide positions of the cloned and subcloned EHV1 
fragments in the recombinant plasmids are summarised in Table 2.
3. 2. 2. Construction of deletion and substitution plasmids
To construct deletion and substitution plasmids, each recombinant plasmid was separately 
digested with restriction enzymes which cut at unique sites to remove the majority of the 
coding sequences of the target genes. The flanking sequences were religated with synthetic 
oligonucleotides with complementary ends, which contain an unique Spel site to allow 
insertion of the lacZ gene and an up-stream in frame stop codon to prevent synthesis of a 
fusion protein from the remaining N-terminal sequence and downstream lacZ insertion. To 
construct the gene 1 deletion plasmid, the majority of the gene 1 ORF (1373-1881 n.p.) was 
removed by AscI and Hpal digestion from Spl/2 and the flanking regions were religated with 
the adaptor 1. For selection the E. coli LacZ gene cassette was inserted into the Spel site in 
the adaptor. To construct the gene 2 deletion plasmid, the majority of the gene 2 ORF (1998- 
2398 n.p.) was removed by Pflml digestion and the flanking regions were religated with 
adaptor 2. For seletion of the mutant, the LacZ gene cassette was inserted into the Spel site 
in adapter 2. To construct the gene 67 deletion plasmid, the majority of gene 67 ORF 
(124416-124929 n.p.) was removed by BsaAI and Styl digestion and the flanking regions
71
Figure 3. Southern blot of restriction enzyme digestion of EHV1 DNA
EHV1 DNA digestions and a kilo base pairs (kbp) molecular weight ladder were separated on 
a 0.8% agarose gel and transferred to a Nylon membrane, and probed with 32p labelled 
recombinant plasmid DNA. Lane 1, EHV1 DNA digested; Lane 2, kbp ladder;
(a). StuI digested EHV1 DNA probed with p75 DNA.
(b). BamHI digested EHV 1 DNA probed by p71.
(c). BamHI digested EHV 1 DNA probed with p67.
(d). StuI digested EHV1 DNA probed by Pl/2 
EHV1 DNA bands are labelled by<.

Table 2. Cloned and subcloned EHV1 fragments which contain the five 
target genes *
Plasmid nucleotide position(n.p.) 
of the fragment
R.E. fragment 
+ size 
in base pairsfbp}
target gene  
included
cloning
site
p l /2 9 7 5 -6 1 5 8 StuI 5183 1 &2 Hindi
S p l/2 9 7 5 -4 5 3 9 Stul/Pstl 3 5 6 5 1 &2 Stul/Pstl
p67 1 2 1 4 0 0 -1 2 6 5 1 7 BamHI 5 1 1 7 67 BamHI
Sp67 1 2 2 9 0 6 - 1 2 5 6 0 6 Sail 2 7 0 0 67 Sail
P71 1 2 6 5 1 7 - 1 3 2 3 0 5 Ba/Eco 5 7 8 8 71 BamHI/EcoRI
Sp71 1 2 7 6 7 6 - 1 3 2 3 0 5 Pstl 4 6 2 9 71 Pstl
p75 1 3 4 5 6 7 - 1 3 9 4 5 2 Hindi 4 8 8 5 75 Hindi
Sp75 1 3 4 5 6 6 - 1 3 8 1 6 8 Sphl 3 6 02 75 Sphl
*The EHV1 fragments were individually cloned into the vector pUCI 9 
polylinker site to construct these  recombinant plasmids.
Ba: BamHI; Eco:EcoRI; R.E.: Restriction enzyme;
Results
were religated with adaptor 3. For selection of the mutant, a LacZ gene was inserted into the 
Spel site in adaptor 3. To construct a gene 71 deletion plasmid, the majority of the gene 71 
ORF (129211-131022 n.p.) was removed by SgrAI and MscI digestion and the flanking 
regions were religated with adaptor 4. For selection of the mutant the LacZ gene cassette was 
inserted into the Spel site in the adaptor 4. To construct the gene 75 deletion plasmid, the 
majority of gene 75 ORF (136115-136304 n.p.) was removed with BsmI and B pu ll02  I 
digestion and the flanking regions religated with adaptor 5. For selection of the deletion 
mutant, the lacZ gene cassette was inserted into the Spel site in adaptor 5. The sequences of 
the synthetic oligonucleotides are summarised in Fig. 4. In this way, 10 deletion and 
substitution plasmids, pD l, pD L l, pD2, pDL2, pD67, pDL67, pD71, pDL71, pD75 and 
pDL75, were constructed. In each case the majority of the target gene ORF was removed and 
replaced by a lacZ gene [a 4.1 kb Xbal fragment of pFJ3 (Rixon and McLauchlan, 1990)] in 
the same orientation as the substituted gene. The construction and sequence arrangements of 
these deletion plasmids are presented in Figs. 5 to 9. The genome structures of the plasmids 
were confirmed by restriction enzyme digestion. The results showed that the constructed 
deletion plasmids had the expected restriction enzyme digestion patterns (data not shown). 
The nucleotide position and size of each deleted region in these constructed plasmids are 
summarised in Table 3.
3. 2. 3. Generation of deletion mutants in the target genes.
To generate deletion mutants in each target gene, monolayers of BHK21/C13 cells were 
cotransfected with the appropriate deletion plasmid DNA and EHV 1 Ab4 DNA as described in 
method 2.2.6. Deletion mutant progeny virus were identified by blue staining in the presence 
of X-gal (see section 2.2.7). Five individual deletion mutants in genes 1, 2, 67, 71 and 75 
were separately isolated and designated as EDI, ED2, ED67, ED71 and ED75, respectively. 
The genome structure of each deletion mutant was confirmed by Southern blotting and 
restriction enzyme digestion of -^P-labelled viral DNA. The results are shown in Figs. 10 
and 11 and diagramatically illustrated in Figs. 12 and 13. In the EDI genome, the deletion 
[1373-1881 nucleotide position (n.p.)] and lacZ substitution introduce a novel EcoRI site into
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Figure 4. Sequence arrangements of synthetic oligonucleotide adaptors.
To construct deletion plasmids, pD l, pD2, pD67, pD71 and pD75, five double-stranded 
oligonucleotide adaptors, called adaptor 1, 2, 3, 4 and 5, were synthesised. These 
oligonucleotides have overhanging complementary ends as indicated and contain an in frame 
stop-codon (underlined) and an unique Spel site (in bold).
Adaptor 1.
AscI ‘sticky end’ Hpal ‘blunt end’
5’ CGC GCC ATA AGC JA G  CAC TAG TGA TAA CT 3’ (29mer)
3’ G G T A T T C G  ATC GTG ATC ACT ATT GA 5’ (25mer)
Adaptor 2.
Pflml ‘sticky end’ Pflml 'sticky end’
5’ CT GGC TAG CAC TAG TGA TAT GTT ATACG 3’ (28mer)
3’ TTAG CCG ATC GTG ATC ACT ATA CAA TA 5’ (27mer)
Adaptor 3.
BsaAI ‘sticky end’ Styl ‘sticky end’
5'-CAAGTAAG TAA GTA AGA CTA GTG C-3’ (24mer)
3'-TTC ATT CTT TC T GAT CAC GAACGT-5’ (24mer)
Adaptor 4.
SgrAI ‘ sticky end’ MscI ‘sticky end’
5’- ACC TAG GAC TAG TCT AAC TAA CTA AC- 3’ (26mer)
3’-GG ATC CTG ATC AGA TTG ATT GAT TGATTGCGGCC-5’ (34mer)
daptor 5
sml ‘sticky end’ Bpull02 ‘sticky end’
5’- C TGC TAG CAC TAG TAA CTA ACT AA-3’ (24mer)
GCG ACG ATC GTG ATC ATT GAT TGA TTACT-5’ (29mer)
Figure 5. Schematic representation of plasmid constructed for gene 1 
deletion and substitution.
Line 1, EHV1 genome consisting of Ul /U s and inverted repeat regions (IRs/TRs) (not to 
scale). Line 2, expanded cloned 5.1 kb StuI fragment. Line 3, subcloned 3.5 kb Stul/Pstl 
fragment containing genes 1, 2 and 3 ORFs. Line 4, deletion plasmid pD l with a deletion 
between AscI site (1373 n.p.) and Hpal site (1881 n.p.) was linked by synthetic 
oligonucleotide adaptor 1. Line 5, deletion and substitution plasmid pDLl with a lacZ gene 
insertion in the pDl Spel site. Spel and Xbal have complementary ends, but ligation between 
them disrupts both Xbal and Spel sites. PI represents SV40 early promoter; T represents 
SV40 polyadenylation signal. Relevant restriction sites: As: AscI; Hp:HpaI; Ps:PstI; St:StuI.
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Figure 6. Schematic representation of deletion plasmid constructed for gene 
2 .
Lines 1, 2 and 3 (see Figure 5 lines 1, 2, 3). Line 4, deletion plasmid; pD2 the sequence 
between two Pflm l sites was removed and the flanking regions were religated by 
oligonucleotide adaptor 2. Line 5, deletion and substitution plasmid pDL2 with a lacZ 
insertion in the pD2 Spel site. Relevant restriction sites: Pf: Pfmll; Ps: PstI; St: Stul. PI and T 
see Figure 5 legend.
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Figure 7. Schematic representation of plasmids constructed for deletion of 
gene 67.
Line 1, EH V 1 genome. Line 2, cloned EHV1 5.1 kb BamHI fragment. Line 3, subcloned 2.7 
kb Sail fragment containing gene 66, 67 and 68 ORFs. Line 4, deletion plasmid pD67. The 
sequence between BsaAI and Styl was removed and the flanking regions were religated by the 
oligonucleotide adaptor 3. Line 5, deletion and substitution plasmid pDL67 with a lacZ  
insertion in the Spel site of adaptor 3. Relevant restriction enzyme sites: Ba: BamHI; Bs: 
BsaAI; S: Styl: Sa, Sail. PI and T see Figure 5 legend.
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Figure 8. Schematic representation of plasmids constructed for deletion of 
gene 71.
Line 1, EHV 1 genome. Line 2, cloned 5.7 kb BamHI and EcoRI fragment. Line 3, subcloned 
4.6 kb Pstl/EcoRI fragment containing gene 70, 71 and 72 ORFs. Line 4, deletion plasmid 
pD71, the sequence from MscI to SgrAI was removed and the flanking regions were religated 
with oligonucleotide adaptor 4. Line 5, deletion and substitution plasmid pDL71 with a lacZ 
insertion in the Spel site of adaptor 4. Pertinent restriction enzyme sites: Ba: BamHI; Ec: 
EcoRI; Ms :MscI; Sg: SgrAI. PI and T see Figure 5 legend.
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Figure 9. Schematic representation of plasmids constructed for gene 75 
deletion.
Line 1, EHV1 genome. Line 2, cloned 4.8 kb StuI fragment. Line 3, subcloned 3.6 kb StuI/ 
SphI fragment containing gene 74, 75 and 76 ORFs. Line 4, deletion plasmid pD75, the 
region from BsaAI to Bpul 1021 was removed and the flanking regions were religated with 
oligonucleotide adapter 5. Line 5, deletion and substitution plasmid pD75, a lacZ gene was 
inserted into the Spel site in adapter 5. Relevant restriction enzyme sites: Bp: Bpul 1021; Bs: 
BsaAI; Sp: sphl. St: StuI. PI and T see Figure 5 legend.
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Table 3. Nucleotide position (n.p.) of the five target genes and the 
deleted regions in the constructed deletion plasmids*
------ —
plasmid target gene Deletion
name location(n.p.) 
start stop
region (n.p.) size (bp)
r ----------
PD1 1 1 2 9 8  1906 1373-1881 508
pD2 2 2 5 6 2  1945 1 9 9 8 -2 3 9 8 400
pD67 67 1 2 5 1 9 3  1 2 4 3 7 5 1 2 4 4 1 6 -1 2 4 9 2 9 513
pD71 71 1 2 9 0 9 6  1 3 1 4 8 9 1 2 9 2 1 1 -1 3 1 0 2 2 1811
pD75 75 1 3 6 0 5 4  1 3 6 4 4 6 1 3 6 1 1 5 -1 3 6 3 0 4 189
*The majority of each target gene ORF in recombinant plasmids was 
emoved by restriction enzymes. The flanking regions were religated with 
an oligonucleotide adaptor and a lacZ gene was inserted into the Spel site 
to construct the five deletion plasmids.
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the wild-type 9.1 kb EcoRI fragment which results in the replacement of the 9.1 kb fragment 
with two new fragments, one of 7.2 kb migrating above the 6.6 kb fragment and the other a 
5.5 kb terminal fragment running between the 6.2 and 4.4 kb fragments. The 9.1 kb 
fragment runs just below the 9.3 kb fragment and therefore the absence of this fragment in the 
mutant could not be clearly seen (Fig. 10a, lane 2 and Fig. 12, a). A Southern blot of Xhol 
digested EDI DNA showed that pUl/2 hybridised to the expected 5.4 kb and 2.8 kb bands 
but not to the wild-type 1.5 and 3.0 kb bands, indicating the mutant was not contaminated 
with wild-type virus (data not shown). In the mutant ED2 the deletion (1998-2398 n.p.) and 
lacZ substitution also introduce a new EcoRI site into the 9.1 kb wild-type EcoRI fragment 
which results in two new fragments, one of 10.7 kb migrating above the 9.5 kb wild-type 
fragment and another terminal fragment of 2 kb, running above the 1.8 kb wild-type fragment 
(Fig. 10b, lane 2 and Fig. 12, a). The 9.1 kb fragment runs just below the 9.3 kb fragment 
and therefore the absence of this fragment in the mutant could also not be clearly seen (Fig. 
10b, lane 2). A Southern blot of Xhol digested ED2 DNA showed that pU 1/2 hybridised to 
the two novel bands (6.18 kb and 0.49 kb), but not to the 3.07 kb wild-type virus band, 
confirming that mutant ED2 is not contaminated with wild-type virus (data not shown). In 
mutant ED67, the deletion of gene 67 (124416-124929 n.p.) and a lacZ insertion introduce a 
new Sail site into the 2.7 kb Sail fragment containing IRs and TRs copies of gene 67. This 
results in two new Sail fragments (1.5 kb and 4.8 kb) (Fig. 11, lanes 3 to 6 and Fig. 13, b). 
In mutant ED71 the deletion (129,211-131,022 n.p.) and a 4.2 kb lacZ substitution results in 
a new 6.2kb Smal fragment replacing the 3.8kb wild-type Smal fragment (Fig. 10, c lane 2 
and Fig. 12, b). The deletion of gene 75 (136,115-136,304 n.p.) and lacZ substitution in the 
wild-type 6.3 kb Smal fragment changes the fragment to a new 10 kb fragment running above 
the 9.2 kb wild-type fragment in Smal digested ED75 DNA ( Fig. 10, d lane 2 and Fig. 13, 
a).
In addition, to confirm that the correct region in each mutant was absent, plasmid DNA was 
digested by the restriction enzymes used to carry out the deletion. The deleted fragments in 
mutants were purified and labelled with 32p used as a probe. Southern blotting
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Figure 10. Autoradiographs of restriction digests of the DNAs of mutants 
EDI, ED2, ED71, ED75 and EHV1 strain Ab4 labelled in  v ivo  
with 32p
32P labelled EHV 1 DNA (Lane 1) and mutant DNA (Lane 2) were separated on agarose gels 
and autoradiographed, ►indicates new fragments; ■ indicates missing fragments. Fragment 
sizes are indicated in kb to the left and the right.
(a). EcoRI digested EHV1 DNA (Lane 1) and EDI DNA (Lane 2)
(b). EcoRI digested EHV 1 DNA (Lane 1) and ED2 DNA (Lane 2)
(c). Smal digested EHV1 DNA (Lane 1) and ED71 DNA (Lane 2)
(d). Smal digested EHV 1 DNA (Lane 1) and ED75 DNA (Lane 2)
r■
Figure 11. Autoradiographs of Southern blots of the DNA of mutant ED67 and 
wild-type virus.
Sail digested viral DNA was separated on a 0.8% agarose gel and transferred to a Nylon 
membrane, and probed with 32p labelled Sp67 DNA and 32P labelled 1 kb DNA marker. 
Lane 1, 1 kb DNA markers. Lane 2, Sail digested EHV1 DNA. Lanes 3 to 6 Sail digested 
ED67 DNA. Fragment sizes are indicated in kb to the right. Molecular weight markers are 
present on the left in KD.
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Figure 12. Genome structures of mutants EDI, ED2 and ED71.
Restriction enzyme sites within the region of the genome encompassing (a) genes 1 and 2, (b) 
gene 71 are shown. The wild-type virus genome is represented by lines 1 and 4. The genome 
of mutants ED I, ED2 and ED71 are represented by lines 2, 3 and 5, respectively. Relevant 
restriction enzyme fragments generated following digestion with EcoRI (a) and Smal (b) are 
shown. Relevant restriction sites: As: AscI; Ec: EcoRI; Hp: Hpal; Ms: MscI; Pf: Pflml; Sm: 
Smal; Sg: SgrAI.
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Figure 13. Genome structures of mutants ED67 and ED75.
Restriction enzyme sites within the region of the genome encompassing (a) gene 75 and (b) 
gene 67. The wild-type virus genome is represented by lines 1 and 3. Mutants ED75 and 
ED67 genomes are represented by lines 2 and 4. Relevant restriction enzyme fragments 
generated following digestion with Smal (a) and Sail (b) are shown. Relevant restriction sites: 
Bp: Bpul 1021; Bs: BsaAI; S: Styl; Sa: Sail; Sm: Smal.
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experiment showed that the deleted sequences could not be detected in the relevant deletion 
mutant genomes by the labelled probe, but the probe hybridised to the appropriate restriction 
enzyme fragment in the wild-type virus genome (data not shown). These results 
demonstrated that the generated deletion mutants, EDI, ED2, ED67, ED71 and ED75 had the 
expected genome structures. The sequence arrangements and nucleotide positions of the 
deleted regions in the mutants are illustrated in Fig. 5 to 9 and Table 3. Each deletion mutant 
was purified a further four times by single plaque purification, before a virus stock was 
prepared. One isolate from the fourth round of purification was chosen to prepare a virus 
stock in BHK21/C13 cells (see section 2.2.2).
3.3. CORRECTION OF THE DELETIONS IN ED67 AND ED71
To confirm the identity of the gene 67 and 71 products and that wild-type growth properties 
could be restored. The wild-type genes 67 and 71 were separately rescued back as
described in section 2.2.8.
To restore gene 67, BHK21/C13 monolayers were transfected with ED67 DNA and 1-, 10-, 
and 100-fold molar ratios of the wild-type 5.1 kb BamHI fragment in p67. To restore gene 
71, monolayers of BHK21/C13 cells were transfected with ED71 DNA and 1-. 10- and 100- 
fold molar ratios of the wild-type virus 5.8 kb BamHI/EcoRI fragment in p71. When c.p.e. 
was complete, the cells were harvested and titrated on BHK21/C13 cells. The plates were 
incubated in the presence of X-gal (0.3mg/ml) at 37°C. After two days, single white plaques 
were isolated and used to infect BHK21/C13 monolayers in Linbro wells. Viral DNA was 
prepared and analysed by restriction enzymes as previously described (Sections 2.2.9 and 
2.2.10). One isolate with a wild-type virus restriction enzyme profile was chosen from each 
rescue experiment (data not shown). Four rounds of plaque purification were carried out 
before growing up a virus stock. The revertant viruses were designated 'Re67 and Re71.
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Results
3 .4 . GROWTH PROPERTIES OF DELETION MUTANTS AND 
REVERTANTS IN TISSUE CULTURE.
To investigate the phenotypes of the five deletion mutants in vitro, their growth properties 
were analysed in tissue culture under different experimental conditions and compared with 
those of wild-type virus and the appropriate revertant virus. Firstly, single and multi step 
growth curves of mutants and wild-type virus were carried out in BHK21/C13 cells at 37°C. 
2x106 BHK21/C13 monolayers were infected with virus either at 5 pfu/cell for single cycle 
growth or 0.01 pfu/cell for multi cycle growth experiments. The cells were harvested at 
various time points post infection. The progeny virus titres were measured on BHK21/C13 
cells (Figs. 14, 15, 16 and 17). The results showed that mutants ED2, ED67 and ED75 grew 
to the same titres as wild-type virus in BHK21/C13 cells at 37°C with EDI growing slightly 
less well than wild-type virus (Fig. 14 and 15). The deletion mutant ED71 grew more poorly 
than wild-type virus with the final yield of infectious virus being reduced by between 5- to 10- 
fold, compared with that of wild-type virus and the revertant, Re71 (Fig. 16 and 17). An 
interesting observation was that ED71 gave higher titres of infectious virus over the first 24 h 
p.i. at low m.o.i. (Fig. 17). This observation is analysed in greater detail later (Section 4.7.). 
ED67, revertant Re67 and wild-type virus grew identically (Fig. 14, 15 and data not shown).
Secondly, the mutants were tested for temperature sensitivity at different incubation 
temperatures (31°C, 37°C and 38.5°C). The results presented in Table 4 showed that mutants 
EDI, ED2, ED67, ED 71 and ED75 did not display any temperature sensitivity, compared 
with wild-type virus at the tested temperatures.
Finally, the mutants were tested in different cell lines (NBL-6, CV1, HFL1 and RK13) for 
host range defects. The results presented in Table 5 showed that mutants EDI, ED2, ED67 
and ED75 have similar growth properties to wild-type virus in all tested cell lines whereas ED 
71 displays the same level of growth defect in all cell lines as seen with BHK21/C13 CELLS.
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Figure 14. Low multiplicity of infection growth experiment of EDI, ED2, 
ED67, ED75 and wild-type virus.
Low multiplicity of infection growth experiments with EHV1 in BHK21/C13 cells. 
Monolayers of BHK21/C13 cells were separately infected with EDI, ED2, ED67, ED75 and 
wild-type virus at 0.01 pfu/cell. After 60 min absorption, the cells were washed three times 
with PBS , overlaid with Eagle's medium containing 5% calf serum, and incubated at 37°C. 
The progeny virus was harvested at 0, 4, 8, 12, 24, 36, 48 and 72h p. i. and titrated on 
BHK21/C13 cell at 37°C. The results are presented as pfu/106 cells.
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Figure 15. High multiplicity of infection growth experiment of EDI, ED2, 
ED67, ED75 and wild-type virus
High multiplicity of infection growth experiment of EHV 1 in BHK21/C13 cells. Monolayers 
of BHK21/C13 cells were separately infected with EDI, ED2, ED67, ED75 and wild-type 
virus at 5 pfu/cell. After 60 min absorption, the cells were washed three times with PBS , 
overlaid with Eagle's medium containing 5% calf serum, and incubated at 37°C. Cultures 
were harvested at 0, 2, 8, 12, 18, 24 and 30 h p.i. The progeny virus was titrated on 
BHK21/C13 cells at 37°C. The results are presented as pfu/106 cells.
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Figure 16. Low multiplicity of infection growth experiment of ED71, Re71 
and wild-type virus.
Low multiplicity of infection growth experiment of EHV1 in BHK21/C13 cells. Monolayers 
of BHK21/C13 cells were separately infected with ED71, Re71 and wild-type virus at 0.01 
pfu/cell. After 60 min adsorption, the cells were washed three times with PBS, overlaid with 
Eagle's medium containing 5% calf serum, and incubated at 37°C. Cultures were harvested at 
0, 4, 8, 12, 24, 48, 72, 96 and 120 (h) p.i. The progeny virus was titrated on BHK21/C13 
cells at 37°C and the titres presented as pfu/106 cells.
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Figure 17. High multiplicity of infection growth experiment of ED71, Re71 
and wild-type virus.
High multiplicity of infection growth experiment of EHV1 in BHK21/C13 cells. Monolayers 
of BHK21/C13 cells were separately infected with ED71, Re71 and wild-type virus at 5 
pfu/cell. After 60 min absorption, the cells were washed three times with PBS, overlaid with 
Eagle's medium containing 5% calf serum, and incubated at 37°C. Cultures were harvested at 
0, 4, 6, 8, 10, 12, 14, 16, 20, 24 and 30 h p.i. The progeny virus was titrated on 
BHK21/C13 cells at 37°C and the titres are presented as pfu/106 cells.
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Table 4 . G row th p ro p ertie s  o f  th e  d e le tio n  m u ta n ts  a t  th r e e  d ifferen t
te m p e r a tu r e s*
Incubation
temperature
Titre (pfu/ml)
EHV1 EDI ED2 ED67 ED71 DE75
6 6 6 6 5 6
f t 2 .5 x 1 0 1.4x10 1x10 1.2x10 6x10 1x10
1------
6 6 5 5 5 5
38°5 C 1.6x10 1x10 8x10 9.5x10 1.5x10 9x10
6 6 6 6 5 6
37°C 3 x10 2 .5x10 1x10 2x10 4.4x10 1.5x10
Ratio of pfu/pfu
titres
31°C/38.5°C 1.56 1.4 1.25 1.26 4 1.1
31°C/37°C 0 .8 0 .5 6 1 0.6 1.3 0.66
*To test whether the mutation affected the temperature stability of 
virus, monolayers of BHK21/C13 cells in 50 mm diameter dishes were 
infected with virus at 5pfu/cell and incubated for 24 h at the indicated 
temperatures. The progeny virus was harvested and titrated on the 
BHK21/C13 cells at 3 7 ^ .
T ab le 5. G row th  p ro p ertie s  o f  th e  five m u ta n ts  in various cell
lines*
Cell line Titre (pfu/ml)
EH VI EDI ED2 ED67 ED71 ED75
6 6 6 6 5 5
p - 1 1x10 1x10 2x10 1.5x10 2.2x10 6x10
i
6 6 6 6 5 6
IHFL1 2 .5 x 1 0 2x10 2x10 3x10 4x10 2x10
6 6 5 6 5 6
RK13 1x10 1x10 9x10 1.1x10 2x10 1x10
6 6 6 6 5 6
NBL-6 4 .8 x 1 0 4x10 3 .6x10 5x10 6 .6x10 2 xIO
^Monolayers of indicated cell lines in 50 mm diameter dishes were 
infected with virus at a m.o.i. of 5 pfu/cell and incubated for 24  h at 37°  
3. The progeny viruses were titrated on BHK21/C13 cells at 37°C.
Results
Overall these results demonstrated that when the five genes were independently deleted, they 
are non-essential for virus growth in vitro at least in the tested cell lines. Deletion of the genes 
1, 2, 67 and 75 does not result in any defect in host range and temperature stability. ED71 
displays defective growth in all tested cell lines, compared with wild-type virus. Revertants 
Re67 and Re71 are indistinguishable from wild-type virus. The Re71 result indicates that the 
growth defect of ED 71 results from deletion of gene 71. Further characterisation of ED71 is 
described in Section 3.8.
It should be noted that the five deletion mutants were also tested for infectivity, 
immunogenesis and pathogenesis in a well established murine model. This study was carried 
out by Tim Fitzmaurice in Cambridge University Veterinary School (see Section 4.7).
3. 5. EXPRESSION OF THE FIVE GENE PRODUCTS AS FUSION 
PROTEINS IN E. CO LI AND PRODUCTION OF SPECIFIC 
ANTIBODIES AGAINST THE GENE PRODUCTS. 
3. 5. 1. Construction of expression plasmids.
To construct fusion protein expression plasmids, the ORFs of the five genes were 
independently cloned into a set of pUR vectors (Riither and Muller-Hill, 1983) to fuse in­
frame with the 3’ end of the 8-galactosidase gene. To construct a gene 1 protein expression 
plasmid, an EHV1 fragment (1329-1927 n.p.), which encodes amino acids 4-202 of the 
putative gene 1 protein, was amplified by PCR from Sp 1/2 with two primers containing 
BamHI and H indlll sites, and inserted, into pUR278 BamHI and Hindlll sites to fuse in­
frame with the B-galactosidase gene (Fig 18). To construct a gene 2 protein expression 
plasmid, an EHV1 Hindll/BamHI fragment (1184-2555 n.p.) in Spl/2, which encodes amino 
acids 2-205 of the putative gene 2 protein, was cloned into pUR278 BamHI and Hindlll sites 
in frame to fuse with B-galactosidase gene from Spl/2 (Fig. 19). To construct the gene 67 
expression plasmid, an EHV1 fragment (124411-125160 n.p.) in Sp67, which encodes 
amino acids 12-260 of the putative gene 67 protein, was inserted into pUR288 BamHI and
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Hindlll sites in frame to fuse with the B-galactosidase gene (Fig. 20). To construct gene a 71 
protein expression plasmid an EHV1 Hindlll fragment (130487-131487 n.p.), which encodes 
464-797 amino acids of the gene 71 protein, was inserted into pUR278 in frame to fuse with 
the B-galactosidase gene (Fig. 21). To construct a gene 75 expression plasmid, an EHV1 
fragment (136095-136910 n.p.), which encodes amino acids 14-130 of the putative gene 75 
protein, was inserted into pUR288 BamHI and Hindlll sites in frame fusing with the B- 
galactosidase gene (Fig. 22). In this way five recombinant expression plasmids were 
constructed and designated as pUIHE, pU2HE, pU67HE, pU71HE and pU75HE. The 
expressed encoding sequences of the target genes in the recombinant plasmids are summarised 
in Table 6. The DNA profiles of the recombinant plasmids were analysed by a series of 
restriction enzyme digestions. Results showed that all recombinant plasmids had the expected 
restriction enzyme digestion patterns (data not shown). Sequence analysis of the junction 
between the B-galactosidase gene and the insertions in each constructed plasmid with a primer 
(5'-GAATTCCAGCTGAGCGCCGGT-3') derived from the upstream sequence of the pUR 
cloning sites (Riither and Miiller-Hill, 1983) confirmed that the inserted amino acid encoding 
sequences were fused in-frame with the 3’ end of the B-galactosidase gene in the pUR vectors 
(data not shown).
3. 5. 2. Expression of the protein products of the genes as B-galactosidase 
fusion proteins in E . coli.
The constructed expression plasmids, pUIHE, pU2HE, pU67HE, pU71HE and pU75HE, 
were separately transformed into E. coli strain XL1 to express the fusion proteins. After 
induction by ImM of IPTG, the transformed cells were lysed and the polypeptides were 
analysed by 6% SDS-PAGE. The results represented in Fig 23 showed that the wild-type B- 
galactosidase was expressed as a 116 KD thick band ( Fig. 23, lane 5 ) and the five fusion 
proteins were expressed from the transformed cells as higher Mr bands (Fig. 23). These 
expressed fusion proteins are designated as FP1 (lane 4), FP2 (lane 7), FP67 (lane 2), FP71 
(lane 3), and FP75 (lane 1), respectively. FP1 and FP2 expressed in pUEHl and pU2EH 
transformed cells consisted of the N-terminus of B-galactosidase fused to amino acids 4-
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Figure 18. Construction of expression plasmid pUEHl
An EHV1 fragment (1329-1927 n.p.) which encodes amino acid 4-202 of the gene 1 protein 
was amplified by PCR with primers:
(1) 5'-ATCATAGGATCCTCCTCTGTCTCCATCTCCAT-3' containing a BamHI site 
(underlined);
(2) 5-TGCGATTAAGCTTTGCGGTACTACAGT-3' containing a Hindlll site (underlined), 
from Spl/2  with Vent polymerase under the conditions: 1 cycle of 95°C for 5 min; 30 cycles 
of 95°C for 30 seconds, 58°C for 40 seconds and 72°C for 1 min. The predicted 598 bp 
fragment was digested by BamHI and H indlll and cloned into pUR278 BamHI/Hindlll sites 
to construct p U E H l. In pU EH l, the gene 1 coding sequence is fused in frame with the 3' 
end of the B-galactosidase gene. The junction sequence between lacZ and the gene 1 protein 
encoding sequence in pUEHl is shown. The arrow indicates the junction. The insertion site 
(BamHI site) is shown in bold. Thicker lines show cloned EHV1 fragments. Arrows show 
the orientation of transcription of genes.
1329 1927(n.p.)
PCR BamHI Hindlll
-------------------^ _____ J______________ I
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Stop codon
imHI
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stop codon 
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Figure 19. Construction of expression plasmid pUEH2.
An EH V 1 BamHI/Hindlll fragment (1184-2555 n.p.) encoding amino acids 2-205 of the gene 
2 protein was cloned into pUR278 Bam HI/Hindlll sites from the plasmid S p l/2  which 
contains EHV1 StuI fragment (975-4539 n.p.) to construct plasmid pUEH2. In pUEH2 the 
gene 2 encoding sequence is fused in frame with the 3' end of the B-galactosidase gene. The 
junction sequence between lacZ  and the gene 2 encoding sequence in pUEH2 is shown. A 
arrow indicates the junction and the insertion site (BamHI site) is shown in bold. Arrows 
show the orientation of transcription of the B-galactosidase gene.
BamHI 2555  n.t.
Pstl 
4539 n.p
stop codon^ind||,
BamHI
BamHI/
Hindlll
BamHI 2555 Hindlll 1184(n.p.)
gene 2 ORF
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The sequence of the junction between lacZ and insertion in 
pUEH2
pUR278 BamHI gene 2 encoding sequence
 CAA AAA GGG GAT CCA GCG TGG AGG AGG CGC CAT-
-— GTT TTT CCC CTA GGT CGC ACC TCC TCC GCG GTA-
Figure 20. Construction of expression plasmid pUEH67.
A N ael/PstI fragment (125160-124411 n.p.) (thicker line) from the plasmid Sp67 which 
contains the EHV1 Sail fragment (122906-125606 n.p.) (thicker line) was cloned into pUC19 
HincII/PstI sites to construct plasmid pUC67. The BamHI/ H indlll fragment in pUC67 
containing the Nael/PstI fragment was cloned into pUR288 BamHI/Hindlll sites to construct 
pUEH67. In pUEH67 the gene 67 encoding sequence is fused in frame with the 3' end of the 
B-galactosidase gene to generate pUEH67. The junction sequence between lacZ and the gene 
67 protein encoding sequence is shown. The arrow indicates the junction and the insertion site 
(BamHI) is shown in bold. The arrows show the orientation of transcription of genes.
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Figure 21. Construction of expression plasmid pUEH71.
The H ind lll fragment (130487-131487 n.p.) containing the coding sequence of 464-797 
amino acids of the gene 71 protein was cloned into the vector pUR278 Hindlll site from the 
plasmid p71, which contains an EHV1 EcoRI/BamHI fragment (thicker line), to construct 
pUEH71. In pUEH the gene 71 coding sequence was fused in frame with the 3' end of the 6- 
galactosidase gene to generate pUEH71. The sequence of the junction between lacZ  and the 
gene 71 protein encoding sequence is shown. The arrow indicates the junction and the 
insertion site (BamHI) is shown in bold. The arrows show the orientation of the transcription 
of the genes.
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Figure 22. Generation of expression plasmid pUEH75.
The HincII/PstI fragment (136095-136910 n.p.) (thicker line) containing the coding sequence 
of amino acids 14-130 of gene 75 protein was cloned into the pUC19 HincII/PstI sites from 
plasmid p75, which contains the EHVI SphI fragment (thicker line), to construct plasmid 
p75-l. The B am H I/H indlll fragment containing the HincII/PstI fragment in p75-l was 
inserted into the pUR288 BamHI/Hindlll sites to construct pUEH75. In pUEH75 the gene 75 
coding sequence is fused in frame with the 3' end of the 13-galatosidase gene. The junction 
sequence between lacZ  and the gene 75 protein encoding sequence is shown. The arrow 
indicates the junction and the insertion site (BamHI site) is shown in bold. The arrows show 
the orientation of the gene transcription.
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Table 6. Sequence data of the constructed fusion protein expression 
plasmids*
recombinant expressec  
plasmid gene
1 inserted 
fragment 
(n.p.)'
V- 3 Send
encoded  
amino acid 
sequence
vector insertion
site
pUEHl 1 1 3 2 9 -1 9 2 7 4- 202 pUR278 B/H"
r
pUEH2 2 2 5 5 5 -1 1 8 4 2-205 pUR278 B/H"
pUEH67
1
6 7 1 2 5 1 6 0 -1 2 4 4 1 1 1 2-260 pUR288 B/H"
pUEH71 71 1 3 0 4 8 7 -1 3 1 4 8 7 4 6 4 -7 9 7 pUR278 H"
PUEH75 75 1 3 6 0 9 5 -1 3 6 9 1 0 14-130 pUR288 B/H"
*The portion of the encoding sequences of the five target genes separately 
cloned into the pUR vector polycloning site to fuse in frame with the 3' end 
of the lacZ gene.
B/H": BamHI/Hindlll; H": Hindlll; n.p.': nucleotide position
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of the gene 1 putative product and amino acids 2-205 of the EHV1 gene 2 putative product 
with Mrs of 154 KD and 159 KD respectively by 6% SDS-PAGE (Fig. 23, lanes 4 and 7). 
They were not present in extracts from pUR288 transformed cells (Fig. 23, lane, 5). 
However, a 116 KD B-galactosidase band was also present as well as the higher Mr bands, 
which indicated that FP1 and FP2 were partially degraded after synthesis (Fig. 23, lanes 4 
and 7). To prevent this degradation, different incubation temperatures (26°C, 31 °C and 39°C) 
and different strains of host cells (E.coli NM522 and JM109) were employed, but 
degradation could not be prevented (data not shown). Fusion protein FP75 which consists of 
the N-terminus of B-galactosidase fused with amino acids 14-130 of EHV1 gene 75 protein 
was expressed from pU75EH transformed cells as a protein with a Mr of 150 KD by 6% 
SDS-PAGE (Fig. 23, lane 1). It was not present in pUR288 transformed cell extracts (Fig. 
23, lane 5). The 116 KD B-galactosidase band was not present in pUEH75 transformed cell 
extracts. FP75 was poorly expressed in pUEH75 transformed cells. To increase the 
expression level, the transformed cells were incubated at different temperatures (27°C, 31°C) 
and induced with different amounts of IPTG. In addition, different strains of E. C o li, 
NM522 and JM109, were used as host cells to express the fusion protein, but the level of the 
FP75 expression could not be increased (data not shown). The fusion proteins FP67 and 
FP71, which consist of the N-terminus of B-galactosidase fused with amino acids 12-260 of 
the EHV1 gene 67 protein and amino acids 464-797 of the EHV1 gene 71 protein 
respectively, were over expressed after induction with ImM IPTG from pUEH67 and 
pUEH71 transformed cells as bands with apparent Mrs of 154 KD and 163 KD in 6% SDS- 
PAGE ( Fig. 23, lanes 2 and 3), but were not present in pUR288 transformed cells (Fig. 23, 
lane 5). The 116 KD B-galactosidase band were not present in extracts from pEH67 and 
pUEH71 transformed cells. Fractionation experiments showed that all the expressed fusion 
proteins were in the insoluble fractions as inclusion bodies (data not shown). These results 
showed that the five B-galactosidase fusion proteins were expressed as insoluble proteins 
from recombinant cells with approximately the expected molecular weight.
78
Figure 23. Expression of five ft-galactosidase fusion proteins.
The XL1 cells transformed with recombinant plasmids, pUEHl, pUEH2, pUEH67, pUEH71 
and pUEH75 were induced with ImM IPTG after 2h incubation at 37°C and incubation 
continued for 2 h. The cells were then lysed and the polypeptides separated by 6% SDS- 
PAGE and stained with Coomassie blue. Lane 1, pUEH75 transformed cell extract; Lane 2, 
pUEH67 transformed cell extract; lane 3, pUEH71 transformed cell extract; Lane 4, pUEHl 
transformed cell extract; Lane 5 pUR288 transformed cell extract; Lane 6 molecular weight 
marker; lane 7, pUEH2 transformed cell extract. Molecular weights are shown on the right 
hand side in KD. The fusion proteins are indicated by small arrows and the B-galactosidase 
band by a large arrow.
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3. 5. 3. Purification of the expressed fusion proteins and immunisation of 
rabbits to raise specific anti-sera.
There are several available methods to purify expressed proteins from E. coli. These produce 
different qualities and quantities of purified proteins. As our aim in purification of the 
expressed proteins was to use them as antigens to raise specific antibodies, and as an 
insoluble protein is usually a better antigen for stimulation of the host immune system than a 
soluble protein (Harlow, 1988), purification of the insoluble inclusion bodies, containing 
insoluble protein, from the lysed transformed cells was chosen as described in section 
(2.2.46). Using this method the fusion proteins FP1, FP2, FP67 FP71 and FP75 were 
purified from transformed cells as insoluble inclusion bodies. The amounts of purified 
insoluble protein (total protein) typically obtained from 100 ml of pUlEH, pU2EH, pU67EH, 
pU71EH and pU75EH transformed cells were 0.96 mg, 1.71 mg, 2.6 mg, 2.8 mg, and 0.71 
mg, respectively.
To raise specific antibodies against the expressed gene products, two female New Zealand 
white rabbits were immunised with 0.9 mg/animal of the purified fusion protein, mixed with 
an equal volume of complete Freund’s adjuvant, for the primary immunisation and 0.5 
mg/animal of purified fusion protein, mixed with an equal volume of incomplete Freund’s 
adjuvant, for the boost injections (see Section 2.2.47). After three boosts, the anti-sera were 
tested against EH V 1 infected cell extracts by western blotting and immunoprecipitation. The 
results showed that two specific anti-sera, anti-67 and anti-71, were induced by FP67 and 
FP71, respectively. The results are presented in the next section.
Unfortunately, the other three fusion proteins did not induce any antisera to the gene poduct. 
(data not shown). To examine the rabbit immune response to the fusion proteins the antisera 
were tested against the fusion proteins on Western blots. The results showed that all sera had 
& strong reaction to the appropriate purified B-galactosidase fusion proteins (data not shown). 
To further determine whether there was a specific target protein band, the deletion mutants, 
EDI, ED2 and ED75, were used as negative controls to test antisera from FP1, FP2 and FP75
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immunised rabbits. The results showed that the antisera did not detect any difference between 
wild-type and deletion mutants infected cell extracts by Western blot analysis (data not 
shown). This suggested that either no detectable specific antibodies against target gene 
products were induced by FP1, FP2 and FP75 or the level of virally expressed products of 
these genes are too low to detected by the antisera. Of significance is the fact that FP67 and 71 
were expressed in the high yield.
3. 6. IDENTIFICATION AND CHARACTERISATION OF THE GENE 67 
PRODUCT
Sequence analysis showed that the putative gene 67 ORF in both repeat regions of the EHV1 
genome encodes a putative 272 amino acids polypeptide with a Mr of 30 KD (Fig. 24) which 
at the time had no homologues in other sequenced herpesviruses. Recently a homologue has 
been identified in equine herpesvirus type 4 (Nagesha et al., 1993) and bovine herpesvirus 
type 1 (Leung-Tack et al., 1994). It has been reported that a mutation in gene 67 was the 
only alteration found in EHV1 strain RacH, an attenuated live vaccine (Mayr et al., 1968; 
Osterrieder et al., 1994a,b, 1995). The characterisation of ED67 in a mouse model also 
showed ED67 was attenuated (Tim Fitzmaurice personal conmunication). These features 
suggest that gene 67 may play a specific role in its natural host, particularly in determination 
of pathogenicity . To help elucidate the function of the gene, the product of gene 67 was 
identified and characterised.
3. 6. 1. Identification of the polypeptide product of EHV1 Ab4 gene 67.
An antiserum, anti-67, was produced against the fusion protein FP67. Western blotting 
experiments with EHV1 infected cell extracts showed that anti-67 at a dilution of 1:100- 
1:1000 recognised a 36 KD EHV1 infected cell (data not shown). To further confirm the 
specificity of anti-67 and to identify the gene 67 product, monolayers of BHK21/C13 cells
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Figure 24. Predicted amino acid sequence of EHV1 gene 67 protein
The predicted gene 67 encoded protein amino acid sequence is shown. The underlined amino 
acid sequence indicates the hydrophobic region (Sun et al., 1994b). The potential asparagine- 
linked glycosylation site is denoted by asterisks. The potential phosphorylation sites are 
indicated by p under the sequence. The numbers of amino acids are given on each side. The 
region (124416-124929 n.p.) removed in ED67 is limited by angle brackets. The sequence 
(124411-125160 n.p.) expressed from pUEH67 is limited by solid triangles.
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were infected with EHV1, ED67 or Re67 and the polypeptides from the infected cells were 
separated by 10% SDS-PAGE and analysed by Western blotting with either anti-67 serum ( 
dilution of 1.200 ) or preimmune serum (dilution of 1:80). The results showed that anti-67 
specifically recognised an infected-cell polypeptide with apparent Mr of 36,000 D in a 10% 
SDS-PAGE in EHV1 and Re67 infected cell extracts (Fig. 25, a, lane 2 and b, lane 1); the 
polypeptide was not recognised in either mock infected cell extracts (Fig. 25a, lane 1 and b 
lane 2) or ED67 infected-cell extracts (Fig.25b, lane 3); it was also not recognised by 
preimmune serum (Fig. 25a, lane 3). The immunoreaction of anti-67 was inhibited by the 
FP67 fusion protein (Fig. 25a lane 5), but not by an unrelated fusion protein, FP71 ( Fig. 25 
a, lane 4 ). An additional infected-cell protein forming a weak band with Mr of 33,000 in 
10% SDS-PAGE was also specifically detected by anti-67 (Fig. 25a, lane 2 and b, lane 1). 
The 36 KD polypeptide is absent in mutant ED67 infected cells and restored in Re67 infected 
cells confirming that the 36 KD polypeptide is encoded by EE1V1 gene 67.
3.6.2. Characterisation of the EHV1 gene 67 protein product.
To further explore the properties of the gene 67 protein, the protein was characterised in terms 
of regulation of expression, localisation and post-translational modifications.
3.6.2.1. Regulation of expression of the gene 67 protein
EHV1 transcription and translation are regulated in a temporal pattern, i.e.. immediate early, 
early and late (IE, E, L) similar to that of HSV1 (Cohen et al., 1975a; Gray et al., 1987; 
Honess & Roizman, 1974; Clements et al., 1977). To determine the kinetics of the gene 67 
protein expression, a time course experiment was carried out in the presence or absence of 
phosphono acetic acid (PAA), an inhibitor of viral DNA replication. BHK21/C13 
monolayers in 33 mm diameter petri dishes were infected with virus at 5 pfu/cell or mock 
infected in the presence or absence of 300 pg/ml of PAA. At various time points post 
infection, the cells were harvested into 150 pi of sample buffer. The polypeptides in the 
extracts were separated by 10% SDS-PAGE and analysed by Western blotting with anti-67. 
The results presented in Fig. 26 show that the 36 KD gene 67 product was first detected at 1 h
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Figure 25. Western blot of electrophoretically separated EHV1 infected cell 
lysates probed with anti-67.
Lysates obtained from infected or mock infected cells at 20h post infection were separated by 
10% SDS-PAGE and transferred to a nitrocellulose sheet which was divided and probed with 
anti-67 or preimmune serum, (a) Lane 1: mock infected; lanes 2, 3, 4, 5: EHV-1 Ab4 infected 
cell extracts; Lanes 1 and 2: probed by anti-67; Lane 3 probed by preimmune serum; Lane 4: 
probed by anti-67 in the presence of an unrelated fusion protein (20pg of FP71) ; Lane 5: 
probed by anti-67 serum in the presence of 20 pg of FP67. (b) Lane 1, Re67 infected cell 
extract; Lane 2, mock infected cell extract; Lane 3, ED67 infected cell extract, probed by anti- 
67.
Molecular weights are presented in KD on the left side. The 36 KD EHV1 gene 67 protein is 
indicated by a large arrow. The 33KD infected cell polypeptide is indicated by a small arrow.
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p.i., with the amount gradually increasing until about 10 h p.i. and remaining constant up to 
24 h p.i. In the presence of 300pg/ml PAA, expression of the 36 KD gene 67 polypeptide 
was slightly inhibited (2-4) fold (Fig. 26). At this concentration of PAA, EHV1 DNA 
replication is reduced to <5% of the level of the untreated control in BHK21/C13 cells (data 
not shown). This result indicated that virus DNA replication was not required for the 
expression of the 36KD polypeptide. For comparison, regulation of expression of a H SV 1 
early protein, 65KDBP, was examined under the same conditions. The results showed that 
the 65KDBP was detected at 2h p.i. and in the presence of PAA, expression of the 65KDBP 
was similarly only slightly inhibited (data not shown). Finally, as the 36 KD polypeptide was 
expressed at a very early stage of virus infection (lh  p.i.), it was necessary to determine 
whether the 36KD polypeptide is regulated as an immediate early protein. To do this EHV1 
immediate early proteins were prepared as described in Section 2.2.23 and subjected to 
Western blotting with anti-67 serum. The results presented in Fig.27 showed that the 36 KD 
polypeptide was not detected among EHV1 immediate early polypeptides (Fig. 27 a, lane 3), 
but it was present in untreated control (Fig. 27 lane 1). As a comparison, using the same 
conditions HSV 1 immediate early proteins were prepared, and the HSV 1 IE polypeptide, 
Vmwl 10 (Stow et al., 1986; Sacks & Schaffer, 1987) was clearly detected in both immediate 
early and total infected cell extracts ( Fig 27 b lanes 3 and 1). These results confirmed that 
the 36 KD gene 67 product was not expressed as an immediate early polypeptide. Overall 
these results indicate that the 36KD gene 67 product is regulated as an early protein in EHV1 
infected cells.
It should be noted that four additional species with Mrs of 33KD, 31.5KD, 29KD and 26KD 
were also detected along with the 36 KD polypeptide by anti-67 in EHV1 infected cells (Fig. 
26). The 26 KD polypeptide was initially expressed at the same time as the 36 KD protein , 
but the amount gradually decreased. The 33KD polypeptide was expressed as a less abundant 
polypeptide with the same kinetics as the 36 KD band, appearing at 1 h p.i. and gradually 
increased until 12 h p.i. Two other polypeptides (31.5 and 29 KD) appeared at 12 h p.i. and 
gradually decreasing until 24 h p.i. These bands were not present in mock infected extracts
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Figure 26. Time course of EHV-1 gene 67 expression.
BHK21/C13 cells were infected with 5 pfu/cell EHV1 or mock infected and harvested at 
various times up to 24h (-0.3 h equal to 33 min after adding virus into cells; 0 h equal to 1 h 
post adsorption; 1, 2, 4, 6, 8, 10, 12, 14, 18, 24 h time post adsorption) post infection. To 
determine if the gene 67 protein is a true late protein, proteins were also extracted at 6, 8, 12, 
16 and I8h p.i. from BHK21/C13 cells infected with EHV-1 in the presence of 300 jag/ml 
PAA. The infected cell polypeptides were separated by 10% SDS-PAGE and transferred to a 
nitrocellulose membrane. Expression of the gene 67 protein was analysed by Western blotting 
with anti-67. Mr are indicated as KD on the left. The gene 67 protein product is indicated by a 
large arrow on the right hand side. The four other detected polypeptides are indicated by small 
arrows on the right hand side.

Figure 27. Western blot of (a) EHV1 and (b) HSV1 induced immediate early 
polypeptides.
a) Probed with anti-67; b) Probed by anti-HSV-1 VmwIEl 10.
Lane 1 untreated 24h infected cell extracts; Lane 2: mock infected extracts; Lane 3: infected 
cell polypeptides prepared under immediate-early conditions; Molecular weight markers are 
shown on the left in KD. The 36 KD and 33 KD proteins and HSV1 Vmwl 10 are indicated 
by arrows.
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(Fig. 26, lane 1) nor in ED67 infected cell extracts (Fig. 25, b, lane 3), indicating that they are 
infected cell polypeptides and probably relate to gene 67. A pulse-chase experiment showed 
that the 36 KD gene protein could not be chased into any other species even after a 3 h chase 
(data not shown). Thus the relationship of these proteins to each other is unclear.
3.6.2.2. Location of the gene 67-encoded polypeptide within infected cells 
and virions.
To determ ine the subcellular distribution of the gene 67 polypeptide, indirect 
immunofluoresence was used. 50% confluent monolayers of BHK21/C13 cells or Vero cells 
were infected with virus atftl pfu/cell and fixed at 16h p.i. For surface staining, infected cells 
were fixed with 4% paraformaldehyde in PBS for 30 min at room temperature; for 
intracellular staining, the cells were fixed with 4% paraformaldehyde and permeabilised by 
1% NP40 for 1 h at room temperature. The cells were stained with anti-67 (dilution of 1:100) 
and an anti-rabbit antibody fluorescent conjugate. The results showed that the gene 67 
product is present in the cytoplasm of infected cells as a ribbon or filament like
structure in the cytoplasm (Fig. 28 a). No staining was detected in non-permeabilized cells 
(data not shown). The structures were not detected in mock infected or ED67 infected cells 
(Fig. 28 b, and c). The distribution of the gene 67 protein in BHK21/C13 cells (Fig. 28 a) 
and Vero cells is indistinguishable (Fig. 28 d).
To further localise the gene 67 product, BHK21/C13 cells were infected either in the presence 
or absence of Nocodazole or Brefeldin A. Nocodazole, a synthetic microtubule inhibitor has 
been shown to cause the disappearance of mictobules from mammalian cells in culture. 
Brefeldin A, an inhibitor of transport between the ER and the Golgi apparatus which 
ultimately leads to dissolution of Golgi cisternae has been found to disrupt the movement of 
newly synthesised membrane proteins into the Golgi apparatus (Dorns et al., 1989, Harris et 
al., 1963; Lippincott-Schwartz et al., 1989). At 20 h p.i., the treated cells were fixed and 
stained with anti-67. The results showed that neither inhibitor affected the distribution of the 
gene 67 product in the cytoplasm of infected cells (data not shown). In addition, infected
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Figure. 28. Indirect im m unofluoresence detection of the gene 67 protein 
product within cells by anti-67.
Infected or mock infected cells were fixed with 4% paraformaldehyde and treated with 1% 
NP40 at 16 h p.i. The dells were then analysed by indirect immunofluorescence with anti-67, 
(a) EHV1 infected BHK21/C13 cells; (b) mock infected cells; (c) ED67 infected 
BHK21/C13 cells, (d) EHV1 infected Vero cells, (e) Mock infected Vero cells, magnification, 
Arrowheads, filament-like strain.
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cells were fixed and stained either with anti-tubulin or anti-actin antibodies plus anti-67 or 
with anti-67 alone. Double staining showed that the gene 67 product did not colocalise with 
tubulin or actin (data not shown).
Amino acid analysis of the gene 67 protein showed that the protein contains a N-terminal 
hydrophobic region (Fig. 24) which could serve as a transmembrane domain. To determine 
whether the protein is associated with cellular membranes, infected cells were fractionated 
into a soluble cytosol fraction and a membrane-containing fraction using the method described 
in 2.2.24. The membrane fraction was further separated into high affinity and low affinity 
membrane bound protein fractions by the addition of 1M -NaCl and lOOmM-sodium 
carbonate buffer (pH 11.5), which converts closed membrane vesicles to open membrane 
sheets subsequently releasing contents and peripheral membrane proteins into the supernatant 
(low affinity membrane proteins). The polypeptides from the fractions were separated by 
10% SDS-PAGE, transferred to a nitrocellulose membrane and Western blotted with anti-67 
serum. The results showed that most of the gene 67 protein was stably bound to the 
membrane fraction in the presence of 1M -NaCl and lOOmM-sodium carbonate, pH 11.5 (Fig 
29 lane 3). A small proportion of the gene 67 protein was also detected in the low affinity 
membrane fraction and the cytosol (Fig. 29, lanes 4 and 5), but not in the supernatant of the 
medium (Fig. 29, lane 6). This result suggests that the gene 67 protein is associated with 
cellular membranes. Together these results suggested that the gene 67 protein was distributed 
in the cytoplasm as a ribbon-like structure, associated with intracellular membranes, but not 
colocalized with microtubule, Golgi, tubulin or actin.
To determine whether the 36 KD polypeptide is a component of virions, virion polypeptides 
were extracted from purified virion particles with sample buffer and separated by 10% SDS- 
PAGE. The polypeptides were then transferred to a nitrocellulose membrane and 
immunoblotted with anti-67 serum. For further localisation of the gene 67 polypeptide within 
virions, purified virions were treated with 5% NP40 and separated into insoluble 
nucleocapsid/tegument and soluble envelope/tegument fractions by centrifugation (12,000 r.
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Figure 29. Western blot of EHV1 infected subcellular fractions.
BHK21/C13 cells were infected with EHV-1 at 5 pfu/cell and at 16h p.i. the infected cells 
were separated into membrane and cytosol fractions. The membrane fraction was further 
separated into high and low affinity membrane protein fractions using 1M NaCl and sodium 
carbonate, pHl 1.5. The polypeptides in the fractions were analysed by Western blotting with 
anti-67. Lane 1: mock infected cell extracts; Lane 2: total cellular extract; Lane 3: membrane 
proteins stable in 1M NaCl and sodium carbonate, pH 11.5; lane 4: low affinity membrane 
proteins stable in only 150mM NaCl; Lane 5: cytosol fraction; Lane 6: infected cell medium. 
The 36 KD EHV1 gene 67 protein is indicated by a large arrow. The 33 KD polypeptide is 
marked by a smaller arrow.
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Figure 30. Western blot of EHV1 virion fractions with anti-67.
Purified EHV-1 virions were treated with 0.5% NP40 and separated into soluble and insoluble 
fractions by centrifugation. The fractions were then Western blotted with anti-67. Lane 1, 
infected cell extract; Lane 2, purified virions; Lane 3, mock infected cell extracts; Lane 4 
supernatant of virions treated with NP40; and Lane 5, insoluble pellet from treated virions. Mr 
are indicated as KD on the left. The 36KD gene 67 product is indicated by a small arrow and 
four other virion background polypeptides by large arrows.
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p.m. for 2 h). The polypeptides extracted from the two fractions were separated by SDS- 
PAGE and Western blotted with anti-67. The results presented in Fig. 30 showed that the 
36KD polypeptide was detected in purified virions (lane 2) and in the tegument/nucleocapsid 
fraction (lane 5).In compared with its high expression in infected cells, only low abundance of 
the protein: incorperated into virions. The anti-67 serum also recognised several other higher Mr 
virion nucleocapsid/tegument polypeptides with apparent Mr of 145KD, 120KD, 65KD and 
55KD, which were not detected in mock infected (Lane 3) or infected cell extracts (Lane 1). 
However, the crossreaction between them on molecular level is unclear.
3.6.2.3. Transient expression of the gene 67 product in BHK21/C13 cells.
To further analyse the gene 67 polypeptide, an expression plasmid, pCMV67, was 
constructed. The gene 67 ORF was amplified by PCR using two primers containing a BamHI 
site. The amplified fragment was digested by BamHI and cloned into the BamHI site of 
pCMV 10 under the CMV immediate early promoter (Fig. 31). To transiently express the gene 
67 protein, 50% confluent monolayers of BHK21/C13 cells were lipofected with pCMV67 or 
control pCMVIO as discribed in section 2.2.32. At 30 h post lipofecton, the cells were either 
fixed and subjected to indirect immunofluoresence or lysed with sample buffer and subjected 
to Western blotting with anti-67 serum. A Western blotting experiment of cell extracts 
showed that the 36 KD gene 67 polypeptide and the 33KD protein were detected by anti-67 
serum in pCMV67 lipofected cell extracts (Fig. 32 lane, 3), but not in mock infected (Fig. 32, 
lane 2) and pCMVIO lipofected cells extracts (Fig. 32, lane 4). Indirect immunofluorescence 
experiments with anti-67 revealed that the transiently expressed gene 67 protein was 
distributed within the cytoplasm coalescing immediately adjacent to the nucleus such that a 
solid band structure surrounded the nucleus (Fig. 33, a). No specific staining was detected in 
pCMVIO lipofected cells (Fig 33, b). This result shows that the protein expressed from the 
cloned gene 67 ORF in BHK21 cells was also recognised by anti-67 serum and had the same 
Mr and distribution pattern as that expressed in EHV1 infected cells (Fig. 32, lane 1). This 
result further confirmed that the 36 KD polypeptide recognised by anti-67 was encoded by 
EHV1 gene 67. In addition, it also indicates that the filament or ribbon-like distribution of
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Figure 31. Construction of expression plasmid pCMV67.
The gene 67 ORF ( 124379-125196 n.p.) was amplified by PCR using primers:
(1),5'-T ACT AGATCT ATG AAC TCC GAT TA-3'
(2),5'-T ATC A G A TCT CAG AGA TAC AGA TTA-3', containing BamHI sites 
(underlined), from Sp67. The amplified 817 bp fragment was digested with BamHI and 
cloned into the pCMVIO BamHI site under the CMV immediate early promoter in the correct 
orientation to construct pCMV67. Arrows show the orientation of gene 67 transcription. The 
initiating codon (ATG) of gene 67 is shown in bold in primer (1).
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Figure. 32. Lipofected BHK21/C13 cell extracts analysed by 
Western blotting.
BHK21/C13 cells were either lipofected with plasmid DNA, infected with EHV1 or mock 
infected. Infected cells were harvested at 16h p.i. and lipofected cells were harvested at 30h 
post lipofection. The cell extracts were analysed by Western blotting with anti-67 serum. Lane 
1: EHV1 infected cell extract; Lane 2: mock infected cell extract; Lane 3: pCMV67 lipofected 
cell extract and lane 4: pCMVIO lipofected cell extract. Molecular weight markers are 
indicated as KD on the left. The 36 KD gene 67 product by a large arrow and the 33 KD 
protein by a small arrow on the right.
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Figure 33. Indirect immunofluorescence of lipofected BHK21 cells.
BKH21/C13 cells were lipofected with pCMV67 (A) or pCMVIO (B). The cells were fixed at 
30 h post lipofection and analysed by indirect immunofluoresence with anti-67.

Results
the gene 67 protein is independent of other EHV1 gene products.
3.6.2.4. Post-translational modification of the gene 67 polypeptide.
Sequence analysis suggested that the gene 67 product contained two putative N-linked 
glycosylation sites and six putative phosphorylation sites. To determine whether the gene 67 
protein is a glycoprotein or a phosphoprotein, infected cells were either labelled with 3^S 
methionine, ^4C glucosamine or 32p orthophosphate or treated by glycosylation inhibitors 
(tunicamycin or monensin). Infected cells were lysed at 20 h p.i. and subjected to 
immunoprecipitation with anti-67 serum. Immunoprecipitation experiments demonstrated 
that the 36KD polypeptide is labelled both by 35S methionine (Fig. 34 a lane 1) and by 32P 
orthophosphate (Fig. 34 b lane 4), but not by 14C glucosamine ( data not shown). The 32P 
labelled 36 KD polypeptide was not precipitated from mock infected cells (Fig. 34 a lane 2 
and b lane 5). The preimmune serum did not precipitate the polypeptide from EHV1 infected 
cells (Fig. 34 a lane 3 and b lane 6). The fusion protein FP67 inhibited precipitation of the 
36KD polypeptide (Fig. 34b lane 3), but an irrelevant fusion protein did not inhibit the 
precipitation (Fig. 34 b, lane 2). Treatment with glycosylation inhibitors showed that neither 
tunicamycin nor monensin, altered the mobility of the gene 67 product on 10% SDS-PAGE 
when analysed by Western blotting (data not shown). These results demonstrated that the 
gene 67 product is a phosphoprotein, but not a glycoprotein.
3.7. IDENTIFICATION AND CHARACTERISATION OF THE GENE 71 
POLYPEPTIDE
Sequence analysis predicted that EHV1 gene 71 encodes a 797 amino acids polypeptide. The 
predicted polypeptide contains amino- and carboxy-terminal hydrophobic domains which may 
serve as a potential signal sequence and transmembrane domain. It also contains a single re­
linked glycosylation site and a serine/threonine rich region which is likely to serve as a O- 
linked glycosylation site (Fig. 35). These features suggested that gene 71 could encode a 
class I membrane glycoprotein with heavy O-linked glycosylation. To elucidate the function 
of the gene and to confirm the predicted features of the gene 71 protein, a specific anti-serum,
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Figure. 34. (a). Autoradiography of immunoprecipitated 35S labelled gene 67 
polypeptide
Extracted proteins from cells labelled with [35S] methionine were immunoprecipitated with 
either anti-67 serum or preimmune serum and analysed by 10% SDS-PAGE. Lane 1: EHV1 
infected cell extract precipitated by anti-67; Lane 2: mock-infected cell extract precipitated by 
anti-67; Lane 3: EHV-1 infected cell extract precipitated by preimmune serum. The gene 67 
36 KD product is indicated by a large arrow on the left hand side. The specific 33 KD and 
31.5 KD bands are marked by small arrows on the left hand side. Mr are indicated as KD on 
the left.
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Figure 34 (b). Autoradiography of immunoprecipitated 32P labelled gene 67 
protein.
Extracted proteins from cells labelled with [32P] orthophosphate, immunoprecipitated with 
anti-67 or preimmune serum and analysed by 10% SDS-PAGE. Lane 1: infected cell extract; 
Lanes 2-4 infected cell extracts immunoprecipitated by anti-67; Lane 2: in the presence of 
20pg unrelated fusion protein; Lane 3: in the presence of 20pg pUEX67 fusion protein; lane 
4: with anti-67 alone; Lane 5: mock infected cell extracts precipitated by anti-67 and Lane 6: 
EHV-1 infected cell extract precipitated with preimmune serum. Molecular weight markers are 
indicated on the left in KD and the 36 KD gene 67 product by an arrow on the right.

Figure. 35. Predicted amino acid sequence of the EHV-1 gene 71 protein.
The amino acid sequence of the EHV1 Ab4 gene 71 protein was predicted from analysis of 
DNA sequence data. Hydrophobic amino- and carboxy-terminal domains are underlined (— ). 
A single potential N-linked glycosylation site is denoted by asterisks. The domain which is 
rich in serine and threonine residues ( potential O-linked glycosylation sites) is delimited by 
angle brackets. The expressed domain in the fusion protein PUEH71 is delimited by solid 
triangles. The domain which was deleted in the mutant ED71 is underlined with a solid line. 
Residue numbers are given on each side.
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anti-71 was used to identify and characterise the protein product of gene 71.
3.7.1. Identification of the EHV1 gene 71 protein product
To identify the gene 71 protein product, a specific antiserum, anti-71, was raised against a 
carboxy-terminal portion of gene 71/B-galactosidase fusion protein, FP71. Anti-71 was tested 
by Western blotting against EHV1 infected cell extracts and pU71HE transformed cell lysates. 
The results show that anti-71 (1:200) could recognise an infected cell polypeptide with a Mr of 
192 KD and the FP71 fusion protein (data not shown). To further determine the specificity of 
anti-71 and subsequently identify the gene 71 product, monolayers of BHK21/C13 cells were 
separately infected with 5 pfu/cell of EHV1, ED71 and Re71, a revertant of ED71, or mock 
infected and the cells were harvested into sample buffer at 20 h p.i. The polypeptides in the 
cell extracts were separated by 8% SDS-PAGE and Western blotted with anti-71. The results 
presented in Fig. 36 show that anti-71 specifically recognises a polypeptide in EHV1 infected 
cell extracts which is present as a broad band at a position corresponding to a Mr of 
approximately 192 KD on 8% SDS-PAGE (Fig. 36, lane 1). The polypeptide was not 
detected in mock-infected cell extracts by anti-71 (Fig. 36, lane 2) and was not recognised by 
the preimmune serum (Fig. 36, lane 4). The immunoreaction between the gene 71 product 
and anti-71 is specifically inhibited by the gene 71 fusion protein (Fig. 36, lane 6), but not by 
an unrelated fusion protein (Fig. 36, lane 5). The 192 KD polypeptide was not detected from 
the deletion mutant ED71 infected cell extracts by anti-71 (Fig. 36, lane 3). However, a band 
corresponding to a Mr of 116KD was detected by anti-71( Fig. 36, lane 3). Since the 
antiserum was raised against a B-galactosidase fusion protein, this 116 KD polypeptide was 
presumed to correspond to B-galactosidase (116 KD) produced by the lac Z gene inserted in 
ED71. This was confirmed by a commercial B-galactosidase monoclonal antibody which also 
recognised this 116 KD polypeptide (data not shown). These results demonstrate that gene 71 
encodes a polypeptide with an apparent Mr of 192 KD in EHV1 Ab4 infected cells.
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Figure. 36. Western blot of electrophoretically separated cell lysates
Lysates obtained from infected or mock infected cells at 20h post infection were separated on 
8% SDS-PAGE and transferred to nitrocellulose and probed with antisera. Lane 2, mock- 
infected cell extract probed by anti-71 (1:100). Lanes 1,4,5 and 6, EHV-1 infected cell 
extracts: probed with anti-71 alone ( lane 1), preimmune serum (lane 4), anti-71 with 20|Hg of 
an unrelated fusion protein (lane 5), anti-71 in the presence of 20pg of pUEH71 fusion 
protein (lane 6); Lane 3, ED71 mutant infected cell extract probed by anti-71 serum. The 
upper arrow marks the 192 KD protein of gene 71. The lower arrow indicates the position of 
the B-galactosidase band. Molecular weight markers are indicated in KD on the left.
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3.7.2. Characterisation of the EHV1 gene 71 protein.
In this section the gene 71 protein was characterised in terms of regulation of expression, 
localization and post-translational modification.
3.7.2.1. Regulation of expression of the gene 71 protein
To study viral gene regulation, a time course of gene 71 expression was analysed. 
Monolayers of BHK21/C13 cells in 33mm diameter dishes were infected with virus at m.o.i. 
of 5 pfu/cell and harvested in sample buffer at various times after infection. The polypeptides 
in extracts were separated by 8% SDS-PAGE and transferred onto a nitrocellulose membrane 
and Western blotted using anti-71 serum. The results presented in Fig. 37 show that the 192 
KD polypeptide of the gene 71 product was first detected at 8 h p.i.; the amount of expressed 
polypeptide increased until about 12 h p.i. and remained constant up to 24 h p.i. This pattern 
was reproducible in duplicate experiments and suggested that gene 71 is regulated as a late 
gene. To further determine the regulation of gene 71, expression of the 192 KD protein was 
examined in the presence of 300 |ig/ml of PAA. As mentioned previously at this 
concentration of PAA, virus DNA replication is reduced to undetectable levels (<5% of the 
untreated control) in cells infected with both EHV1 and HSVl(Sun et al.f 1995; Johnson et 
al., 1986). Infected cells were harvested at 0, 6, 12, 18 and 24 post-adsorption. The 192 
KD Mr protein was first detected at 12 h after adsorption. Although virus DNA replication 
was not essential for gene 71 expression, it was significantly reduced in the presence of PAA 
(Fig.37, PAA). For comparison, regulation of expression of a HSV1 true late gene US11 
(Johnson et al., 1986) and a delayed early gene UL42 (Goodrich et al., 1989) were also tested 
under the same conditions. The results showed that in the presence of PAA synthesis of the 
U S11 encoded protein could not be detected at any time after infection, whereas the UL42 
protein was clearly detected by 6 h p.i. and only slightly reduced by inhibition of PAA (data 
not shown). Overall results from these experiments demonstrated that gene 71 is regulated as 
a leaky late gene in EHV1 infected cells.
Figure 37. Time course of accumulation of the gene 71 product during 
infection
BHK21/C13 cells infected with EHV-1 strain Ab4 in the absence or the presence of 300|ig/ml 
PAA were harvested at the times shown (in hours) after infection and the proteins extracted 
from the cells separated by 8% SDS-PAGE. Polypeptides were transferred to a nitrocellulose 
membrane and probed by anti-71 serum. The product of gene 71 is indicated by an arrow. 
Molecular weight markers are shown on the left in KD. PAA indicates the lysates of infected 
cells in the presence of PAA.
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3.7.2.2. Location of the gene 71-encoded polypeptide within infected cells
The gene 71 protein was predicted to be a class I membrane protein. To determine whether the 
protein is associated with cellular membranes, monolayers of BHK21/C13 cells in 50 mm 
diameter dishes were infected with virus at a m.o.i. of 5 pfu/cell and at 16 h p.i., the cells 
were fractionated into a soluble cytosol fraction and a membrane-containing fraction by the 
method described in 2.2.24. The polypeptides in the fractions were separated by 8% SDS- 
PAGE and Western blotted with anti-71 serum. The results presented in Fig. 38 showed that 
the 192KD polypeptide is detected in the membrane fraction in the presence of 1 M NaCl and 
100 mM-sodium carbonate, pH 11.5. (Fig. 38, lane 3). The 192 KD protein is not present 
either in the peripheral membrane fraction, the cytosol or in the supernatant (Fig. 38, lanes 4, 
5 and 6). This result showed that the gene 71 protein has a high affinity association with 
cellular membranes confirming that the gene 71 protein is a membrane bound protein. In 
addition, a 80 KD species corresponding in size to the predicted primary translation product of 
the gene 71 protein was specifically detected in the cytosol fraction (lane 5) and in the total 
infected cell extract (lane 1), but was not present in mock infected cells nor in the membrane 
fraction (Fig. 38, lanes 2 and 3).
3.7.2.3. Virion localisation of the gene 71 polypeptide.
EHV1 virus preparations consist of virions and light particles (L particles). L particles are 
essentially envelope-tegument structures (McLauchlan & Rixon, 1992). To determine the 
location of the gene 71 protein within virions, purified virions and L particles were prepared 
and extracted with sample buffer. The extracted polypeptides were separated by 8% SDS- 
PAGE and Western blotted with anti-71 serum (Fig. 39a, lanes 1 and 2). For comparison of 
the amount of loaded protein, the same amounts of extracts from virions and L particles were 
run in adjacent lanes in the same gel and stained with Coomassie blue (Fig. 39 a, lanes 3 and 
4). The gene 71 polypeptide was detected in both purified L particles and virions as a wide 
band with a molecular weight over 200 KD ( Fig. 39, a, lanes 1 and 2). This result showed 
that the gene 71 protein was a virion component, present in the envelope and tegument,
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Figure 38. Western blotting analysis of subcellular fractions with anti-71 
serum.
Cells infected with EHV-1 Ab4 were fractionated as described in section 2.2.24. The 
fractionated polypeptides were then separated by 8% SDS-PAGE and Western blotted using 
anti-71 serum. EHV-1 infected cell extracts lanes 1, 3, 4, 5 and 6; Lane 1, total infected cell 
extract; Lane 2, mock infected cell extracts; Lane 3, the insoluble pellet of the membrane 
fraction treated with 1M NaCl and a pH 11.5 acid buffer; Lane 4, the soluble fraction of the 
treated membrane fraction; Lane 5, cytosol; Lane 6, culture supernatant. Molecular weight 
markers are shown on the left in KD. The products of gene 71 are indicated by arrows .

Figure 39. (a) Western blotting analysis of purified virions and L-particles 
with anti-71.
Virions (lanes 1 and 3) and L particles (lanes 2 and 4), purified as described in section 2.2.11, 
were analysed by 8% SDS-PAGE. Lanes 1 and 2, virions and L particles probed with anti- 
71. Lanes 3 and 4, the same samples were loaded onto adjacent lanes and stained with 
Coomassie blue. The product of gene 71 is indicated by an arrow. Molecular weight markers 
are shown on the left in KD.
(b) Autoradiography of surface labelled virion proteins.
Purified virions were either labelled and analysed by 8% SDS-PAGE or analysed by western 
blotting with anti-71. L anel, purified virions labelled with U D P -[^C ] galactose by the 
galactosyl transferase as described in methods. Lane 2, purified virions probed with anti-71. 
The gene 71 product is indicated by an arrow. Molecular weight markers are shown on the 
left in KD.
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To further determine the precise location of the gene 71 protein, freshly purified virions were 
labelled in vitio with UDP-[14cj galactose by enzymatic labelling which specifically labels 
the exposed carbohydrate residues on the virion envelope surface. Labelled virions were 
purified from unbound radioactivity and analysed by 8% SDS-PAGE, the gel dried and 
exposed to film. The size of the labelled gene 71 protein was determined by alignment with 
the gene 71 polypeptide recognised by immunoblotting with the anti-71 serum in the adjacent 
lane. The result shows that a high molecular weight virion polypeptide with the same 
molecular weight as that of the gene 71 polypeptide recognised by anti-71 (Fig. 39 b lane 2) 
was surface labelled by UDP-14C galactose ( Fig. 39 b, lane 1). This result suggests that the 
gene 71 polypeptide was present on the surface of the EHV1 virion envelope.
3.7.2.4. Post-translational modification of the gene 71-encoded 
polypeptide.
Sequence analysis showed that the gene 71 protein contains a single putative N-linked 
glycosylation site and an extensive region encoding a high proportion of serine and threonine 
residues (amino acids 22-465), which is likely to be heavily O-glycosylated (Telford et al., 
1992). It has been demonstrated that the gene 71 encoded polypeptide had a much higher 
molecular weight (192 KD) than the predicted primary product (80 KD). These data 
suggested that the gene 71 protein is likely to be a heavily O-linked glycoprotein leading to a 
high molecular weight on SDS-PAGE.
To determine whether the gene 71 protein is glycosylated, three experiments were carried out. 
Firstly, infected cells were labelled with [35S] methionine, [3H] mannose or [14C] 
glucosamine from 3 h to 16 h p.i. 14C glucosamine specifically labels the inner complex-O- 
linked carbohydrate chains on a glycoprotein. At the end of labelling, the cells were lysed 
with extraction buffer and the polypeptides immunoprecipitated with anti-71 and analysed by 
SDS-PAGE. The results showed that the gene 71 polypeptide was labelled with [35S] 
methionine (Fig. 40a, lane 2) and [^ C ]  glucosamine (Fig. 40b, lane 2), but not by [ H] 
mannose (data not shown). The polypeptide was not precipitated from mock infected cell
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extracts by anti-71 (Fig. 40a,b lane 1) nor by preimmune serum from EHV1 infected cell 
extracts (Fig. 40a,b lane 3). A high Mr protein band (>200 KD) labelled with 14C- 
glucosamine was also specifically precipitated by anti-71 (Fig. 40b, lane 2). Secondly, two 
metabolic inhibitors of glycosylation, tunicamycin and monensin, were used. Tunicamycin 
specifically inhibits transfer of N-acetyl glucosam ine-1 phosphate from UDP-N- 
acetylglucosamine to dolichol monophosphate and thereby blocks the formation of protein- 
carbohydrate linkages of the N-glycosidic type (Mahoney and Duksin et al., 1979). 
Monensin catalyses the exchange of sodium and potassium ions across biological membranes 
and is thought to disrupt ion gradients that appear to be crucial to the budding of vesicles from 
the Golgi complex (Pressman, 1976), thus inhibiting the processing of herpes simplex virus 
glycoproteins, particularly O-linked glycoproteins, in Golgi apparatus (Johnson, and Spear, 
1982). Monolayers of BHK21/C13 were infected with virus at a m.o.i of 5 pfu/cell in the 
presence of tunicamycin (lpg/ml) or monensin (1 pM). The cells were harvested in sample 
buffer at 16 h p.i. and analysed by Western blotting with anti-71. The results showed that the 
apparent Mr of the gene 71 protein was reduced by 9KD following treatment with tunicamycin 
indicating that the gene 71 protein is N-glycosylated (Fig. 41 a, lane T). Treatment with 
monensin caused the disappearance of the high Mr form (192 KD) of the gene 71 protein and 
an increase in the amount of the 80 KD Mr polypeptide band (Fig. 41a, lane M), with the 
same M r as that of the predicted primary gene 71 product. Thirdly, purified EHV1 virions 
were digested with glycanases. These enzymes include N-glycanase, which appears to 
hydrolyse the high mannose and complex forms present in the core region of N-linked 
oligosaccharides (Elder and Alexander, 1982); neuraminidase, which removes sialic acid and 
exoglycanidases including a-L-fucoside fucohydrolase, 6-galactosidase and B-N-acetyl 
hexosaminidase. These exoglycanidases have been reported to liberate terminal O-L-fucoside, 
6-linked galactose and 6-linked N-acetylglucosamine and N-acetylgalactosamine from a 
variety of substrates (Carlsen and Pierce, 1972; Bahl and Agarwal, 1969; Li and Li, 1970). 
Digested polypeptides were separated by 8% SDS PAGE and analysed by Western blotting 
with anti-71. The results showed that the apparent Mr of the gene 71 polypeptide was only 
slightly reduced by treatment with N-glycanase (Fig. 41b, lane N-g). Digestion with
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Figure. 40. Autoradiography of precipitated gene 71 polypeptide with anti-71 
serum
Cells labelled with (a) [35S] methionine or (b) [14C] glucosamine were extracted with lysis 
buffer and immunoprecipitated with either anti-71 (Lanes 1 and 2) or preimmune serum (Lane 
3) and analysed by 8% SDS-PAGE. Lane 1, mock infection; Lanes 2 and 3, EHV1 infected 
cell extracts. The gene 71 product is indicated by a small arrow. A high Mr band is indicated 
by a large arrow. Molecular weight markers are shown on the left in KD.
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Figure 41. (a) western blotting of tunicamycin or monensin treated infected 
cell extracts
BHK21 cells were infected with EHV1 either in the presence or absence of tunicamycin or 
monensin. The cells were extracted at 16h p.i. Extracts from cells mock-infected (MI), 
infected with EHV-1 Ab4 (EV), infected with EHV-1 in the presence of tunicamycin (T) or 
monensin (M) were separated by 8% SDS-PAGE and probed by anti-71. The high molecular 
weight gene 71 polypeptide are indicated by large arrows and the 80 KD species by a small 
arrow. Molecular weight markers are indicated on the left in KD.
(b) Western blotting of glycanase digested EHV1 virions probed 
with anti-71
Purified EH V 1 virions (Vir) were either directly extracted or digested with N-glycanase (N-g), 
neuraminidase (Neu), or exoglycanases (Ex-g) (B-N-acetylhexosaminidase, L-fucosidase 
fusohydrolase and 6-galactosidase), prior to extraction with the sample buffer. The extracts 
were separated by 8% SDS-PAGE and Western blotted with anti-71. The gene 71 polypeptide 
is marked by a large arrow and the new species by a small arrow. Molecular weight values are 
shown on the left in KD.
a b
M 1 T EV M M
3 0 -
—
u cn 3 o> ■- i <v
>  Z  2
200 - iik
97 -
6 9 -
t
4 6 - i
3 0 -
Ex
-
Results
neuraminidase reduced the molecular weight and amount of the high Mr form of the gene 71 
protein and produced a new species with a 80 KD Mr ( Fig. 41b, lane Neu). Finally digestion 
with exoglycanases completely removed the high Mr form of the gene 71 protein and also 
produced a band with 80 KD Mr (Fig. 41b, lane Ex-g), which corresponds to the 80 KD 
primary product of the gene 71 protein seen in infected cells. As a control, HSV1 strain 17+ 
virions were digested under the same conditions with these glycanases and the digestion 
analysed by Western blotting with the antibody against HSV1 glycoprotein D (gD). The 
results showed that as expected the enzymes reduced the molecular weight of HSV1 gD (data 
not shown). Overall the results demonstrated that the high molecular weight gene 71-encoded 
polypeptide was heavily O-glycosylated and also contains limited N-linked oligosaccharides.
3.7.3. The relationship between the gene 71 protein and EHV1 
glycoprotein gp300
The glycoprotein gp300 had been previously identified as an EHV1 membrane protein 
modified as a heavy 0-1 inked glycoprotein with a high Mr over 400 KD on DATD cross 
linked SDS-PAGE (Allen & Yeargan, 1987; Whittaker et al., 1990). It was also shown to be 
encoded by EHV1 gene 28 (Whittaker et a l, 1992a). During the present study it became 
apparent that the high Mr glycoprotein encoded by gene 71 of EHV1 Ab4 had very similar 
characteristics to gp300. Sequence analysis data suggested that the EHV 1 gene 28 protein 
was not a typical class I membrane protein and not likely to be a heavily O-linked glycoprotein 
(Sun et al., 1994). The accumulated data therefore raise the question whether the two EHV1 
proteins are the same polypeptide and if so, which gene encodes the protein.
To determine if gp300 recognised by P19 and the gene 71 protein recognised by anti-71 were 
the same protein, the following experiment was carried out. Polypeptides from EHV1, ED71 
and the revertant, Re-71 infected cells were extracted and analysed by Western blotting with 
anti-71 serum which is specific for the gene 71 protein and a monoclonal antibody P I9 which 
specifically recognises gp300 (Whittaker et al., 1990) on the same gels. The results showed 
that a polypeptide identical to gp300 was recognised by P19 and the anti-71 serum from
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EHV1 and Re71 infected cell extracts on 8% SDS-PAGE cross-linked with either bis- 
acrylamide (a) or N',N'-dialliltratardiamide (DATD) (b) (Fig. 42, lanes 1, 2, 6, 7, 8, 12). 
Both antibodies, P19 and anti-71, detected the same Mr shift following treatment with 
tunicamycin ( Fig. 42, lanes 5, and 11). Neither P I9 nor anti-71 detected gp300 or the gene 
71 protein in mock infected or ED71 infected cell extracts (Fig. 42, lanes 3, 4, 9 and 10), 
although the anti-71 serum recognised the 116k Mr 13-galactosidase polypeptide (lane 10).
Overall these results demonstrated that the protein (gp300) recognised by MAb P I9 is the 
same polypeptide as the product of gene 71 identified by anti-71 and that this polypeptide is 
encoded by EHVI gene 71 and not by EHV1 gene 28 as previously published (Whittaker et 
al., 1992a).
A high Mr infected cell polypeptide (>200 KD) was also picked up by both antibodies (P19 
and anti-71) along with the gp300 and the gene 71 protein, this protein was more strongly 
recognised by p i 9 than by anti-71 (Fig. 42 lanes 1, 2, 6, 7, 8 and 12). This high Mr 
polypeptide was not present in ED71 infected cell extracts and its Mr was reduced following 
treatment with tunicamycin (Fig.42 lanes 5 and 11). A similar Mr protein heavily labelled 
with 14C glucosamine was also precipitated by anti-71 (Fig. 40b, lane 2). These data indicate 
that this high Mr protein is likely to be a highly glycosylated form of the gene 71 protein, 
which appears to be the predominant form recognised by P I9.
3.8. CHARACTERISATION OF THE DELETION MUTANT OF EQUINE 
HERPESVIRUS TYPE 1 GENE 71, ED71
The results from section 3.4. showed that deletion of EHV1 gene 71 obviously impaired the 
growth properties of the virus in vitro, the final titre of ED71 being 5- to 10-fold lower than 
that of wild-type virus or its revertant. ED71 was also found to be attenuated in its 
pathogenicity in a murine model (Tim Fitzmaurice, personal conmunication). These features 
of ED71 suggested that the gene 71 protein plays an important role in the virus life cycle 
which could not be fully complemented by host proteins. Characterization of ED71 could
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Figure. 42. Western blotting of the EHV1 gene 71 product and gp300 probed 
with anti-71 serum and P19 monoclonal antibody.
Extracts from cells mock-infected (lanes 3 and 9), infected with mutant ED 71 (lanes 4 and 
10), infected with revertant Re71 (lanes 1 and 7), infected with EHV-1 Ab4 (lanes 2, 6, 8 and 
12) and infected with EHV-1 Ab4 in the presence of tunicamycin (lpg/m l) (lanes 5 and 11) 
were analysed by 8% SDS-PAGE cross-linked with bisacrylamide (a), or DATD (b) and 
probed with anti-71 serum (lanes 7-12) and the P I9 monoclonal antibody (lanes 1-6). The 
gene 71 polypeptide and gp300 are indicated by large arrows and the 116K B-galactosidase 
band is indicated by a small arrow. Molecular weight values are shown on the left in KD.
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reveal the role of the gene 71 piotein in the virus life cycle and provide data to explain the 
reason for the attenuation of ED71 in vivo. Since the gene 71 protein was demonstrated to be 
a class I membrane glycoprotein, it possibly plays a role in virus entry into cells, egress from 
cells and transmission from cell to cell. The deletion mutant (ED71) was characterised in 
terms of entry into cells, egress from cells and transmission from cell to cell, compared to the 
wild type virus and its revertant, Re71.
3.8.1 ED71 entry into cells
To determine the efficiency of ED71 adsorption onto cells, precooled monolayers of 
BHK21/C13 cells were infected with 300 pfu/plate of purified EHV1 virions and adsorption 
allowed to proceed for various times at 4°C. At each time point the plates were washed 
thoroughly with PBS and incubated at 37°C. After two days, the plates were stained and the 
plaques counted. Virus adsorption is presented as a percentage of pfu from the final time point 
plates (4 hr). Each point on the graph represented an average of 3 plates. The results 
represented in Fig 43. show that purified ED71 adsorbs more slowly onto cells than wild-type 
and revertant virus at 4°C. Its 50% adsorption time being 110 min compared to 60 min for 
wild type and revertant. These experiments were repeated several times with similar results. 
A similar effect was also observed in an experiment performed at 37°C (data not shown). 
These results demonstrated that the rate of adsorption of ED71 virions onto cells is obviously 
lower than that of wild-type virus and Re71.
To determine whether there is a defect in penetration during entry of ED71 into cells, 
monolayers of BHK21/C13 cells in 50 mm plates were infected with 400 pfu/plate of purified 
virions which were allowed to adsorb for 2h at 4°C. After washing with PBS, the infected 
cells were shifted to 37 C and treated with either an acid buffer (pH3.0) or PBS (as a control) 
for 5 min at various times after shift. This protocol is described in 2.2.14. Thenumbersof 
plaques on the plates, which was treated with acid buffer, was determined and compared with 
that of the untreated control. Acid resistance represents the efficiency of virion penetration 
and is taken as a measure of virion penetration. The results (Fig. 44) show that penetration of
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Figure. 43. Adsorption of purified ED71, Re71 and wild-type virus onto 
BHK21/C13 cells.
Monolayers were infected with 300 pfu of virus and adsorption allowed to take place for 
various times at 4°C. Unbound virus was washed off with PBS and the cells overlaid with 
medium containing methylcellulose and incubated at 37°C. After 2 days the cells were stained 
and the plaques counted. The rate of virus adsorption was expressed as a percentage of the 
control (the numbers of plaques from the 4 h time-point plate). Results are averages from an 
experiment done in triplicate and error bars indicate standard deviations.
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Figure 44. Penetration by ED71, Re71 and wild-type virus into BHK21/
C13 cells.
Monolayers of cells were inoculated with 400 pfu of purified virions for 2 h at 4°C to allow 
adsorption to take place. The monolayers were then shifted to 37°C. At indicated time points, 
monolayers were treated for 5 min with 1 ml of citric acid buffer or with PBS. The 
monolayers were overlaid with medium containing methylcellulose and incubated at 37°C for 
2 days and plaques counted. The virus surviving from citrate treatment at each time point is 
presented as a percentage of the PBS treated control value. Each time point value is the 
average of three plates and the error bars represent standard deviations.
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ED 71 as a percent of the untreated control was significantly lower than that of wild-type and 
revertant. For 50% penetration, ED71 virions took 55-60 min, while wild-type virus took 
only 20 min. This experiment was repeated several times with similar results. Re71 showed 
a very similar penetration rate to wild-type virus. These results demonstrated that the 
penetration of adsorbed ED71 into cells is less efficient than for wild-type virus and Re71.
3.8.2. Egress of ED71 from cells
The specific infectivity of the virions purified from infected BHK21/C13 cells (presented in 
Table 7) showed that the particle/pfu ratio of purified ED71 is significantly higher (10-20 fold) 
than that of wild-type virus and Re71, suggesting that there could be a defect in ED71 virion 
maturation or egress. Similar results were obtained following both high and low m.o.i. 
infection. To test if ED71 has a defect in release from infected cells, infectious progeny virus 
from extracellular and intracellular fractions at various times post infection was harvested and 
quantitated separately. The results presented in Fig. 45 compared the yields of total, cell 
released and cell associated infectious virus from ED71, wild-type virus and Re71 infected 
cells. The total yield from ED71 infected cells decreased by 7 fold compared with that of 
wild-type virus and revertant (Fig.45, Total). The yield of infectious progeny released from 
ED71 infected cells is significantly lower than that from wild-type and revertant infected cells. 
The final yield of released infectious virus from ED71 infected cells decreased about about 
100-fold compared to wild-type and Re71 infected cells (Fig.45 cell-relased). Another 
notable difference between ED71 and wild-type virus infection was that the onset of infectious 
virus release from ED71 infected cells was significantly delayed (Fig 45 cell-released). The 
amount of infectious wild-type virus and Re71 released from infected cells increased by 1000- 
fold between 8 to 16 h post infection, whereas no significant release of infectious ED71 from 
infected cells occurred until after 16 h post infection (Fig. 45, cell-released). The yield of 
infectious virus from ED71 infected cells increased by only 20-fold from 16 to 24 h post 
infection (Fig.45 cell-released). The yields of cell-associated infectious virus from ED71 
infected cell are about 2 to 3 fold lower than that from wild-type and revertant virus infected 
cells (Fig. 45 cell-associated). These observations show that egress of ED71 from infected
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Table 7. The specific infectivity (particle/pfu) of ED71, Re71 and wild-type virus 
(EHV1).
Virus *particle/pfu “particle/pfu
EHV1 101.7/1 63.8/1
Re71 103.5/1 107.7/1
ED71 1440/1 2128/1
8
* Virus from 4x10 BHK21/C13 cells infected at a m.o.i. of 0.01 pfu per cell and 
harvested at 72 h post infection.
8
“Purified virions from 4x10 BHK21/C13 cells infected with virus at a m.o.i. of 5 
pfu/cell and harvested at 20 h post infection.
Figure. 45. Quantitation of cell-released infectious virus from the wild-type 
virus (EHV1), Re71 and ED71 infected cells.
BHK21/C13 monolayers were infected with virus at a m.o.i. of 5 pfu/cell and cell-released 
(CR) and cell-associated (CA) infectious virus harvested separately at various times (indicated 
in h) post infection were titrated in BHK21/C13 cells. Total graph shows total infectious virus 
titres. Cell-released graph shows cell-released infectious virus titres. Cell-associated graph 
shows cell-associated infectious virus titres. The titres at each time on the graph are shown as 
pfu/106 cells. ED71: infectious virus from ED71 infected cells; EHV1: infectious virus from 
wild-type virus infected cells; Re71: infectious virus from revertant infected cells.
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cells is impaired and that this defect is due to deletion of gene 71, suggesting that deletion of 
gene 71 greatly impairs virus release from cells to the extracellular space.
3.8.3. ED71 virion maturation
To examine ED 71 virion maturation within cells, the distribution of capsids and virions in 
infected cells was analysed by electron microscopy. BHK21/C13 monolayers(4 x 106 cells) 
infected with virus at 3 pfu/cell, were scraped from petri dishes at 24 h post infection and 
pelleted in Been Capsules (Taab Laboratories). The pellet was fixed and 80 nm sections cut 
and stained. For counting, 50 complete cell profiles (non-serial and including nuclei) were 
examined (the cell fixing, sectioning and electron microscope examination were carried out by 
James D. Aitken). The results presented in Table 8 show that all three viruses produce very 
similar numbers (Total) of capsids in infected cells. However, in ED71 infected cells, a large 
number of capsids accumulate in the nuclei adjacent to the nuclear membranes, and the 
percentage of capsids in the ED 71 infected cell nuclei is much higher than that in wild-type 
and Re71 infected cells (92% compared to 73-77%). Another notable difference between 
ED71 and wild-type virus is the low number of particles (6.7% compared to 20% of total 
particles) and the low ratio of enveloped to unenveloped capsids (1% of ED71 cytoplasmic 
capsids were enveloped compared to 8% for w.t.) in the cytoplasm of ED71 infected cells. In 
addition, the percentage of extracellular virions from ED71 infected cells was much less than 
that from wild-type infected cells (0.8% compared to 2.4 %). These observations indicated 
that virion maturation is decreased in ED71 infected cells and could be an explanation for the 
higher particle/pfu ratio of purified ED71 virions and the defective growth of ED71. Since the 
revertant R e71 showed a similar pattern to wild-type virus deletion of gene 71 is responsible 
for this decrease.
3.8.4. Cell to cell transmission of ED71
Removal of the gene 7 1 product results in a defect in virus adsorption/penetration and virus 
egress from infected cells. This could imply that transmission of ED71 from cell to cell via
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Table 8. Distribution of capsids in different subcellular locations of infected BHK21/C13 
cells*
Location and condition
No. (%) of total capsids
EHV1, Ab4 ED71 Re71
Nucleus
Total 1649 (77.6) 1443 (92.5) 1200(73.1)
Inside the nucleus 1649 (77.6) 1443 (92.5) 1200(73.1)
Between the lamellae 0 0 0
Cytoplasm
Total 425 (20.0) 104 (6.7) 389 (23.7)
“Enveloped(%) 8 1 17
“Unenveloped(%) 92 99 83
Extracellular 51 (2.4) 13 (0.8) 52 (3.1)
Total (all locations) 2125 (100) 1560(100) 1641 (100)
* The data is from 50 randomly selected sections of BHK21/C13 cells infected with virus at 
pfu/cell and harvested at 24 h post infection.
“ Percent of total cytoplasmic capsids.
Results
the extracellular medium could be affected and that virus transmission mainly occurs via direct 
cell to cell spread. To determine if this is the case, BHK21/C13 monolayers were infected 
with ED71, Re71 and wild-type virus at 100 pfu/plate. After 1 h adsorption, the cells were 
overlayed with EMC 10 in the presence or absence of a horse antiserum (1:25), which 
neutralises the infectivity ot ED71 and wild-type virus equally (data not shown), and 
incubated at 37 C for 2 days. The plates were stained and the plaques counted and 
photographed. The effect of neutralising antiserum on plaque size was examined. The results 
summarised in Table 9 and illustrated in Fig. 46 show ED71 formed smaller and tighter 
plaques than those of wild-type and revertant in the absence of antiserum. In the presence of 
antiserum, the plaques formed by wild-type virus and revertant virus were reduced and 
became similar to those formed by ED71. In contrast the plaques formed by ED71 were only 
marginally reduced by the presence of neutralising antiserum. This observation indicated that 
mutant release and readsorption transmission was impaired and the plaques formed by ED71 
mainly arise from direct cell to cell transmission which consequently results in smaller and 
tighter plaques. The plaques formed by wild-type and revertant virus are the consequence of 
both direct cell to cell transmission and release and readsorption resulting in larger plaques. 
This data confirmed the conclusion that deletion of gene 71 impairs virus entry into cells and 
release from cells.
To further examine the transmission of ED71 in vitro, BHK21/C13 monolayers were infected 
with ED71 and wild-type virus at a low multiplicity of infection (0.01 pfu/cell) and incubated 
in the presence or absence of the anti-EHVl horse serum. At various times after adsorption, 
the cell-associated infectious virus (CA) was harvested and titrated on BHK21/C13 cells. The 
result in Fig. 47 showed that the yield of infectious progeny from ED71 infected cells was 
decreased only about 5-10 fold in the presence of the antiserum, whereas the yields of wild- 
type and Re71 progeny were reduced about 80-100 fold by the neutralising antiserum. In the 
presence of the antiserum, the yield of infectious cell-associated virus from ED71 infected 
cells was only 2 fold lower than that from wild-type and revertant, compared to 10-20 fold in 
its absence. This result indicated that spread of ED71 via release and readsorption is
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Figure 46. Effect of antiserum on the sizes of plaques formed by the wild- 
type (W.T.), Re71 and ED71 on BHK21/C13 cells.
W ild-type virus (W .T.), ED71 revertant (Re71) and mutant (ED71) were assayed on 
BHK21/C13 cells and overlaid either with 1% carboxyl methylcellulose medium (-) or with 
1% carboxyl methylcellulose mediuimcontaining neutralising horse antiserum at a dilution of 
1:25 (+). After two days the cells were stained and plaques photographed.

Table 9. The sizes of plaques* formed by wild-type, revertant virus and ED71 
in the presence or absence of a horse neutralizing anti-EHVI serum
Antiserum
Average plaque weight (gram)
EHV1 Re71 ED71
—
2 .7 4  (±0 .18) 2.61 (±0 .3) 0 .572  (± 0 .0 4 1 )
+ 0 .4 9 2  (± 0 .065) 0 .4 8 0  (± 0 .05 ) 0 .4 2 8  (± 0 .0 3 1 )
*Monolayers of BHK21/C13 cells were infected with the indicated virus and 
overlaid with methylcellulose(-) or with methylcellulose containing a 
neutralizing horse antiserum (1 :25) (+). The cells were fixed and stained 
at 2 days post infection. 100 randonly chosen plaques were photographed in a 
OLYMPUS CR2 microscope and cut out from photographs. The plaque size of 
each virus is represented as average weight (gram) of the photographed 
plaques.
Figure 47. Effect of neutralising antiserum on the yield of ED71
Monolayers of BHK21/C13 cells were infected with O.Olpfu/cell of virus in the presence 
(+serum) or absence of a neutralising horse antiserum. Cell associated virus was harvested at 
the indicated time points p.i. The virus titres were determined on BHK21/C13 cells and are 
presented on the graph as pfu/106cells. Symbols: ED71: virus from ED71 infected cells; 
EHV1: virus from EH V 1 infected cells; Re71: vims from Re71 infected cells.
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impaired, compared with that of wild-type and revertant, and the transmission of ED71 in 
vitro (BHK21/C 13 cells) is mainly mediated by direct cell to cell spread.
Again as observed in Section 3.4 the cell associated titre of ED71 during the first 24h p.i. was 
higher than that of wild-type and Re71 (Fig. 47). Since the yield from Re71 infected cells are 
similar to that from wild-type virus infected cells, the increase is attributable to the deletion of 
gene 71. This is discussed in Section 4.7.
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CHAPTER 4. DISCUSSION
discussion
4 .1. O BJEC TIV E S
The aim of the study presented in this thesis was to investigate the role of five EHV1 genes, 1, 
2, 67, 71 and 75 in the virus life cycle. It included three objectives: (i) Generation and 
characterisation of individual deletion mutants in each of these genes to determine if they are 
essential and the effects on the virus life cycle, (ii) Characterisation of mutants with a detailed 
analysis of mutants in genes whose deletion impaired the growth of EHV1, and (iii) 
Identification and characterisation of the gene products of the five genes.
4. 2. GENERATION OF DELETION MUTANTS
Mammalian and avian herpesviruses in all the subfamiles possess a set of some 40 core genes 
(Davison, 1993) which have been inherited from a common ancestral virus. They represent all 
the major functional classes of genes, especially DNA replication, capsid structure and virion 
assembly, and their activities are seen as necessary for the function of a herpesvirus. The non 
core genes are representative of a particular subfamily, certain are specific to a member of a 
subfamily. Most genes involved in gene regulation, pathogenesis, latency, components of the 
envelope and tegument and in immune evasion are non core genes. Sequence analysis indicated 
that EH V -1 strain Ab4 genes 1, 67 and 75 have no homologues in the human herpesviruses, 
VZV and HSV1, and although genes 2 and 71 correspond in location to VZV gene 1 and HSV1 
gene US 5, respectively, there is no similarity between their amino acid sequences (Telford et 
al., 1992). This suggests that these genes are not conserved in herpesvirus subfamilies, appear 
to be non core genes, and these might play specific roles in the horse i.e. determination of
pathogenesis.
In an attempt to investigate the roles of these genes in the EHV-1 replication cycle, an individual 
deletion mutant in each of the 5 target genes was generated. To delete the target genes, the 
majority of the target gene ORF was removed using restriction enzyme digestion. The deletions
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were also made in such a way that the likelihood of disruption of adjacent genes was 
minimised. To aid in distinguishing mutant from wild-type virus, the deleted region was 
replaced by the E. coli. lacZ gene as a marker gene. In addition, an in frame stop codon was 
created between the remaining N-terminal portion of the target gene and the lacZ  insertion to 
prevent the synthesis of a B-galactosidase fusion protein.
Genes 1 and 2 are transcribed in a tail to tail pattern and their putative 3'-terminal 
polyadenylation (poly A) signals do not overlap (Fig. 2) (Telford et al., 1992). To construct a 
deletion mutant in gene 1, 87% of the coding sequence was deleted. The deletion terminates 64 
bp downstream from the stop codon of gene 2. To construct a deletion mutant in gene 2, 73% 
of the coding sequence was removed. The deletion extends from 92 bp downstream of the stop 
codon of gene 1, to 443 bp upstream of the start codon of gene 3. Gene 66 lies leftward and in 
a tail to tail orientation with gene 67 in IRs/TRs and their poly A sites do not overlap. 
Rightward oriented gene 68 in IRs and leftward oriented gene 76 in TRs are 3'-coterminal 
transcripts with the downstream gene 67 (Fig. 2) (Breeden et a l, 1992; Holden et al., 1992). 
For the construction of a gene 67 deletion mutant, 70% of the coding sequence was removed in 
both copies. The deletion extends from 845 bp downstream of the stop codon of gene 66 to 89 
bp downstream of the stop codon of gene 68 in IRs and 680 bp downstream of the stop codon 
of the gene 76 ORF in TRs which is 135 bp upstream from their 3'-coterminal poly A site 
(Telford et al., 1992; Breeden et a l, 1992). Genes 70, 71 and 72 transcribe in a head to tail 
pattern. The putative poly A signal of the gene 70 transcript does not overlap with the gene 71 
ORF. 66 bp of 3' end of gene 71 ORF overlaps with the 5' end of gene 72 ORF (Fig 2) 
(Telford et al., 1992). For construction of a deletion mutant in gene 71, 85% of the coding 
sequence was deleted. The deletion extends from 296 bp downstream of the stop codon of 
gene 70 within the gene 71 ORF and 510 bp upstream of the start codon of gene 72. Genes 74, 
75 and 76 are also transcribed in a head to tail pattern. The 3 -coterminal ploy A site of genes 
74 and 75 does not overlap with the gene 76 ORF (Fig. 2). For construction of the deletion 
mutant in gene 75, 87% of the coding sequence was deleted. The deletion extends from 58 bp 
downstream of the stop codon of gene 74 to 478 bp upstream of the start codon of gene 76
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within the gene 75 ORF. It is clear that the deletion in each target gene sould completely disrupt 
the gene product but is unlikely to have an effect on the neighbouring genes. With these 
constructs five mutants in genes 1, 2, 67, 71 and 75 were generated. Restriction enzyme and 
Southern blot analysis confirmed that the 5 deletion mutants had the expected genome structures 
without any other detectable differences from wild-type virus. As all the mutants were isolated 
and purified to homogeneity in non-complementary BHK21/C13 cells, the viability of the 
mutants demonstrated that genes 1, 2, 67, 71 and 75 are non-essential for virus growth in vitro. 
Analysis of the growth properties showed that the deletion mutants EDI, ED2, ED67 and ED75 
were indistinguishable from wild-type virus in vitro and that these genes did not independently 
influence the virus lytic replication cycle in tissue culture; the mutants also did not exhibit a host 
range phenotype in the tested cell lines or a temperature restriction. In contrast, the deletion 
mutant in gene 71 grew significantly less well than the wild-type virus and its revertant in vitro. 
The final yield of ED71 was about five to ten-fold lower than that of wild-type virus and it also 
forms smaller and tighter plaques, compared to that of wild-type virus. The growth properties 
of the revertant of ED 71 were identical to those of wild-type virus as was the yield, plaque size 
and morphology. The restoration of the wild-type phenotype indicated that deletion of gene 71 
is responsible for the defective growth of ED71.
4. 3. EXPRESSION OF VIRAL GENES IN E . C O L I  A N D  
GENERATION OF SPECIFIC ANTISERA AGAINST THE 
VIRAL GENE PRODUCTS
To identify the products of the five viral genes specific antibodies were raised against portions 
of the five target genes which had been separately expressed as 8-galactosidase fusion proteins 
in E.coli.. To construct expression plasmids, the parts of the encoding regions of the target 
genes were separately cloned into pUR vectors to fuse in frame with the 3' end of the 8- 
galactosidase gene. Restriction enzyme digestion analysis showed that all the constructed 
recombinants had the expected digestion pattern indicating that the insertions were correct. 
Sequence analysis confirmed that the inserted coding sequences were fused in frame with the 
3'-end of the 8-galactosidase gene. Using the constructed expression plasmids, the gene 67
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and 71 fusion proteins were overexpressed as full length fusion proteins with the expected 
molecular weights from transformed E. co li . The gene 1 and 2 fusion proteins were expressed 
at a high level, but the expressed fusion proteins were partially degraded and proteolysis could 
not be prevented under modified conditions. The gene 75 fusion protein was expressed at a 
low level. Expression could not be increased by expression in different host cells or at different 
temperatures and by induction with different amount of IPTG, which may indicate that the gene 
75 fusion protein is toxic to host cells. Cell fractionation experiments demonstrated that all the 
expressed fusion proteins were present as insoluble inclusion bodies. In general insoluble 
antigen is better than soluble antigen for raising antibody (Harlow, 1988 ). As the aim of 
expression of the target genes was to raise specific antibodies against the gene products, 
purification of inclusion bodies was chosen for preparation of the antigens.
Since there are individual differences among rabbits in terms of the immune reaction to antigens 
(Harlow, 1988), each of the fusion proteins was injected into two rabbits. To enhance the 
antigenicity of the fusion proteins, Freund's adjuvent was used and multiple sites of injection 
were also chosen to avoid skin damage and to obtain a good immune reaction. As there is little 
cross-reaction between E.coli and mammalian cells, the EHV1 infected cells extracts were 
directly used as antigens to check the antiserum in Western blotting and immunoprecipitation 
assays. Two specific antisera were detected from rabbits immunised by fusion proteins, FP67 
and FP 71 after one initial immunization and four boosts and designated anti-67 and anti-71, 
respectively. Anti-67 specifically recognised an infected cell polypeptide with Mr of 36KD and 
anti-71 recognised a 192 KD polypeptide in EHV 1 infected cell extracts.
Unfortunately, the fusion proteins FP1, FP2 and FP75 did not induce any detectable specific 
antibodies against their gene products in the immunised rabbits. Although as stated previously, 
analysis of the fusion proteins showed that FP75 is not well expressed, compared to the FP67 
and FP71 and FP1 and FP2 were partially degraded, the data from Western blotting against the 
expressed fusion proteins, FP1, FP2 and FP75, showed that a high level of anti-fusion protein 
antibodies was induced in the antisera. For negative control the cell extracts from deletion
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mutant ED I, ED2 and ED75 infected cells were also used as antigen in Western blotting and 
immunoprecipitation to check the antisera. The results show that that no differences were 
detected between mutant and wild-type virus infected cells. These observation suggest two 
possibilities, one is that the products of these genes may be regulated as low abundance proteins 
and could not be distinguished from mock background bands; another is that these fusion 
protein did not induce any specific antisera against the gene products as the reation to the fusion 
protein could be due to anti-p-gal antibodies. However, the reason for the failure in antibody 
induction is not clear. Since no obvious phenotype was observed from the characterisation of 
these deletion mutants, no further effort was put into producing antisera against these gene 
products.
4. 4. IDENTIFICATION AND CHARACTERISATION OF THE 
EHVI GENE 67 POLYPEPTIDE.
The sequence analysis predicted that gene 67 in EHV-1 Ab4 encoded a 272 amino acids 
polypeptide which contains a short putative amino-terminal membrane signal sequence and two 
N-linked glycosylation sites. It also contains six phosphorylation sites. Sequence analysis also 
indicated that gene 67 appeared to be unique to equine herpes vims. A homologous gene has 
been found in EHV-4 (Nagesha etal .,1993) and bovine herpesvirus type 1 (Leung-Tack et al.,
1994). At the begining of the project, the product of the gene had not been identified and its 
function was unknown. The construction and characterisation of the gene 67 deletion mutant 
showed that gene 67 is nonessential for virus growth in vitro and deletion of gene 67 does not 
affect virus growth properties in vitro. However, the deletion mutant is somewhat attenuated in a mouse 
model, which indicate that gene 67 protein may play a important role in vivo, particularly in 
determination of pathogenicity (Tim Fitzmaurice, personal conmunication). To elucidate the 
function of gene 67, the gene 67 polypeptide was identified and characterised by using a 
specific rabbit antiserum, anti-67, which was raised against the fusion protein pUEH67. The 
results showed that anti-67 specifically recognised a polypeptide with a Mr of 36 KD on 10% 
SDS-PAGE in EH V 1 infected cell extracts, but not in ED67 or mock infected cells. The same 
polypeptide was not recognised by preimmune serum in EHV1 infected cells extracts. This
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recognition was specifically inhibited by the fusion protein pUEH67. These results 
demonstrated that EHV1 gene 67 encodes a 36 KD Mr polypeptide in EHV1 infected cells. To 
further explore the properties of the gene 67 protein, the protein was characterised in terms of 
regulation of expression, cellular and virion localization and post-translational modification. 
The 36 KD protein product of gene 67 is first detectable by one hour post infection, expression 
is not dependent on viral DNA replication, but it is not synthesised under immediate early 
conditions. The transcriptional pattern of the genome of EHV-1 is similar to that of HSV-1 
(Cohen et al., 1975a ; Gray et al., 1987a, b; Honess & Roizman 1974; Clements et al., 1977). 
Therefore, in comparison with two HSV-1 genes, an immediate-early gene (IE1) and an early 
gene (UL42), it was concluded that the gene 67 polypeptide is regulated as an early protein.
Sequence analysis data showed that gene 67 contains two N-linked glycosylation sites and 6 
phosphorylation sites throughout the amino acid sequence. Labelling experiments demonstrated 
that the protein is phosphorylated, but not glycosylated which implies that the predicted N- 
glycosylation sites are not used.The protein of gene 67 is phosphorylated and in contrast to its 
cell-associated form which is an abundantly expressed polypeptide the protein is also found in 
the nucleocapsid/tegument fraction at low abundance. This suggests that gene 67 plays roles in 
both infected cells and virions.
Sequence analysis showed that a short putative membrane signal sequence is present near the 
amino terminus of the gene 67 ORF at residues 28-46. This hydrophobic sequence is followed 
by a signal cleavage-like sequence, which conforms to the -3, -1 rule of Von Heijne (1983,
1986), at residues 43 and 44; however this signal cleavage site is likely to be buried within the 
ER membrane and may not be utilised. Since other potential membrane spanning sequences are 
lacking in the protein sequence, the possibility exists that the putative signal sequence serves as 
a membrane-spanning segment for the gene 67. Cellular fractionation experiments showed that 
the majority of the 36 KD polypeptide is present in the cellular membrane fraction in the 
presence of 1 M NaCl and pH 11.5 100 mM-Sodium carbonate buffer, suggesting that the 
protein is highly associated with cellular membranes. It should be noted that the method used
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to fractionate cellular membranes will not separate cytoplasmic virions from membranes. 
However, this contamination would have little effect on the distribution of the gene 67 protein 
within cells, because (1) the gene 67 protein is a low abundance virion protein and (2) the 
majority of EHV 1 virions were released into the cell medium at late stage of infection.
An interesting finding is that anti-67 also specifically picks up four other proteins from EHV1 
infected cell extracts, but not from mock or ED67 infected cell extracts. The preimmune serum 
did not recognise these proteins. The expression of these polypeptides was different from each 
other and also different from that of the 36 KD gene 67 protein. The 33KD polypeptide was 
sxpressed in a similar manner as the gene 67 protein (36KD), except at a lower level of expression. 
The expression patterns of the other three polypeptides were quite different to that of the gene 
67 protein. The 26 KD polypeptide was initially expressed at the same time as the 36 KD 
protein, but the amount of the protein gradually decreased. The 31.5 KD and 29 KD 
plypeptides appeared at 12 h p.i.and gradually decreased until 24 h p.i. Pulse-chase experiment 
shows that the 36 KD gene 67 product is not chased into any of these low Mr polypeptides. 
Since sequence analysis shows that there are five methionine codons downstream of the start 
codon of the gene 67 protein, these data suggest the possibility that the lower Mr polypeptides 
could be expressed from these downstream ATGs within the gene 67 expression cassette.
One of the most interesting characteristics of the gene 67 protein is its filament or ribbon-like 
distribution pattern within the infected cell as detected by immunofluorescence. A similar 
distribution of the transiently expressed gene 67 protein with pCMV67 was also seen in 
lipofected cells suggesting that the formation of the filament-like structure by the gene 67 
protein is independent of other virus proteins. As far as we are aware, this is a novel pattern 
not previously described for any other herpes virus polypeptide. The staining arrangement is 
striking and varies depending on the extent of infection. Specific filaments, or ribbon-like 
structures confined entirely to the cytoplasm are apparent in both virus infected and lipofected 
cells. Small rod shaped structures appear to coalesce to form large filaments which become 
concentrated in a perinuclear location although stiands continue to wind through the entire
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cytoplasm. This overt configuration suggests that the protein may be associating with some 
component of the cytoskeleton although the filaments are much thicker than those normally 
observed on routine staining of cytoskeletal elements (Klymkowsky and karnovsky et al., 
1994; DwyerNield et al., 1996). However, staining by double labelling immunofluorescence 
with anti-67 and anti-tubulin or anti-actin and treatment with tubulin, actin or Golgi inhibitors 
demonstrated that the protein did not colocalise with either microtubulin or Golgi apparatus. An 
association with intermediate filaments has not yet been assessed although the gross 
morphology of the staining pattern is not indicative of intermediate filaments. As a non­
glycoprotein, the strong association with membranes requires further analysis for post 
translational modifications such as myristylation which may lead to membrane binding (Bryant 
& Ratner 1990).
A gene called IR6, equivalent to strain Ab4 gene 67, has also been found in EHV1 strain 
Kentucky A. As expected, it has very similar characteristics to those of gene 67. It is 
transcribed as a 1.2-kb mRNA whose synthesis begins at very early times (1.5 h) after infection 
and continues throughout infection (Breeden et al., 1992). O'Callaghan et al. (1994) have 
shown that the IR6 gene encodes an approximately 33 KD polypeptide, which is expressed as 
early as 1 to 2 h postinfection and is synthesised throughout the infection. The IR6 protein is 
phosphorylated, associates with purified EHV1 virions and nucleocapsids and was also found 
to be distributed as "dash-shaped" structures that localised to the perinuclear region.
Overall the results from these experiments showed that EHV1 gene 67 encodes a 36 KD 
phosphoprotein which is regulated as an early protein and accumulates throughout infection, but 
is a low abundance component of virions. It is associated with cellular membranes and is 
distributed as ribbon or filament-like structures in the cytoplasm. Although deletion of gene 67 
does not affect virus growth in tissue culture, an in vivo study has shown that ED67 is 
attenuated pathogenicity in a mouse model of EHV1 infection (H. J. Field personal 
communication). In addition, it has been found that the modification or deletion of gene 67 is 
the only alteration in the genome of the RacH strains (Osterrieder e t a l ,  1994a, 1994b ), which
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are apathogenic for laboratory animals and the horse, and have been used as a live vaccine 
against EHV1 infection (Mayr et al., 1968). These mutations include deletion of the gene 67 
ORF in both TRs/IRs in RacM36 and amino acid substitutions at positions 34, 42, 110 and 134 
in RacLl 1, RacL22 and RacM24, respectively (Osterrieder et al., 1996a). It is suspected that 
the substitution at position Leu-134 affects the formation of the ribbon-like structure of the gene 
67 protein. Recently, Colie and O'Callaghan (1996) have found that the EHV 1 protein kinase 
(PK) encoded by gene 69 forms a complex with the gene 67 protein, and also colocalised with 
the gene 67 protein in the cytoplasm as a novel ribbon-like structure. The normal distribution of 
the gene 67 protein is essential for the localisation of EHV1 PK protein in the cytoplasm and 
this colocalisation is required for the maximal protein kinase enzyme activity. The Us PKs of 
HSV1 and PRV have been shown to be involved in virus egress and determination of virulence 
(Wagenaar et al., 1995; Kimman etal ,  1992; Nishiyama et al., 1992 and Kurachi et al., 1993), 
although they are dispensable for virus growth in tissue culture (Longnecker and Roizman,
1987). These findings suggest that gene 67 may function as a cofactor required for activation 
of the PK or simply serve as an anchor to retain the EHV 1 Us PK protein in the cytoplasm.
Together these features of the gene 67 protein suggest that it could play an important role in the 
virus replication cycle, particularly in determination of pathogenicity. However its precise role 
in the virus life-cycle remains unknown.
4. 5. IDENTIFICATION AND CHARACTERISATION OF THE 
EHY1 GENE 71 POLYPEPTIDE.
EHV-1 gene 71 is located in the short unique region of the genome and is predicted to encode a 
797 amino acids polypeptide with a Mr of 80.IK (Telford et al., 1992). The putative gene 71 
polypeptide possesses hydrophobic amino and carboxy-terminal domains which may serve as a 
potential signal sequence and transmembrane domain respectively (Fig.35). It also contains a 
single potential N-linked glycosylation site and an extensive region encoding a high proportion 
of serine and threonine residues. These features suggest that the gene 71 product is a class 1 
membrane glycoprotein with heavy O-linked and N-linked glycosylation. Similar sequence
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features have been found in HSV-1 gC and HSV-2 gG (Serafini-Cessi et al., 1985) which are 
heavily O-glycosylated and have an extended region containing a high proportion of serine and 
threonine residues, presumed to contain most of the 0-1 inked glycosylation sites (McGeoch et 
al., 1987; Serafini-Cessi et al., 1985). HSV1 gC plays a major role in virus adsorption and 
penetration (Herold, et al. 1991) and mutants in HSV2 gG are attenuated pathogenicity in a 
mouse model (Taha, Ph.D. thesis; Meigneir et al., 1988).
The data on identification and characterisation of the gene 71 protein, presented in this thesis 
support the predicted features of gene 71 from the sequence analysis. To identify the product 
of gene 71, the C-terminal portion of the gene 71 encoding sequence was expressed as a 3- 
galactosidase fusion protein. A specific antiserum, anti-71, was raised from rabbits immunised 
with this fusion protein. Anti-71 specifically recognises a polypeptide with a Mr of 192 KD in 
EHV1 infected cell extracts. The reaction between the gene 71 protein and anti-71 is 
specifically inhibited by the fusion protein pUEH71. The preimmune serum did not recognise 
this protein in EHV1 infected cell extracts. The polypeptide was not detected in mock and 
ED71 infected cell extracts, and it is restored in Re71 infected cells. These findings clearly 
demonstrate that gene 71 encodes a 192KD Mr polypeptide in EHV-1 Ab4 infected cells.
The carbohydrate motifs (either high mannose or complex) of virus glycoproteins are most 
commonly linked to asparagine residues via the dolicholphosphate pathway and are sensitive to 
the inhibitory effects of tunicamycin (Leavitt, et al., 1971) and digestion with endo glycosidase 
F (endoF) (Elder and Alexander, 1982; Maley et al., 1989). It has also been shown that several 
animal viruses, including herpesviruses, contain tunicamycin resistant O-linked carbohydrates 
on their envelope glycoproteins (Holmes et a l, 1981; Johnson and Spear, 1983; Niemann et 
al., 1983,1982; Olofsson et a l ,  1981; Shida and Dales, 1981). These oligosaccharides are 
sensitive to the treatment with monensin or neuraminidase/O-glycanidases (Carlsen and Pierce, 
1972; Bahl and Agarwal, 1969; Li and Li, 1970) and are primarily responsible for the proteins 
slow electrophoretic mobility in SDS-PAGE (Johnson and Spear, 1983). Sequence analysis 
showed that the gene 71 protein contains a single putative N-linked glycosylation site and an
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extensive region (residues 22-465) encoding a high proportion (87%) of serine and threonine 
residues which is likely to be heavily O-glycosylated (Telford et al., 1992). As expected, the 
Mr of the gene 71 poypeptide on SDS-PAGE is much greater than the putative Mr from the 
amino acid sequence (80.1 KD). This suggests that the gene 71 protein is likely to be modified 
as a heavily O-glycosylated protein. Post-translational modification experiments confirmed this 
hypothesis. Firstly the 192 KD gene 71 protein was labelled by 14C glucosamine. The 192 
KD gene 71 protein was reduced to a 183 KD polypeptide following treatm ent with 
tunicamycin, and the digestion with endo glycosidase F only slightly reduced the Mr of the gene 
71 protein. Treatment with monensin or neuraminidase/exoglycanidases dramatically reduced 
the molecular weight of the gene 71 protein to 80 KD which is same as the molecular weight of 
the primary product of gene 71. These results confirmed that the gene 71 protein is a 
glycoprotein with heavy O-linked glycosylation and limited N-linked glycosylation. These 
findings are consistent with the putative features of the gene 71 protein from sequence analysis. 
The 80 KD species produced following treatment with either monensin or exoglycanses was 
also shown to be present at low abundance in total infected cell extracts and the cytosol fraction, 
but not in mock infected cells. It was not found in ED71 infected cells. These data suggest 
that it is likely to be the primary product of gene 71.
The putative EHV1 gene 71 protein contains a N-terminal signal sequence of hydrophobic 
amino acids with one charged side chain between the N-terminus and the hydrophobic region; it 
also contains a 25 residue hydrophobic region near the C-terminus (Fig. 36). These sequence 
features suggested that the gene 71 protein is likely to be present on the surface of cell 
membranes and on virion envelopes as a class I membrane glycoprotein. Cellular fractionation 
experiments confirmed that the gene 71 polypeptide is strongly associated with cellular 
membranes. Virion surface labelling experiments further confirmed that the product was 
located on the surface of virion envelopes. These results demonstrate that the gene 71 protein is 
class I membrane glycoprotein which is present on both cellular membranes and virion 
envelopes.
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As a virus structural protein, the gene 71 polypeptide is expected to be regulated as a late protein 
in infected cells. Transcription and translation of the EHV-1 genes, like those of HSV1, are 
temporally regulated into an immediate-early, early and late pattern (Cohen et al., 1975a; 
Caughman et al., 1985; Gray et al., 1987a, b; Clements et al.., 1977). A timecourse of 
expression showed that the gene 71 protein is first detected at 8 h p.i. and its synthesis is 
significantly reduced by the presence of PAA. In control experiments, the regulation of two 
HSV1 genes, a true late gene (US11) and an early gene (UL42), was examined and shown to 
have the expected patterns. In comparison, it was concluded that the gene 71 protein is 
regulated as a leaky late polypeptide.
Overall these results demonstrate that the EHV1 gene 71 encodes a typical class I membrane 
glycoprotein which is heavily O-glycosylated with a Mr 192KD in infected cells and a Mr over 
200 KD in virion envelopes. It is regulated as a leaky late polypeptide.
4. 6. DETERMINATION OF THE RELATIONSHIP BETWEEN  
THE EHV1 GLYCOPROTEIN GP300 AND THE GENE 71 
PO LYPEPTIDE.
Among the identified EHV-1 glycoproteins (Abodeely et al.., 1971; Kemp et al.., 1974; Perdue 
et al., 1974; Turtinen and Allen, 1982; Meredith et al.., 1989), one with a Mr in excess of 
200K, designated either gpl, gp2, gp 1/2 or gp300 was first observed in purified virions and 
mapped to an EcoRI fragment of the genome between map units 0.279 to 0.344 (Allen & 
Yeargan, 1987). It was subsequently found to be sensitive to monensin and exoglycanases 
which indicated that gp300 was modified as a heavily O-linked glycoprotein. It was also found 
to be a virion surface protein with a Mr estimated as 400KD on SDS-PAGE cross-linked with 
DATD (Whittaker et al., 1990). Whittaker et al., (1992a) appeared to demonstrate that gp300 
was encoded by EHV-1 gene 28 using an anti-gp300 monoclonal antibody, P I9, and a fusion 
protein composed of the portion of the protein encoded by codons 107 to 504 of gene 28 fused 
to the 3’ end of glutathione S-transferase (GST) . They found that MAb P19 recognised a 70 
KD species corresponding to the expected size of the fusion protein from the recombinant
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fusion protein expression plasmid transformed cell extract. This 70 KD species was not 
present in cells transformed with the parent plasmid and P I9 did not recognise GST. From 
these findings, the authors concluded that EHV 1 gene 28 encodes the high Mr glycoprotein 
gp300.
During the course of this study it became apparent that the EHV 1 gene 71 polypeptide had very 
similar characteristics to the EHV1 gp300. It was reasonable therefore to raise the question 
whether the two proteins are identical and if so which gene encoded it. From the amino acid 
sequence feature, EHV 1 gene 28 did not appear to be a typical membrane glycoprotein modified 
with heavy O-linked glycosylation. It has no apparent signal sequence (McGeoch, 1985) and 
there is only one region (amino acids 130-148) of sufficient length and hydrophobicity which 
could be predicted to be membrane spanning (Kyte and Doolittle, 1982). Furthermore, unlike 
gene 71 there is no region rich in serine or threonine residues which could serve as O-linked 
glycosylation sites in the gene 28 amino acid sequence.
To resolve the anomaly, polypeptides from EHV1 wild-type virus, ED71 and Re71 infected 
cells were compared under the same SDS-PAGE conditions with both antibodies, anti-71 which 
is specific to the gene 71 protein and P I9 which was used to identify gp300 (Whittaker et al., 
1992a). Comparative experiments demonstrated that the gene 71 polypeptide and gp300 
synthesised in EHV-1 Ab4 infected cells had identical electrophoretic mobilities to each other on 
both SDS-PAGE cross-linked either with bisacrylamide or DATD in the presence or absence of 
tunicamycin. Both gp300 and the gene 71 protein were absent in cells infected with the mutant 
ED71 in which the gene 71 ORF was deleted, but were detected in cells infected with the 
revertant Re71 in which the gene 71 ORF has been restored. This restoration of the gene 71 
protein in Re-71 ruled out the possibility of a secondary mutation in ED71 which could have 
disrupted gene 28. These results demonstrated therefore that (1) gp300 is the same polypeptide 
as the gene 71 product and (2) is actually encoded by EHV-1 gene 71 and not by gene 28 as 
previously determined by Whittaker et al. (1992a).
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It has recently been found that none of the monoclonal antibodies (MAbs) made against gp300 
specifically recognise the transiently expressed EHV1 gene 28 gene protein product in RK13 
cells from a gene 28 expression vector, but most of these MAbs can specifically recognise the 
EHV1 gene 71 protein product transiently expressed by a gene 71 expression vector (D. M. 
Meredith, personal communication). These data is in agreement with our conclusion that EHV1 
gp300 is the same polypeptide as the gene 71 protein and is encoded by gene 71.
4. 7. INVESTIGATION OF THE ROLE OF GENE 71 IN THE 
VIRUS LIFE CYCLE.
Herpesvirus membrane proteins have been found to be involved in virus entry, egress and 
transmission. Mutants in HSV1 and other alphaherpesvirus genes which encode gD, gH, gL, 
and the U L 11 and UL20 proteins have been shown to be defective in adsorption, penetration 
and egress, and appear to be responsible for different steps of the process of virus entry and 
release (Baines et al., 1991; Capadelli-Fiume et. al., 1991; Desai et al., 1988; Baines and 
Roizman, 1992; Hutchinson et al., 1992a; Roop et al., 1993; Rauh and Mettenleiter, 1991a, b; 
Peeters, 1992a.b).
EHV 1 strain Ab4 gene 71 has no known homologue in other herpesviruses, except a positional 
counterpart, US5, in HSV1 (Telford et. al., 1992). It has been demonstrated that gene 71 
encodes a large (Mr 192kD) heavily O-linked membrane glycoprotein which is associated with 
cellular membranes and the virion envelope. Sequence analysis suggested that the serine and 
throenine-rich region (amino acids 22 to 465) in the protein may form highly extended semi- 
flexible rods of 71 nm in length on the virion surface (McGeoch et. al., 1993). As a typical 
class I membrane glycoprotein, the gene 71 product could possibly play a role in virus entry 
into cells, egress from cells or transmission from cell to cell. It has been demonstrated that the 
gene 71 negative mutant, ED71, has defective growth and produces smaller and tighter plaques, 
compared to that of wild-type virus and its revertant. The in vivo study showed that ED71 was
s°mewhat
attenuated in a mouse model of pathogenicity (H.J. Field, personal communication). These
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phenotypes suggested that the gene 71 protein may play an important role in the virus life cycle 
and in determination of pathogenesis.
To investigate the role of gene 71 in the virus life cycle, the efficiency of entry into cells, egress 
from cells and transmission from cell to cell of ED71 was examined in vitro and compared with 
wild-type virus and its revertant. The adsorption/penetration assays demonstrated that ED71 is 
defective in both adsorption and penetration. This finding supports the predicted features of the 
gene 71 protein as a long protruding membrane glycoprotein on virion envelopes (McGeoch et. 
al., 1993). As the defect in adsorption may also make virus vulnerable to acid buffer, we could 
not rule out the possibility that the demonstrated defect in the efficiency of virus adsorption 
could consequently result in a decrease in penetration.
It was found that purified ED71 virions display a 10 -20 fold higher particle/pfu ratio than that 
of wild-type virus and revertant which suggested that the deletion may effect virion maturation. 
Quantitation of progeny virus showed that the release of infectious virus from ED71 infected 
cells was decreased by 100 fold and significantly delayed. The yield of cell-associated 
infectious virus from ED 71 infected cells is also decreased about 2-3 fold, compared to that of 
wild-type virus and revertant. E.M. analysis of virion distribution showed that (1) The 
percentage of capsids in the nuclei of ED71 infected cells is much higher than that in wild-type 
virus and revertant infected cells. (2) The amount of particles (enveloped and unenveloped 
capsids) in the cytoplasm of ED71 infected cells is much less than in wild-type virus and 
revertant infected cells and the ratio of enveloped to unenveloped ED71 capsids in the cytoplasm 
is lower than that of wild-type and revertant. (3) The percentage of extracellular virions in 
ED71 infected cells is less than that in wild-type infected cells. These observationsindicated that 
deletion of gene 71 impairs nucleocapsid maturation and virion release from infected cells 
suggesting that the gene 71 protein plays a role in virus maturation and egress. These defects 
could also be the reason for defective growth of ED71 and the higher particle/pfu ratio of 
purified ED71 virions.
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As a result of the defect in adsorption/penetration and release, it seemed likely that transmission
via release and re adsorption would be affected. Since in the presence of appropriate amounts
of neutralising antiserum, the virus transmission from cell to cell via the medium can be blocked
in vitro, the effect of neutralizing antiserum on plaque size was examined. The data show that
in the absence of neutralising antiserum the plaques formed by ED71 are contained and smaller
than those formed by wild-type virus. In the presence of neutralising antiserum, the size of
plaques formed by ED71 is not significantly reduced, while the size of those formed by wild-
type virus and revertant are markedly reduced and become similar to those formed by ED71.
These data demonstrated that the plaques formed by wild-type virus and revertant are mediated
by transmission via medium and direct cell to cell transmission, while those formed by ED71
(smaller and contained) are only mediated by direct cell to cell spread indicating that
transmission of ED71 via the medium is greatly impaired. When low m.o.i. growth was
carried out in the presence of neutralising serum the yield of ED71 was only reduced 5-10 fold,
in
but the yield of EHV1 and Re71 was reduced 80-100 fold, resulting little difference in yield
A
between ED71 and EHV1/RE71, compared to the 10-20 fold difference in the absence of 
neutralising serum. This again is in agreement with the main mode of spread of ED71 in vitro 
being via direct cell to cell transmission, compared to that of wild-type virus being spread via 
both direct cell to cell and the medium. These results confirmed the hypothesis that the defect in 
virus release and readsorption consequentially affects virus transmission.
Interestingly, at low m.o.i. the yield of infectious virus from ED71 infected cells before 24 h is 
about 10 fold higher than that from wild-type virus and revertant infected cells, and this increase 
is not reduced by the presence of a neutralising antiserum. The same increase is not clearly seen 
following a high m.o.i. Electron microscopy analysis showed that very similar numbers of 
particles were produced from ED71, wild-type and revertant infected cells. This pattern of infection 
implies’ that gene 71 protein may indirectly enhance virion de-envelopment or transport to the 
nucleus, leading to a more rapid decline in input titre and production of progeny virus. 
Alternatively it may be due to the delayed/impaired release of ED71 leading to a build up of 
infectious virus in the cells. However, at the moment the mechanism of this increase is not
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clear.
Overall these studies show that deletion of gene 71 impairs virus egress from cells which 
indicates that the gene 71 protein plays a role in virus maturation and egress. Deletion of the 
gene 71 protein also decreases virus entry into cells. At this stage it is reasonable to assume that 
this is the result of the predicted semi-flexible spikes being absent from the virus surface. The 
deletion has a consequential role in the efficiency of virus transmission from infected cell to 
uninfected cell, and the mode of infection. These defects could account for the virus attenuation 
in vivo (H. J. Field, personal communication). However, the molecular mechanism by which 
the gene 71 protein performs its function(s) in the virus life cycle is still unclear.
It should be noted that the 3' terminal 80 % of the gene 71 ORF is deleted in ED71 and the gene 
71 product is not detected by a specific antiserum (anti-71) and a monoclonal antibody (P I9) 
(Sun et al., 1994). The B-galactosidase expressed from the lacZ insertion in gene 71 ORF 
should not affect virus behaviour in virus entry into cells and release from cells since a deletion 
mutant with a similar lacZ substitution in EHV1 gene 75 ORF (Sun and Brown, 1994) does not 
show any defect in virus growth and entry into cells, egress from cells and transmission from 
cell to cell (Section 3.4 and data not shown).
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4. 8 FUTURE PROSPECTS
Characterisation of ED71 demonstrated that the gene 71 protein plays multiple roles in the virus 
life cycle such as mediation of virus egress from cells and virus entry into cells. Subsequently 
it plays a role in virus transmission. ED71 has also been demonstrated to be attenuated in vivo. 
Sequence analysis showed that the gene 71 protein is a class I membrane glycoprotein. It 
contains N- and C-terminal hydrophobic regions which serve as signal sequence and 
transmembrane domains. It also contains an extended region with a high proportion of serine 
and threonine residues, presumed to contain most of the O-linked glycosylation sites (McGeoch 
et al., 1987; Serufini-Cessi et a l, 1985). It has been suggested if the serine and threonine rich 
region is heavily O-glycosylated it could form a highly extended semi-flexible rod of 70nm in 
length on the surface of the virus particle (McGeoch et al., 1993). Some reports about the 
possible functions of O-linked oligosaccharides suggest that they could play a role in 
polypeptides acquiring their final conformation (Gibson eta l ,  1980), in increasing hydration of 
cells, in protecting virus from degradation or in transport of viral glycoproteins or virions to the 
cell surface (Johnson and Spear, 1983). These data suggest that the gene 71 protein is involved 
in different stages of virus life cycle and contains different domains which could be the 
molecular basis of its function. Characterisation of these domains will provide essential 
information for further understanding the functions of the protein, for example use of antibodies 
to specific domains of the protein in conjunction with electron microscopy to reveal the precise 
arrangement of the gene 71 polypeptide such as the semi-flexible rod structure formed by the O- 
glycosylated serine and threonine rich region on the virion envelope and construction and 
characterisation of deletion mutants in which the different domains of the gene 71 protein such 
as the serine and threonine rich region and N-terminal or C-terminal hydrophobic domains of 
the gene 71 protein.
Characterisation of the gene 67 protein demonstrated that it is expressed as a very abundant 
early protein during the virus lytic infection. The gene 67 protein is modified as a 
phosphoprotein and distributed as a novel filament like structure in the cytoplasm. Although
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the gene 67 protein is nonessential for virus growth in vitro, the gene 67 deletion mutant is 
attenuated. These data indicate that the gene 67 protein could play role in the
determination of virus pathogenicity. To address the role of the gene 67 protein it will be 
necessary to determine the subcellular location of the protein using immune electron microscopy 
plus different antibodies against specific cellular components or organelles. Construction of 
different length of truncated forms of the gene 67 protein, to determine the essential amino acid 
sequence requirements for the normal processing and distribution of the protein, will also 
provide important data for understanding the function of the protein. In addition, further 
characterisation of the gene 67 deletion mutant in vivo, particularly in the natural host, 
compared with wild-type and revertant is essential for elucidating the role of the protein in 
pathogenicity.
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